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ABSTRACT 
 
Rhabdomyosarcoma (RMS) is a pediatric cancer for which common 
therapeutics include cytotoxic chemotherapeutics that result in adverse health 
outcomes later in adulthood. Previous studies have found NR4A1 expression 
contributes to the oncogenicity of several solid tumors and this study aims to 
determine if the established NR4A1-dependent mechanisms are observed in 
RMS. 
The orphan nuclear receptor NR4A1 is expressed in tumors from RMS 
patients and RMS cell lines. NR4A1 knockdown/antagonism also decreases the 
expression of growth promoting/pro-survival genes, inhibits mTOR signaling and 
induce oxidative stress. 1,1-Bis(3-indolyl)-1-(p-substituted phenyl)methane (C-
DIM) analogs are NR4A1 ligands in RMS cells and inhibit RMS cell growth in 
vitro and in vivo.  
We also report overexpression of the nuclear receptor NR4A1 in 
rhabdomyosarcoma that is sufficient to drive high expression of the oncogenic 
PAX3-FOXO1A protein. RNAi for NR4A1 or C-DIM treatment decreased 
expression of PAX3-FOXO1A and its downstream effector genes. NR4A1 also 
regulated expression of β1-integrin, along with PAX3-FOXO1A, contributed to 
tumor cell migration that was blocked by C-DIM/NR4A1 antagonists.  
RNASeq studies using NR4A1 knockdown and antagonism and PAX3-
FOXO1A antagonism in RMS cells revealed several genes that are commonly 
  iii 
regulated by PAX3-FOXO1A and NR4A1, including the tumor suppressor-like 
factor interleukin-24 (IL-24). Studies show IL-24 expression is repressed in 
ARMS tumors and PAX3-FOXO1A positive tumors and transfection of ARMS 
cells with siPAX3-FOXO1A or siNR4A1, or treatment with C-DIM/NR4A1 
antagonist result in IL-24 induction. In cells cotransfected with siPAX3-FOXO1A 
and siIL-24 or in IL-24 KO Rh30 cells, effects of siPAX3-FOXO1A were 
significantly abrogated. These data show that the oncogenic activity of PAX3-
FOXO1A was due to, in part, IL-24 repression. Therefore, IL-24 induction 
contributes to the anti-carcinogenic actions observed upon PAX3-FOXO1A 
suppression.  
Previous studies have demonstrated the ability of C-DIMs to inhibit 
NR4A1-dependent pathways, yet these compounds exhibit low serum half-life, 
making them unsuitable for therapeutic applications. The current studies using 
selected p-hydroxyphenyl-substituted analogs (second-generation C-DIMs) 
show up to 10 times more potent than the parent compound in vitro and in vivo. 
This new class of potent NR4A1 antagonists is being developed for future 
clinical applications for treating RMS, a cancer which has a poor prognosis with 
current treatments.  
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
CANCER OVERVIEW 
Cancer is a complex, multifaceted disease and it is estimated that 14 
million individuals are diagnosed with this disease. 8.2 million people per year 
will die from cancer [1]. Furthermore, the estimated cost of cancer in the United 
States, including treatment and loss of productivity, is approximately $226 billion 
annually [1]. These statistics point to the continued need for cancer research 
and the development of new methods for diagnosis and treatment. Breast, 
colorectal, and lung cancer are the most prevalent cancers in the United States 
and together, account for approximately 175,000 new cases and 250,000 deaths 
every year [1]. While a cancer diagnosis in adulthood can be life-altering, it is 
even more tragic when the diagnosis is in children. In 2016 alone, an estimated 
10,000 new cases of cancer were diagnosed along with 1,200 deaths among 
children from birth to age 14  [2]. The most commonly diagnosed childhood 
cancers include acute lymphocytic leukemia (ALL), neuroblastoma, and other 
central nervous system (CNS) cancers [2].  
Tumors can arise from various specialized cells throughout the body, yet 
most human cancers arise from epithelial cells. Epithelial cells are sheets of 
cells that line the walls of cavities or channels in the body and skin cells, are 
epithelial in origin and protect tissues from external insults. Furthermore, these 
specialized cells give rise to the most common cancer type, carcinomas, which 
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are responsible for more than 80% of cancer-related deaths in the Western 
world [3]. Carcinomas affect various tissues, including the esophagus, stomach, 
intestines, lung, liver, and mammary glands [3]. The remaining tumor types arise 
from nonepithelial tissues throughout the body and are divided into three major 
classifications;  neuroectodermal, hematopoietic, and stromal [3]. 
Neuroectodermal tumors are derived from components of the central and 
peripheral nervous system [3]. This cancer type includes gliomas, 
neuroblastomas, medulloblastomas, and glioblastomas [3]. The second cancer 
type includes hemotopoietic, or blood-forming, tissues, and cells of the immune 
system, including erythrocytes, plasma cells, and T and B lymphocytes [3]. The 
common cancer types within this group include leukemias, which are 
malignancies of circulating immune cells, such as white blood cells, and also 
include lymphomas, which encompass tumors of lymphoid lineage, such as B 
and T lymphocytes [3]. The latter will commonly aggregate into solid tumors in 
lymph nodes, while leukemias are usually dispersed, single cell populations of 
malignancies. The third subtype includes cancers that are derived from 
connective tissues throughout the body and have developed from the mesoderm 
layer of the early embryo. Common cell types include collagen-secreting cells or 
fibroblasts, bone-forming cells or osteoblasts, and muscle forming cells or 
myocytes [3]. The most common sarcomas are osteosarcomas, liposarcomas, 
rhabdomyosarcomas, and Ewing sarcomas.  
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Indeed, some cancers are associated with the 3 germ cell layers that are 
formed during the gastrulation phase of embryonic development, including the 
ectoderm, mesoderm, and endoderm [3]. The ectoderm layer is the basis for 
both the outer skin layer and the nervous system; this cell type is primarily 
associated with the development of neuroectodermal malignancies that arise 
from the outer cell layer of the early vertebrate embryo [3]. The mesoderm layer 
develops into connective tissues, such as muscle, cartilage, and blood vessels 
and this layer is implicated in the development of various sarcomas [3]. The 
endoderm gives rise to epithelium of the digestive and respiratory system as well 
as the liver and pancreas; this cell type can develop into adenocarcinomas [3]. 
During the last phase of gastrulation, the cells in the embryo undergo epithelial 
to mesenchymal transition (EMT) to form germ cell layers [3]. This process 
allows three germ cell layers to form from a single layer of cells. During this 
process, the cells must lose their epithelial characteristics, such as cell-cell 
adhesion, and become mobile. Various signaling pathways are key for this 
process to occur. Fibroblast growth factor (FGF) signaling is required for the 
upregulation of snail family transcriptional repressor 1 (SNAI1), which then 
downregulates E-cadherin, resulting in a loss of cell adhesion [3]. Mesenchymal 
cell formation is important in cancer development because they are the basis for 
the formation of connective tissue as well as lymphatic and circulatory systems 
[3]. Therefore, sarcomas are derived from mesenchymal cell types. 
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 Over the years, research has shown that a normal cell requires multiple 
heritable changes to evolve into a cancer cell and this process is called 
carcinogenesis. Carcinogenesis is a multistage process involving several genes 
and includes three major phases, initiation, promotion, and progression [4]. The 
underlying premise of this multistep model of carcinogenesis is the role of 
genetic or epigenetic alterations of multiple, independent genes. The initiation 
step usually requires some type of DNA damage and may involve a mutational 
event associated with an oncogene or tumor suppressor gene [5]. Evidence for 
this step is supported by findings showing that ras proto-oncogene activation is 
the result of mutational activation in various animal models, such as mouse skin 
papillomas and rat mammary carcinomas [6, 7]. Furthermore, initial studies in rat 
liver observed the immediate progeny of initiated cells form altered heptatic foci 
[5]. The mechanisms by which initiation occurs can vary across tissue types, but 
it is understood that most initiated cells do not progress through the following 
stages of cancer, but rather remain quiescent in the organism [5]. This has been 
confirmed by the observation of numerous initiated cells in most organs of the 
body with only a select few that undergo promotion [5].  
The next step in the process is promotion, during which the initiated cells 
undergo clonal expansion into a benign lesion, such as a papilloma or foci of 
preneoplastic cells. This step does not involve direct genomic changes that 
occur during initiation, but is rather characterized by altered expression of the 
genome of the initiated cell [4]. During this step, the precancerous cell may 
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exhibit decreased expression of tumor suppressor genes such as p53 or 
retinoblastoma protein (RB1), among others. An alternate mechanism is through 
upregulation of oncogene expression, which can result in the activation of 
survival signals and growth factors, such as Ras, mitogen activated protein 
kinase kinase (MAPKK), and vascular endothelial growth factor (VEGF) [3], 
among others.  
The third step, cancer progression, occurs following promotion and is an 
irreversible step during which malignant neoplasms and major genetic and 
structural changes occur within the cells, including karyotypic alterations. These 
karyotypic alterations can result in the evolution of cancerous characteristics, 
such as invasion, increased growth rate, and increased angiogenesis [8]. While 
normal cells can regulate the structure of their genome and karyotype, malignant 
cells are unable to do this [8], resulting in the genomic instability that is a 
hallmark of cancer. 
Cancer Hallmarks  
 During the last 50 years there have been remarkable advances in cancer 
research. From identifying the link between cigarette smoking and lung cancer, 
oncogene and tumor suppressor discovery, identifying the P53 gene, to the 
establishment of cancer hallmarks, these discoveries have been integral to our 
current understanding of cancer and how it develops. Most notably, cancer 
research has revealed that cancer is a dynamic disease involving multiple 
stages and various alterations to the genome. These genetics changes are the 
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basis for the transformation of normal cells to highly malignant ones. While the 
genetic changes that occur are diverse, they normally fall into one of six 
categories that represent the major hallmarks of cancer. These six hallmarks, 
put forth by Weinberg and Hanahan, include self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evading apoptosis, limitless replicative 
potential, tissue invasion and metastasis, and sustained angiogenesis (Figure 1) 
[4]. Each of these steps represents a bypass of the cell’s normal defense against 
pathways/genes leading to the formation of transformed cells.  
 
 
Figure 1. Cancer Hallmarks. Six cancer hallmarks as put forth by Hanahan and Weinberg. Reprinted with 
permission: Hanahan Cell Volume 144; 5 March 2011. 
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Self-sufficiency in Growth Signals 
All cells rely on mitogenic growth signals to move from a dormant state to 
a proliferative one and these signals are transmitted via transmembrane 
receptors. These receptors bind several ligands including cell-to-cell adhesion 
molecules, diffusible growth factors, and extracellular matrix components [4]. 
These molecules activate growth-stimulatory signaling pathways that cause the 
cell to proliferate. One of the ways malignant cells can take advantage of this 
process is by producing their own growth signals and thereby become 
autonomous and eliminate their need for external growth signals [4]. 
Additionally, many oncogenes act by mimicking normal growth signaling 
molecules. While growth factor dysregulation is a mechanism by which cells can 
acquire self-sufficiency, the cell surface receptors that bind growth factors can 
also be hijacked. Growth factor receptors are frequently overexpressed in a 
variety of cancers. For example, the epidermal growth factor receptor (EGFR) is 
overexpressed in breast and stomach cancer [9] and the HER2/neu receptor is 
upregulated in both breast and stomach carcinomas [10]. Furthermore, highly 
overexpressed receptors often exhibit ligand-independent signaling due to 
constitutively active receptor signaling [4]. Malignant cells can also alter the 
expression of extracellular matrix receptors, known as integrins, and these also 
enhance transmission of growth signals. For example, the a5b1 integrin 
heterodimeric receptor can induce the expression of the anti-apoptotic protein 
Bcl-2 [11], thereby enhancing cell survival and inhibiting apoptosis. Yet another 
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integrin avb3, promotes melanoma and endothelial cell survival via suppression 
of the p53 pathway and activation of the transcription factor nuclear factor kappa 
B [12]. 
Insensitivity to Anti-growth Signals 
Normal tissues have two major mechanisms by which they maintain 
cellular homeostasis and block proliferation, both of which are associated with 
the cell cycle. Cells may transition from an active proliferative state to the 
quiescent (G0) state from which they may re-enter to activate proliferation if the 
proper signals are present [4]. Alternatively, cells may be induced to enter a 
post-mitotic state. Normal cells sense the external environment for signals that 
dictate whether cells will proliferate, be quiescent, or enter a post-mitotic state 
[4]. While the process by which this occurs is complex, there are a few key 
components. Many of the antiproliferative signals are mediated by pocket protein 
family members, which consists of the retinoblastoma protein (Rb) as well as 
p130 and p107 [13], all of which act together to regulate the cell cycle. pRb acts 
as a tumor suppressor protein that inhibits cell cycle progression until the cell is 
ready to divide, thereby inhibiting excessive cell growth [13]. pRb normally 
blocks proliferation by sequestering E2F transcription factors that control 
expression of genes that determine progression through the cell cycle [14]. 
When pRb is mutated or disrupted, during carcinogenesis, E2F transcription 
factors are released from pRb-dependent inactivation results in enhanced 
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expression of E2F-dependent genes required for DNA replication and for 
production of cyclins E and A [13].  
For cancer cells to grow, they must be able to bypass these anti-
proliferative signals, and particularly the pRb pathway. When this pathway is 
disturbed, it allows for E2F transcription factors to be liberated, leading to cell 
growth and progression through the G1 phase of the cell cycle [4]. This also 
allows for proliferative actions that are independent of the growth inhibitory 
actions of the pRb pathway [4]. One of the best documented cases of 
interactions between pRb and growth inhibitory factors is that of TGFb. While the 
complete activity of TGFb is not fully understood, studies have shown that TGFb 
inhibits the inactivating phosphorylation of pRb, thereby blocking the advance of 
cells through the G1 phase of the cell cycle [15]. TGFb also suppresses c-myc 
expression, the latter of which plays a role in regulating the cell cycle machinery 
[15]. Additionally, TGFb plays a more direct role by enhancing synthesis of 
p15INK4B and p21, both of which block the cyclin:CDK complexes that are 
responsible for pRb phosphorylation [16, 17]. TGFb signaling can be inhibited in 
cancer cells via downregulation or mutation of TGFb receptors [18]. The Smad4 
transcription factor transduces signals from TGFb receptors to downstream 
targets and Smad4 is commonly lost in colorectal cancer and pancreatic ductal 
adenocarcinoma due to loss of chromosome 18q21[19, 20]. Furthermore, CDK4, 
one of the cyclin:CDK complexes, can become unresponsive to the inhibitory 
action  of p16INK4a, due to missense mutations affecting INK4A, and this mutation 
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is commonly found in melanoma cases [21]. While disruptions can occur 
upstream to pRb, pRb can also be lost through mutations, which is the case in 
retinoblastoma, a highly aggressive malignancy of the eye primarly observed in 
young children; Rb can also be sequestered by viral oncoproteins, as is the case 
with HPV associated cervical carcinomas [22]. These results indicate that 
various disruptions that occur with the pathways upstream and downstream of 
Rb, and this results in cell cycle dysregulation.  
Acquired Capability: Evading Apoptosis 
 Uncontrolled cell proliferation is one mechanism by which cancer cells 
grow and this can be enhanced or complemented by alterations of pathways 
associated with cell survival and apoptosis. Apoptosis is a precisely planned 
program of cell death that can be triggered by certain physiological signals. The 
process results in the breakdown of cellular membranes and cytoskeleton as 
well as chromosome and nucleus degradation [4]. Intracellular and extracellular 
sensors are responsible for monitoring the external and internal cell environment 
and for conveying the appropriate signals to cells. Many of these pro-apoptotic 
signals converge on the mitochondria, which responds with the release of 
cytochrome C, a hemeprotein found in the inner membrane of the mitochondria 
[4]. The release of cytochrome C, activates caspase 9, which then activate 
caspases 3 and 7, both of which are responsible for activating various 
downstream effector caspases and cell death pathways [23, 24]. Members of the 
Bcl-2 family that either have proapoptotic (Bax, Bak, Bim) or antiapoptotic (Bcl-2, 
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Bcl-XL, Bcl-W) function also regulate mitochondrial death signaling through 
cytochrome C release. One mechanism by which p53 can elicit apoptosis is via 
upregulation of proapoptotic Bax in response to DNA damage; Bax in turn 
stimulates mitochondrial release of cytochrome C [4].  
Acquired Capability: Limitless Replicative Potential 
 While growth signal autonomy, resistance to apoptosis, and insensitivity 
to antigrowth signals together can dysregulate growth of normal cells, tumor 
formation requires the alteration of the cell autonomous program that normally 
limits replicative potential. Early studies showed that cells in culture have a finite 
replicative potential which results in senescence. These studies found that 
senescence can be circumvented by disabling the pRb and p53 tumor 
suppressor proteins, which allowed for additional generations [25]. This “crisis” 
state is usually categorized by chromosomal fusion and genetic abnormalities 
and variants (1 in 107) that have acquired limitless replicative potential, termed 
immortalization [26]. Chromosomal fusion usually occurs as a result of 
progressive erosion of telomeres through many cycles of replication, leaving the 
chromosomes unprotected and allowing them to participate in end-to-end 
chromosomal fusions [27], which in most cases leads to cell death. Alternatively, 
almost all malignant cells have sustained telomere maintenance and usually do 
so by upregulation of telomerase enzyme [28, 29]. Both in vitro and in vivo 
studies have demonstrated the importance of telomerase activity and when 
telomerase is ectopically expressed in late passage cells about to crisis, the 
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cells continue to proliferate without any sign of crisis [30, 31]. Furthermore, 
tumor susceptible mice exposed to carcinogens develop tumors with elevated 
telomerase activity [32]. Telomere maintenance is crucial in obtaining 
immortalization and is a key mechanism by which cancer cells bypass the 
normal mechanisms for growth limitations.  
Acquired Capability: Sustained Angiogenesis 
 All cells require oxygen and nutrients which are supplied by the 
vasculature and nearby capillaries. The process of forming and developing new 
blood vessels is termed angiogenesis. Research has found that the initial 
proliferative lesions that develop in cancer lack angiogenic ability, which 
hampers their ability to expand; as tumors begin to develop and grow to a larger 
size, these neoplasias must develop angiogenic ability in order to obtain the 
proper vasculature needed for growth [33, 34]. Early research in tumor 
development using in vivo bioassays demonstrated the need for angiogenesis 
for tumor development [35] and this was confirmed by showing that VEGF 
antibodies impaired new vascularization and tumor growth [36]. These results 
are further supported by the increasing number of antiangiogenic substances 
that impair tumor growth in various mouse models [37], leading to development 
of a class of anticancer drugs known as angiogenic inhibitors that target factors 
such as VEGF and the VEGF receptor (VEGFR).  
Angiogenic signals are transmitted via receptor-ligand complexes on the 
cell surface. The ability to acquire and sustain signaling necessary for 
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angiogenesis occurs in steps during the midstages of lesion development and 
before tumors develop [4]. Some of the most common angiogenesis-initiating 
signals include VEGF and fibroblast growth factor (FGF) [34], both of which bind 
to transmembrane tyrosine kinase receptors [38]. Integrin signaling is also an 
important aspect of vasculature development. Quiescent vessels express one 
class of integrins and while growing capillaries express a different class of 
integrins, demonstrating the importance of cell adhesion to the angiogenic 
processes [4]. In addition to altered integrin signaling, cancer cells can also 
modulate transcription of angiogenesis-associated genes, resulting in increased 
VEGF and/or FGF expression compared to normal tissues [4]. Alternatively, 
some cells acquire the ability to downregulate endogenous angiogenesis 
inhibitors such as b-interferon or thombospondin-1 [4]. While the regulation of 
many of these angiogenic factors is not fully understood, there are some well-
documented examples, including thombospondin-1 regulation. The angiogenesis 
inhibitor thombospondin-1 is positively regulated by the p53 tumor suppressor, 
which is commonly mutated or inactive in cancer. Suppression of p53 activity is 
suppressed, it results in decreased levels of thombospondin-1, leading to the 
loss of its inhibitory activity [39]. These studies indicate some of the various 
mechanisms by which cancer cells can hijack normal angiogenic signaling.  
Tissue Invasion and Metastasis 
 Tumor metastasis accounts for approximately 90% of all cancer deaths 
[40], and emphasizes the importance of tumor cells to acquire the ability to 
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detach from the primary tumor and invade adjacent tissues. The mechanism of 
tumor metastasis is not completely understood, but several classes of proteins 
that are integral to this process include proteins involved in cell adherence and 
extracellular structure maintenance such as cell-cell adhesion molecules 
(CAMs), integrins, and cadherins. Studies focused on CAMs have identified N-
CAM as an important factor in neuroblastoma as well as small cell lung cancer 
during which N-CAM undergoes a switch in expression from a highly adherent 
form to a poorly adherent one [4]. Furthermore, studies in pancreatic and 
colorectal cancers have shown an overall decrease in the adherent form of N-
CAM, leading to a decrease in pro-adherent factors [41]. Functional studies on 
N-CAM support these observations and have established its role in metastasis 
suppression in mouse models since overexpression of N-CAM prevents tumor 
metastasis [41].  In addition to CAMs, integrins also play an important role in 
cancer cell invasion and metastasis. In order to adapt to the new invading 
environment, cancer cells sometimes demonstrate a shift in integrin a and b 
subunit expression, and this can also change the integrin substrate preference. 
Cancer cells typically shift integrin expression from those that favor the 
extracellular matrix present in normal epithelium to those that bind the degraded 
stromal component produced by extracellular proteases [42]. Furthermore, 
forced expression of integrins in cultured cells can induce integrin-specific 
inhibition or enhancement of this behavior, identifying integrins as key 
determinants of this process [42].  
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Genomic Instability 
 Cell cycle checkpoints pathways and tumor suppressors are key players 
in the maintenance of genomic stability and their disruption leads to instability. 
One mechanism by which genomic instability ensues is when these genetic 
“caretakers” are malfunctioning. While many cell cycle checkpoints and tumor 
suppressors are known, the most prominent member is the p53 tumor 
suppressor protein which plays an integral role in DNA damage repair in most 
human cancers [4]. Upon sensing DNA damage, the p53 protein either induces 
apoptosis or arrest of cells in G1 of the cell cycle, and also induces cyclin 
dependent kinase inhibitors [4]. The study of tumor suppressor genes and their 
behavior identified one-hit and two-hit mechanisms that explain how tumor 
suppressor genes malfunction and can drive cancer. Some tumor suppressors 
require that both alleles are lost in tumors (two hits) and this results in failure of 
cells to produce the correct protein [43]. Conversely, the one-hit hypothesis 
describes a dominant negative or haploinsufficiency expression indicating one 
mutated allele can prevent the function of normal protein from the un-mutated 
allele [43]. This mechanistic hypothesis accounts for the action of various tumor 
suppressor genes including, p53 in many cancers, the Adenomatous polyposis 
coli (APC) in colon cancer, and Von hippel-Lindau (VHL) in renal cell carcinoma 
[43]. These observations demonstrate the relative “ease” by which a single 
mutation can cause genomic instability. The loss of function of p53 and other 
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tumor suppressors allows for genome variability and mutant cells with selective 
advantages that contribute to the hallmarks of cancer. 
RHABDOMYOSARCOMA (RMS) BACKGROUND 
 Rhabdomyosarcoma (RMS) is a malignant tumor of mesenchymal origin 
arising from cells that normally develop into skeletal muscle [44] with common 
sites including the head and neck, urinary and reproductive organs, trunk, arms, 
and legs [44]. RMS is part of a large group of soft tissue sarcoma cancers  
that affect connective tissues throughout the body while RMS specifically affects 
skeletal muscle cells [44]. Soft tissue sarcomas comprise about 7% of all 
malignancies in children and adolescents under the age of 20, and RMS 
accounts for 40% of these cases [45, 46]. Overall, in the United States, there are 
approximately 350 cases of RMS in children/adolescents annually with more 
than 50% of cases occurring in the first decade of life [46]. RMS is commonly 
observed as a systemic disease, and it is likely to spread to lymph nodes, bone 
marrow, and spaces adjacent to the primary site [47]. There are three major 
subtypes of RMS, embryonal RMS (ERMS), alveolar RMS (ARMS), and 
anaplastic (undifferentiated) RMS; this thesis will focus on ERMS and ARMS. 
RMS Subtypes 
Embryonal RMS 
 Embryonal RMS (ERMS) accounts for approximately 65% of all cases of 
RMS and most commonly occurs in young patients, from birth to age 10. Tumors 
of this type are primarily observed in the head/neck region as well as the 
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genitourinary tract [47]. Additionally, there is a subtype of ERMS called boytroid 
RMS which represents approximately 7-10% of RMS cases and occurs 
commonly in the bladder, vagina, or nasopharynx [47]. Boytroid tumors exhibit a 
similar appearance to a cluster of grapes and therefore received its name for the 
Greek word for grapes, or botrys [47]. Boytroid tumors also occur during the 
same life stages as ERMS. ERMS and boytroid RMS do not have characteristic 
abnormalities, but often exhibit loss of heterozygosity or imprinting in the short 
arm of chromosome 11 [47].  
Alveolar RMS 
Alveolar RMS (ARMS) is common in children and adolescents and 
comprises approximately 25% of all RMS cases [47]. ARMS tumors are 
commonly found in the extremities or on the trunk of the body [47]. This tumor 
type gets its alveolar name because it has a similar histological appearance to 
lung tissue [47]. ARMS is also distinguished from ERMS and boytroid RMS 
because of a characteristic chromosomal abnormality in the form of a 
chromosomal translocation. This translocation is present in the majority of 
ARMS tumors and is the result of the translocation of chromosomes 13 and 
either 2 or 1, to form the PAX3-FOXO1A and PAX7-FOXO1A fusion genes, 
respectively. Those patients with the t(2;13) translocation are usually older than 
5 years of age and exhibit a worse prognosis than younger patients that 
commonly have the t(1;13) translocation [48, 49]. While the histology and 
chromosomal characteristics of each RMS subtype are different, one common 
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feature is that they stain positive for vimentin and desmin as well as myosin, 
MyoD1, and myogenin upon immunohisotchemical analysis [47].  
RMS Etiology & Risk Factors 
 There are a variety of factors that are associated with the development of 
RMS. Childhood cancers usually have a relatively short lag time between 
exposure and disease onset [50] which means early childhood diseases such as 
RMS could manifest after prenatal or early infancy exposures. Previous studies 
have found that individuals that have undergone radiotherapy for a previously 
treated cancer have been known to develop soft tissue sarcomas in the 
irradiated area [47]. While evidence of environmental exposure has not been 
shown to result in RMS, there is evidence demonstrating that most cases are 
sporadic and only 7-33% of RMS results from a familial predisposition, such as 
Li-Fraumeni syndrome and neurofibromatosis [51]. In addition, pleuropulmonary 
blastoma with DICER1 mutations [52, 53], Beckwith-Widemann syndrome [54], 
as well as Noonan syndrome [55, 56] have all been associated with 
predisposition to RMS. 
  Studies have shown that some genetic aberrations are associated with 
RMS, including TP53 mutations [57] and RMS tumors are often characterized by 
overexpression of insulin-like growth factor 2 (IGF2). Very little information has 
been gathered regarding environmental factors that lead to increased 
susceptibility to childhood cancers such as RMS but recent studies have found 
parental use of marijuana, maternal stillbirth history, prenatal X-ray exposure, 
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higher maternal age at childbirth, and high birth weight as contributing factors in 
RMS development [51, 58].  
Diagnosis & Staging 
 There are a variety of ways to diagnose a case of RMS since clinical 
presentations vary with age at diagnosis, tumor site, and other factors. The 
presence of abnormal chromosomes and genetic markers can inform or confirm 
diagnosis when microscopic and immunohistochemical analysis tests are 
inconclusive [47]. Such techniques also can provide additional information on 
ensuing disease behavior and biology as each RMS subtype has a distinct 
histological and chromosomal abnormalities [47]. ERMS has the appearance of 
embryonic muscle tissue upon microscopic evaluation [47]. Patients with RMS 
will usually present with an enlarging mass that may obstruct the sinus, nasal 
cavity, or blood vessels, and can also cause nerve, bowel, and urinary tract 
compression [47]. Additionally, a painless mass on the trunk of the body may 
cause a patient to seek medical attention. An MRI for the patient is usually the 
first test to determine the presence of a tumor. Furthermore, an open incision or 
needle biopsy is needed to establish a diagnosis and it will also be used for 
chromosomal analysis if the lesion is malignant [47]. RMS also has a tendency 
to spread to lung parenchyma [47].   
RMS Patient Staging 
Patient outcome and risk stratification for RMS patients is based on both 
pretreatment staging as well as surgical groupings established by the Intergroup 
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Rhabdomyosarcoma Study Group (IRSG), now called Children’s Oncology 
Group (COG). Pretreatment staging is performed before any therapeutic 
intervention occurs while surgical or clinical groupings are determined following 
initial surgical intervention but before chemotherapeutic intervention; the latter is 
based on the extent of residual tumor and lymph node involvement after surgery 
[59]. The COG represents the most comprehensive and up to date resource for 
RMS therapeutics and outcomes and they commonly recruit patients for long-
term treatment studies. Furthermore, the classifications set forth by the COG are 
widely used by facilities that commonly see RMS patients. Furthermore, the 
COG has put forth staging groups from 1-4, which specifies tumor site and 
presence of metastasis [47] (Figure 2).  
 
 
Figure 2. Children’s Oncology Group (COG) Pretreatment Staging Classifications. COG staging 
includes 4 stages that uses tumor site, size, lymph node involvement, and metastasis status to determine 
staging and subsequent treatment. Reprinted with permission: Denes FT Pediatric Genitourinary Oncology 
Frontiers in Pediatrics 1;48 2013. 
 
 
Stage 1 includes orbit, head/neck, and biliary tract tumor sites with no 
metastasis, and tumor size ranging from 0 cm to >5 cm. Stage 2 includes 
bladder/prostate, extremity, parameningeal tumor sites with no metastasis and a 
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tumor size of <5cm. Stage 3 encompasses the same tumor sites, size, and 
metastasis status as Stage 2, but differs in lymph node involvement. Stage 4 
includes any tumor site, tumor size from 0 cm to >5 cm, various lymph node 
involvement, and metastases present. In addition to the use of staging, the COG 
also uses surgical/clinical Group classifications to produce a comprehensive risk 
stratification scheme [47]. Group I describes local, completely resected tumor. 
Group II defines total resection with evidence of regional spread. Group III 
describes a biopsy or incomplete resection and residual disease present, while 
Group IV describes distant metastatic disease. The majority of patients 
(approximately 50%) have Group III disease while the remaining patients have 
Group I (15%), Group II (20%), or Group IV (15%) [60]. 
Using both the staging information as well as the surgical/clinical group 
classifications, the COG has developed four risk groups, Low (subset 1), Low 
(subset 2), Intermediate, and High. Each risk stratification group is associated 
with a Stage, Group, and RMS subtype (either ARMS or ERMS). The 5-year 
failure free survival (FFS) of Low risk (subset 1) is 90%, while that of Low 
(subset 2) is 87%. Moving from Low to Intermediate decreases the 5 year FFS 
to 65-73%, while High risk has a FFS of less than 30%. 
RMS Treatment Strategies 
 Most cases of RMS require a multimodal therapeutic approach which 
usually will include a combination of systemic chemotherapy with either surgery, 
radiation therapy, or both, to maximize tumor control with surgical resection 
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performed first [61, 62]. Furthermore, treatment regimens are usually determined 
by risk group (I,II,II,IV) with surgery and radiation therapy used for local control 
management while chemotherapy is used for systemic control. Yet another 
variable factor in a treatment regimen depends on the coordinating group with 
the major groups including Children’s Oncology Group (COG), Intergroup 
Rhabdomyosarcoma Study Group (IRSG), and International Society of Pediatric 
Oncology Malignant Mesenchymal Tumor (MMT) Group, all of which differ in 
management and treatment philosophies [62]. For example, the primary goal of 
the COG is to utilize local therapy following surgical resection to obtain event 
free survival as the target endpoint, while MMT employs chemotherapy as a 
front line therapeutic and the use of surgical resection only when the patient 
demonstrates a poor clinical response to initial chemotherapy; the goal of the 
latter approach is to avoid major surgical procedures and the damaging effects 
of radiation therapy [62].  
Recent observations of clinical groups have found local recurrence as the 
primary site of treatment failure in those patients initially presented with localized 
RMS. While surgical removal as an initial therapy has shown promise, this 
approach has had minimal success in patients with metastatic disease [63]. 
Furthermore, patients with only microscopic residual tumor following surgery 
generally have an improved prognosis over those that undergo debulking 
surgery (leaving macroscopic residual tumor) followed by chemotherapy or 
radiation therapy [63].  
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As local control and recurrence is a significant problem in children with 
RMS, radiation therapy is commonly used to gain local control. A recent IRSG 
study found those patients that achieve complete remission with chemotherapy 
and surgical intervention had a 20% relapse rate if in Groups I to III, while the 
relapse rate for patients in Group IV was 30% [64]. As an alternative, radiation 
therapy has been successful in achieving local control for patients with a lower 
relapse rate [64]. There has been some success in ERMS patients that undergo 
radiation therapy whereas in most ARMS patients radiation therapy does not 
achieve local control of the tumor site [65]. Furthermore, radiation therapy is 
recommended at all COG risk levels (Groups I,II,III,IV) regardless of ARMS or 
ERMS classification, with the exception of Group I ERMS patients [66]. In 
addition to gaining local control, metastasis to extremity sites is a common 
problem in RMS, especially in high risk groups. Pooled analysis from four RMS 
study groups showed regional lymph node involvement was two times higher in 
ARMS when compared to ERMS [67], and intensity modulated radiation therapy 
can successfully manage extremity RMS as well as provide optimal soft tissue 
targeting [68].  
Chemotherapeutic treatment options after surgery for patients can vary 
depending on staging, tumor site, and age, among other factors. Across all of 
the major study groups, chemotherapy is recommended at some point during 
the course of treatment with the intensity and duration dependent upon the risk 
group. It is the general trend that adolescents treated for RMS experience 
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decreased adverse side effects than younger patients [69]. A recent COG study 
for low risk RMS patients achieved close to 90% survival rate after treatment 
with a combination of vincristine and dactinomycin followed by radiation therapy 
[70]. Previous studies have found vincristine, dactinomycin, and 
cyclophosphamide (VAC) chemotherapy for 43 weeks to be successful in 
obtaining a 5-year FFS of 93% compared to previous treatments of vincristine 
and dactinomycin (VA) for 54 weeks resulting in an 83% FFS in a previous study 
[70]. Furthermore, there has been success and improvements in 5 year FFS with 
the addition of cyclophosphamide to VA therapy [70]. Treatment of metastatic 
and or intermediate risk group disease are commonly administered VAC therapy 
which has been established as the standard regimen and has been successful in 
eliminating residual tumor from metastatic sites [52]. Despite these efforts, a 
curative outcome is achieved in less than 30% of those patients with a high-risk 
classification [71].  
While there has been treatment success with the addition of 
cyclophosphamide, it has been advised to keep the dose as low as possible due 
to the side-effects which may include myelosuppression, infectious 
complications, as well as infertility in all men and some women [72, 73]. A 
comprehensive cohort study published in 2013 investigated a variety of clinical 
outcomes to determine the prevalence of chronic health conditions of adults 
treated for childhood cancer. The study found a high incidence of 
cardiomyopathy from anthracyclines, such as cyclophosphamide, which is a 
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common component of the multi-modal treatment strategy [74]. Thyroid 
disorders from radiation are also a common adverse effect as a result of the 
common area of tumor occurrences of the head and neck [74]. Additionally, 
male and female infertility and reproductive dysfunctions were observed in 
patients treated with radiation therapy, a common treatment modality for RMS 
tumors occurring in the bladder and reproductive region [74]. In addition to these 
effects, neurocognitive impairment from cranial irradiation or neurosurgery are 
also observed and these treatments are commonly used with RMS patients [74]. 
The currently used treatments for RMS are also associated with various 
adverse health outcomes. It is estimated that one-third of childhood cancer 
survivors report severe or life-threatening complications up to 30 years after 
primary diagnosis and 95% of adults treated for childhood cancer have chronic 
health condition while 80.5% develop a life threatening chronic condition [75].A 
large cohort study of survivors of young adult cancers found a 2-fold increased 
hospitalization risk in those that achieve 5-years of recurrence free disease. This 
increased risk does not decrease in 20-year survivors, indicating the health 
burden of young adults that have been previously treated for cancer [76]. 
Several large studies have observed childhood cancer survivors to have a 6-fold 
increased risk in developing a secondary cancer and this risk continues from 
remission into adulthood [75, 77]. Furthermore, long term childhood cancer 
survivors have an estimated 8.4-fold increased risk of premature death when 
compared to age and sex-matched controls in the general population [78], and 
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also have a 6-fold increased risk for developing a second cancer [79]. Late stage 
treatment associated mortalities often occur as a result of the development of 
respiratory, circulatory, and second cancers, with an increased relative risk of 
14.8, 12.7, and 11.6, respectively [80].  
To aid in the characterization and evaluation of adverse events, the 
National Cancer Institute has established a new set of guidelines called, the 
National Cancer Institute’s Common Terminology Criteria for Adverse Events 
(CTCAE)), providing a common system for grading severity of adverse 
outcomes in cancer patients, and is widely used in clinical trials [81]. This 
system has established guidelines for the evaluation of late stage adverse 
events, including growth, developmental, and cognitive disorders, as well as 
cancer development. These guidelines are applicable for late stage adverse 
events, while there is still a need for guidelines for acute stage adverse events 
[81], which will aid in system harmonization and collaborative work. 
NOVEL DRUG TARGETS 
 Due to the various adverse outcomes that have been associated with the 
current RMS treatments as well as the minimal 5-year survival of ARMS 
patients, recent studies have brought to light various novel drug targets that can 
be utilized for treating this decrease. Recently the National Cancer Institute 
Pediatric Oncology Branch conducted a pilot study utilizing cryoreductive 
treatment followed by T-cell therapy in addition to a tumor vaccine which 
resulted in minimal toxicity and improved outcomes in those with the most 
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aggressive ARMS subtypes, including PAX3-FOXO1 fusion positive cases [82]. 
There also is a current clinical trial that is studying the effectiveness of 
etoposide, an established chemotherapeutic, in combination with vorinostat, a 
histone deacetylase (HDAC) inhibitor [83].  
 HDAC inhibitors were initially used as mood stabilizers and anti-epileptics 
but recently have been investigated for their effectiveness as chemotherapeutics 
for treating acute myeloid leukemia, acute lymphoblastic leukemia, lung cancer, 
and breast cancer, among others [84, 85]. HDACs are a part of the epigenetic 
machinery that are responsible for the accessibility of DNA for transcription. 
Histone acetyl transferases act to acetylate lysine residues on histones, resulting 
in less compact and more transcriptionally active chromatin, whereas histone 
deacetylases remove acetyl groups from lysine residues, making the chromatin 
condensed and transcriptionally silent [86]. Previous studies have found that 
HDAC inhibitors exhibit antiproliferative activity, cell cycle arrest, induction of 
apoptosis and tumor growth inhibitory activity [86].  
Previous studies have utilized genomic analysis of patients and have 
reported that skeletal muscle or RMS exhibit higher levels of ROS than other 
cancer cells and are therefore more highly sensitive to inducers of oxidative 
stress [87]. This observation is thought to occur because of high basal levels of 
ROS, leaving minimal tolerance for additional oxidative stress. This observation 
has been confirmed in studies showing RMS tumor growth inhibition after 
treatment with ROS inducers [87], which also inhibit growth of pancreatic cancer 
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cells and tumors [87]. This mechanism is believed to be due to a novel 
epigenetic mechanism by which ROS-inducing HDAC inhibitors decrease RMS 
cell and tumor growth by first targeting cMyc, resulting in downregulation of 
microRNAs and induction of ZBTB transcriptional repressors, which in turn 
downregulate Sp transcription factors; the latter of which are overexpressed in 
many cancers and regulate numerous pro-oncogenic genes [88, 89] (Figure 3). 
 
 
Figure 3. ROS agents regulate Sp-regulated genes. ROS agents downregulate cMyc and Myc regulated 
miR-27a and miR-20a/miR-17, resulting in induction of miR-regulated transcriptional repressor 
ZBTB10/ZBTB34 and ZBTB4. Reprinted with permission: Safe S MicroRNA-Specificity Protein (Sp) 
Transcription Factor Interactions and Significance in Carcinogenesis Current Pharmacology Reports 1:2; 
2015. 
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regulated genes are themselves individual drug targets for treating RMS, and 
these include genes such as CXCR4, cyclin D1, epidermal growth factor 
receptor (EGFR), bcl-2, hepatocyte growth factor receptor (c-MET), and platelet-
derived growth factor receptor a (PGFRa), which are important for RMS cell 
growth, survival, and angiogenesis [88]. Furthermore, Sp transcription factors 
serve as a promising drug target as evidenced by results of a phase I/II clinical 
trial evaluating the effectiveness of mithramycin in solid tumors, such as RMS 
[91]. Mirthramycin acts by decreasing chromatin accessibility by binding to GC-
rich promoter sequences, resulting in decreased Sp binding to oncogenic 
promoters [90]. Furthermore, studies in this laboratory show that ROS-inducing 
anticancer agents downregulate cMyc (epigenetic) and Myc-regulated miR-27a 
and or miR-20a/miR-17 resulting in increased expression of the miR-regulated 
transcriptional repressors ZBTB10/ZBTB34 and ZBTB4 [92-94] (Figure 3). The 
ZBTB family of proteins competitively bind and displace Sp transcription factors 
from Sp-regulated gene promoters and GC-rich sites and thereby decrease 
gene expression [95]. Previous studies using panobinostat as an ROS inducer in 
RMS cells resulted in activation of this pathway (Figure 3) and demonstrate that 
Sp transcription factors (Sp1, Sp3, Sp4) are a novel drug target for RMS 
treatment [96]; The results also show that Sp transcription factors are also 
important for maintaining the RMS phenotype and exhibit properties of non-
oncogene addiction genes [97]. 
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 One of the most promising drug targets at the forefront of RMS 
therapeutics is the fusion protein PAX3-FOXO1. The PAX3-FOXO1 fusion gene 
results from the chromosomal translocation between chromosomes 2 and 3 and 
is a genetic signature of ARMS [98]. This translocation fuses the DNA binding 
domain of PAX3 with the transactivation domain of FOXO1 [98]. PAX3 and 
FOXO1 are transcription factors and, this fusion gene results in the generation of 
a novel transcription factor with altered transcriptional targets as well as post-
translational regulation [98]. While a relatively small number of tumors harbor a 
PAX7-FOXO1 translocation from the rearrangement of chromosomes 1 and 13, 
the clear majority of patients harbor the PAX3-FOXO1 fusion gene [98]. PAX3-
FOXO1 also has clinical relevance as a prognostic factor since studies have 
found those patients expressing the PAX3-FOXO1 fusion gene are classified as 
a high risk subgroup [99]. This high-risk group also has a high rate of relapse, 
metastasis, and drug resistance [98]. Furthermore, initial studies on PAX3-
FOXO1 found its expression to result in anchorage-independent growth and 
when expressed as a single genetic change, failed to cause tumorigenesis in 
vivo [100]. These early observations suggest this fusion gene contributes to 
oncogenesis but cannot alone cause tumorigenesis, which requires additions 
genetic lesions. Later studies using ectopically expressed PAX3-FOXO1 in cells 
that do not normally express PAX3-FOXO1 found it to contribute to 
tumorigenesis by several mechanisms, including increased proliferation, support 
of cell survival, and inhibition of differentiation [98].  
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 While initial studies identified the role of PAX3-FOXO1 in ARMS 
tumorigenesis, later studies identified the transcriptional targets by which PAX3-
FOXO1 exerts its tumorigenic effect. While a variety of genes have been 
identified, they can be clustered into groups that are involved in myogenic 
differentiation, myogenic signaling, and transcription factors involved in 
mesoderm development [101], and these include MyoD1, DAPK1, Nmyc, and 
RASSF4, among others. Furthermore, genomic analysis revealed that the genes 
expressed in RMS are closer to that of fetal muscle than of normal muscle, 
which suggest that the embryonic transcriptional programs are illegitimately 
reactivated [102]. PAX3-FOXO1 also has the ability to promote several 
characteristics of cancer hallmarks. Studies have shown PAX3-FOXO1 
expression results in stimulation of cell proliferation, as evidenced by an 
increased proliferation rate and growth in low-serum conditions [103]. Also, 
ectopic expression of PAX3-FOXO1 accelerated the transition of cells from 
G0/G1 to S phase by increasing the degradation of cyclin dependent kinase 
inhibitor 1B as well as cyclin dependent kinase inhibitor 1C [104]. In addition to 
modulating cell proliferation, PAX3-FOXO1 also plays a major role in promoting 
cell survival and this conclusion is supported by downstream targets of PAX3-
FOXO1 that are involved in cell survival. Inhibition of PAX3-FOXO1 also causes 
decreased expression of the anti-apoptotic protein Bcl-XL which is regulated by 
both PAX3 and PAX3-FOXO1 [98]. Furthermore, PAX3-FOXO1 suppresses 
terminal differentiation which is an important characteristic since the ability to 
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ignore or suppress differentiation signals contributes to tumorigenesis [105]. 
Evidence to support this comes from studies in murine myoblasts transfected 
with MyoD1 that showed PAX3-FOXO1 inhibition of low serum-induced 
myogenic differentiation [106]. This mechanism is thought to be due in part to an 
indirect loss of function of cyclin dependent kinase inhibitor 1C, which is a cell 
cycle regulator known to effect terminal differentiation [107]. In addition to these 
characteristics, there is some evidence suggesting that PAX3-FOXO1 plays a 
role in tumor angiogenesis. Subcutaneous injection of RMS cells that do not 
express PAX3-FOXO1A develop fewer blood vessels in the xenografts. This 
process is thought to be controlled by regulation of VEGF signaling as a 
potential target of PAX3-FOXO1 [108]. However, comparable experiments with 
ARMS cells lines that express PAX3-FOXO1 exhibit upregulation of VEGFR1, 
and increased angiogenesis [109]. One of the most widely studied 
characteristics of ARMS cells includes their propensity to metastasize and there 
is evidence suggesting that PAX3-FOXO1 is promotes a metastatic phenotype. 
For example, when PAX3-FOXO1A is ectopically expressed in ERMS cells, 
these cells exhibit heightened invasion and increased matrix metalloproteinase 
MMP-2 activity [103, 110]. In terms of this mechanism, upregulation of 
chemokine receptor CXCR4 by PAX3-FOXO1 is thought to be a major player 
due to its role in regulating the cell microenvironment [111]. These observations 
demonstrate the important role of PAX3-FOXO1 in the growth, invasion, and 
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metastasis of ARMS which is consistent with the poor prognosis of patients with 
ARMS. 
 The mTOR pathway is often dysregulated in RMS, and has been linked to 
reduced survival and promotion of cell growth; therefore, it represents a 
therapeutic target in RMS. The Preclinical Pediatric Testing Program (PPTP) 
has utilized an mTOR inhibitor, AZD8055, that exhibits antitumor activity in vivo 
[112]. They have also utilized another drug, ABT-737, that is a novel inhibitor of 
the antiapoptotic proteins Bcl-2 and Bcl-XL and has greater efficacy than 
previous Bcl-2 inhibitors because it has a higher affinity for Bcl-2 [112]. Recently, 
the synergistic effect of both ADZ8055 and ABT-373 has been reported and this 
combinatorial therapy induces apoptosis by triggering loss of mitochondrial 
membrane potentiatial, and activation of caspases [112]. 
Receptor tyrosine kinases also represent potential RMS drug targets. 
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase 
responsible for cell survival and proliferation and is inversely correlated with 
patient survival in head/neck, ovarian, cervical, bladder, and oesophageal 
cancer [113]. EGFR is commonly overexpressed in cancer and is mutated in 
47% of RMS cases [113]. PDGFRa is mutated in more than 40% of RMS cases 
and has been shown to be a transcriptional target of PAX3-FOXO1A [114]. 
Previous studies have used RNA interference and PDGFRa neutralizing 
antibodies to decrease tumor volume in in vivo mouse studies [114]. In addition 
to PDGFRa, cMET is a receptor tyrosine kinase involved in growth, invasion, 
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and metastasis [114]. cMet is also a downstream target of PAX3-FOXO1A and 
is overexpressed in more than 50% of RMS patient samples and also in RMS 
cell lines [115]. Treatment with MET inhibitors, such as SU11274, inhibited RMS 
cell proliferation and migration via G1 cell cycle arrest in vitro [115].  
NUCLEAR RECEPTORS 
Structure, Function and Location  
 The nuclear receptor (NR) superfamily of transcription factors include 
nuclear hormone receptors, enigmatic receptors, adopted orphan and orphan 
receptors. Nuclear hormone, enigmatic, and adopted orphan receptors have 
endogenous ligands whereas ligands for orphan nuclear receptors have not yet 
been identified. Nuclear hormone receptors are ligand-activated transcription 
factors that bind glucocorticoids, mineralcorticoids, sex steroids, thyroid 
hormones, and vitamin-derived ligands [116]. One of the unique properties of 
nuclear receptors is their ability to directly interact with DNA and regulate 
expression of genes that play a role in embryonic development as well as adult 
homeostasis. Nuclear receptors regulate expression of target genes through 
recruitment of various coactivators, corepressors, and other nuclear factors 
[117]. Coactivation recruitment is an integral step in ligand-induced transcription 
whereas recruitment of corepressors mediates repression of non-ligand bound 
nuclear receptors [117] and these interactions regulate various physiological 
responses in the cell. 
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While their ligands may vary, nuclear receptors have common structural 
features, which include an amino-terminal activation domain (AF-1) a DNA 
binding domain (DBD), a hinge region, a conserved ligand binding domain, and 
a second activation domain (AF-2), which is located at the carboxy-terminal end 
[116]. DBD of NRs are highly conserved zinc finger proteins and responsible for 
targeting the receptor to specific DNA sequences, known as response elements 
[116]. The ligand binding domain recognizes and binds specific ligands that 
dictate the biological response. Nuclear receptors can exist as homo or 
heterodimers and each partner can bind to specific response element 
sequences that are represented by half-sites separated by nucleotide spaces 
between direct or inverted half-site repeats [116].  
NRs can be categorized by their interactions with other nuclear receptors 
to form homo- or heterodimers. Class 1 receptors function as homodimers that 
bind to half site response element inverted repeats and include the steroid 
hormone receptors [116]. In the absence of ligand, these receptors are primarily 
in the cytosol bound to heat shock proteins; and upon ligand binding, they 
translocate into the nucleus, bind to hormone response elements and recruit 
coactivators and other nuclear factors to initiate transcription of target gene 
sequences [116].  Class 2 receptors exist as heterodimers that act in 
combination with RXR receptor partners and function in a ligand dependent 
manner. This class of receptors remain in the nucleus regardless of ligand 
binding [116], in the absence of ligand, these receptors are often bound to 
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corepressor proteins. Ligand binding induces both dissociation of the bound 
receptor from corepressors and recruitment of coactivators for initiation of 
transcription [116]. The remaining two NR classes include orphan nuclear 
receptors that either function as homodimers that bind direct response element 
repeats (Class 3), or monomers that bind single site response elements (Class 
4) [116]. Nuclear receptors play a role in almost all aspects of human physiology 
and therefore, represent important therapeutic targets for various diseases. This 
underscores the importance of studying these systems for new drug 
development across many areas of study. The 48 NRs have been extensively 
investigated; this review will focus on selected receptors that are important in 
various disease processes and are drug targets. 
Nuclear receptors can also be divided into groups based on their 
endogenous ligands. The endocrine receptors include steroid hormone 
receptors that bind steroid hormones such as 17b-estradiol (E2) and also 
heterodimeric receptors that partner with retinoid X receptor (RXR) and bind 
thyroid hormones, retinoids, and vitamin D [116]. Research on endocrine 
receptors and their ligands has led to the development of selective receptor 
modulators (SRMs) for the endocrine receptor that exhibit tissue specific agonist 
or antagonist activity and are commonly used in treating hormone-dependent 
diseases, such as ER positive breast cancer [116]. The second type of nuclear 
receptors are adopted orphan receptors that initially were not associated with an 
endogenous ligand, but were identified in subsequent studies [116]. The 
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adopted orphan receptors are divided further into two major groups one of which 
include the lipid sensor receptors such as the retinoid X receptor (9-cis-retinoic 
acid), peroxisome proliferator-activated receptors (PPARs) (fatty acids), liver X 
receptor (oxysterols), farnesoid X receptor (bile acids), and pregnane X receptor, 
which binds cholesterol derivatives [118]. The other subgroup are the enigmatic 
orphan receptors and these include constitutive androstane receptor 
(androstane and drugs/xenobiotics), hepatocyte nuclear factor-4, steroidogenic 
factor-1/liver receptor homolog 1(LRH-1) (phospholipids), and retinoid acid-
related orphan receptor (cholesterol and retinoic acids) [116, 118]. The third 
class of nuclear receptors are orphan receptors for which endogenous ligands 
have not yet been identified.  
Estrogen Receptors 
ER Structure Binding and Activation 
There are several well defined nuclear receptor (NR) systems that have 
been studied for their biological relevance as well as their clinical implications. 
One such example is the estrogen receptor (ER) which belongs to the Class 1 
category of the nuclear receptor superfamily of ligand activated nuclear 
receptors and ER has also been classified as an endocrine type nuclear 
receptor. Two subtypes of ER have been identified, namely ERa (NR3A1) and 
ERb (NR3A2) (Figure 4).  
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Figure 4. Estrogen receptor isoform homology and organization of the two isoforms. Different 
domains are highlighted in different colors: NTD—amino terminal domain—in red; DBD—DNA binding 
domain—in green; hinge region—in blue; LBD—ligand-binding domain—in yellow; F region located towards 
the C-terminal end—in grey. Amino acid sequence position is given for each domain. Reprinted with 
permission: Kumar R The Dynamic Structure of the Estrogen Receptor Journal of Amino Acids vol 2011, 
article ID 812530 
 
 
The ER binds to cis-acting estrogen response elements (EREs) to facilitate 
transactivation and the DBD is the most conserved region of the ER [119]. The 
ER acts in the nucleus as a homodimer to regulate expression of genes through 
interactions with and recruitment of coactivators and corepressors on EREs or 
modified/imperfect EREs. [119].  
ERs regulate gene transcription via two major pathways which include 
direct recruitment of the ER to ERE promoter region or through protein-protein 
interactions with other DNA-bound transcription factors where the ER acts as a 
ligand-activated cofactor. In the absence of a hormone/ligand, the ER is 
sequestered in the cytosol as an inhibitory complex with heat shock protein 90 
(Hsp90) and Hsp70 [119]. The addition of a ligand induces a conformational 
change in the ER, nuclear import and homodimerization and binding to specific 
DNA response elements. These EREs are palindromic half sites separated by a 
3-base pair spacer and are commonly found in promoters of the EBAG9, 
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ZNF147 (Efp), and COX7RP (5′-AGGTCAnnnTGACCT-3′) genes [120]. In 
addition to this canonical ERE sequence, there are REs that are slightly different 
from the canonical sequence and the ER binds these “imperfect” EREs identified 
in promoters of several genes including TERT, TGFa, and Lactoferrin [119]. The 
liganded ER binds with the highest affinity to canonical EREs and less efficiently 
to imperfect EREs, and this can influence ER-mediated transactivation with 
respect to the magnitude of the response and sensitivity to ligand [119]. In 
addition to direct ER/DNA interactions, ER can interact with other DNA-bound 
transcription factors and ER-protein/DNA interaction can also be activated by 
estrogens [119]. For example Specificity protein 1 (Sp1) binds to GC-rich 
promoter regions and ER can enhance Sp1 binding to DNA and estrogen 
induced transactivation [121]. Nuclear factor kB (NFkB) also interacts with ERa, 
and this inhibits NFkB/DNA binding and instead of NFkB-dependent induction of 
inteleukin-6, ligand/ER interactions decreases interleukin-6 expression [122].  
In both direct and indirect DNA mechanisms of ER signaling, the ER 
forms a complex with various cofactors that are required for ER-mediated gene 
regulation. One of the most well-characterized coactivator family includes SRC1, 
SRC2, and SRC3, of which SRC1 and -2 have the highest affinity for the AF2 
domain of agonist bound ERa [119]. SRC-family coactivators contain two 
transcription activation domains, AD1 and AD2, and they are involved in 
recruitment of CBP/p300 coactivators as well as acetyltransferases and protein 
modifying enzyme coactivator-associated arginine methyltransferase (CARM1) 
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[119], respectively. These coactivators serve to recruit chromatin-modifying 
proteins to ligand activated ERs. Other factors such as steroid receptor RNA 
activator (SRA), Med-20, and Bgr/Brm, function as a protein binding scaffolds 
and serve as a bridge between ligand bound ER and the coactivator complex 
[123]. In addition, several ER corepressors have been identified, including 
receptor interacting protein-140 (RIP-140) and short heterodimer partner (SHP), 
both of which compete for ER binding and antagonize SRC1 coactivator activity 
[123]. Both NCoR and SMRT are corepressors that inhibit ER-mediated 
transactivation and these corepressors are involved as repressors for other NRs 
[123]. In addition, sin-associated polypeptide 30 (SAP30) is important for NCoR 
mediated repression of ERa while SMRT/HDAC1 associated repressor protein 
(SHARP) indirectly represses ligand induced ERa activity by repression of the 
SRA coactivator [123]. ER and other NRs interact with multiple nuclear cofactors 
and the specific set of cofactors required for ligand-induced transactivation is 
ligand-, gene-, and cell context-dependent.  
Differential Expression of ERa and ERb and Physiological Function 
 ERa and ERb have distinct tissue distributions and this provides some 
insight on ER-isoform targeted effects in specific tissues. ERa is expressed in 
testis, ovary, kidney, bone, and adrenal tissues, with moderate amounts present 
in the prostate gland, bladder, liver, pituitary gland, and various brain sections 
[124]. High levels of ERb are found in the prostate gland, bone, and ovary [124]. 
The uterine tissue and pituitary gland are distinctive in that ERb is expressed 
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during development whereas ERa is expressed upon tissue maturation [124]. In 
the brain, ERa is found in cholinergic neurons of the basal forebrain and 
enhances cognition by modulating acetylcholine production [125]. ERa and ERb 
knockout mouse studies have been essential for determining the normal function 
of ER during all life stages.  
While ERa and/or ERb loss results in physiological alterations, this loss is 
not lethal. ERa knockout (KO) adult female mice have a hyperplastic uterus and 
are unresponsive to ERa ligands [126]. These females also demonstrate a lack 
of sexual behavior or responses, indicating a role for ERa in mediating nervous 
system effects [126]. ERa KO in male mice results in decreased sperm motility, 
sperm counts, and testis weight, resulting in infrequent ejaculations and reduced 
fertility [127]. In bone, ERa KO females also show decreased femoral length, 
diameter, and density [128]. ERa is also expressed in adipose tissue and in KO 
mice this results in a 2-fold increase in mouse weight compared to wild type 
controls [129].  ERb KO mice also exhibit physiological changes; female mice 
have decreased corpora lutea and exhibit follicular development arrest and 
decreased follicular maturation, but they exhibit normal sexual behavior and 
mammary gland structure [130]. ERb KO male mice are fertile but show 
epithelial hyperplasia in the prostate and bladder wall [130]. These mice also 
show no altered effects in bone characteristics [130], emphasizing the 
importance of ERa in bone.  
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Pathophysiological Differences of ERa and ERb 
 In humans, the ER has been implicated in several disease states. Low 
ERa expression is associated with the development of coronary artery disease 
in females since ERa is expressed in normal arteries but not in those individuals 
with coronary artery disease [124]. This observation is supported by an increase 
in silencing methylation epigenetic marks on the gene encoding ERa in human 
atherosclerotic plaques compared to normal aortic tissue. In addition, ERa 
polymorphisms are associated with increased blood pressure in men while ERb 
polymorphisms are associated with ventricular wall thickness and high blood 
pressure in post-menopausal women [124]. This observation is supported in 
animal models showing that ERb KO mice develop hypertension at a later age 
[131].  
 In addition to these non-cancer endpoints, differential ER expression is 
also associated with several cancer endpoints. In both human and rodent normal 
prostate tissue, ERb expression is higher than ERa whereas ERb expression is 
reduced in prostate tumors while epithelial hyperplasia of the prostate is 
observed in ERa KO mice [132]. In addition, ERa expression was observed in 
65% of high grade prostate tumors while ERb expression was decreased in both 
local and metastatic tumor sites when compared to normal prostate tissue [132]. 
Furthermore, aromatase-deficient mice that do not express ERb display prostate 
hyperplasia and administration of an ERb agonist suppresses that effect [132]. 
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Reintroduction of ERb signaling in prostate carcinoma cells results in 
antiproliferation, invasive and pro-apoptotic responses [132]. 
ER expression is also important in development of cervical cancer. A 
cervical cancer mouse model using HPV transgenic mice deficient in ERa 
showed that these mice fail to develop any of the progressive lesions that lead to 
cervical cancer and did not develop cervical hyperplasia when administered 
estrogen, which is common in cervical cancer development [133], indicating the 
requirement for ERa in cervical cancer development. ERα and ERb expression 
is observed in 2/3 of human ovarian tumors, and several studies show that 
expression of ERα is a predictor of overall survival compared with patients with 
ERα negative tumors [134, 135]. ERb expression was not associated with 
overall survival, but instead with chemosensitivity, treatment response, and 
decreased lymph node infiltration [134]. 
 Several studies using cell culture and animal models have demonstrated 
the role of ER in breast cancer development. ERb expression is high in normal 
mammary tissue and decreases as the tumor progresses with high ERb 
expression associated with low grade tumor, higher disease free survival rate, 
decreased metastasis and angiogenesis [136]. This indicates ERb may have a 
tumor suppressor role and loss of ERb promotes breast cancer progression 
[137]. ERα is an important biomarker in breast cancer, since approximately 70% 
of all primary breast tumors are ERα positive [136]. Breast tumors lacking ERα 
often demonstrate an aggressive phenotype while ERα expression is a favorable 
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predictor of prognosis in patients treated with endocrine therapy [136]. However, 
ERα seems to loses its prognostic potential with a longer (>5 years) follow-up 
[136].  
ER Ligands 
 Several endogenous and exogenous ligands have been identified for the 
ER. The most potent estrogen produced in the body is 17b-estradiol (E2) and its 
metabolites, estrone and estriol, have weaker agonist activity than E2. Both ERα 
and ERb have high binding affinity for E2 with KD values of .04 nM and .11 nM, 
respectively [138]. Treatment of human breast cancer cells with E2 induced 
anchorage-dependent growth and invasiveness, demonstrating its 
carcinogenicity and ER agonist activity [138]. In addition, administration of E2 to 
HPV transgenic mice results in cervical cancer development [133]. 
E2 represents a classic ER agonist that activates ER signaling and 
faslodex (ICI 182,780) is a prototypical ER antagonist that binds, inhibits, and 
promotes degradation of ERs [139]. ICI 182,780 binds both ERα and ERb with 
Kd values of .42 nM and 1.3 nM, respectively [139].  ICI 182,780 treatment is 
effective in postmenopausal women with advanced breast cancer or patients 
who have become tamoxifen-resistant, which is a common first line treatment for 
breast cancer [138]. In addition, ICI 182,780 has no estrogenic effects in target 
tissues such as the uterus and breast cancer cells and tumors that are 
tamoxifen-resistant remain sensitive to growth inhibition by ICI 182,780 [138]. In 
randomized human studies of post-menopausal women with advanced breast 
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cancer treatment with ICI 182,780 did not induce any estrogen agonist activity 
and increased the rate of remission [140].  
Selective estrogen receptor modulators (SERMs) represent a class of 
synthetic ER ligands that exhibit tissue-selective effects. SERMs can act as 
antagonists that oppose estrogen action in certain tissues, while mimicking the 
effects of estrogen in other tissue [138]. This class of compounds was initially 
developed as contraceptives, until their use as a hormonal treatment for breast 
cancer. Tamoxifen is the most studied SERMs to date and exhibits clinical 
efficacy in treating several diseases. Tamoxifen is a common first-line treatment 
for patients with ERa-positive breast cancer and demonstrates antagonist 
activity in breast [141]. Tamoxifen also exhibits agonist activity in bone and has 
been used in the treatment for bone density diseases in postmenopausal women 
[141]. One of the adverse side-effects of tamoxifen use for breast cancer is the 
increased risk of endometrial cancer development in both mice and humans 
[141]. A recent cohort study found a 69% increased incidence of endometrial 
cancer in patients treated with tamoxifen, with a 4-fold increased risk in patients 
over the age of 35 [142]. The overall risk-benefit for using tamoxifen is the low 
overall rate of endometrial cancer and this risk from can be decreased by 
decreasing the duration of treatment [142] In addition, tamoxifen administered to 
postmenopausal women prevents bone loss and results in loss of bone mineral 
density in premenopausal women [143, 144] 
 
  46 
Glucocorticoid Receptor 
GR Binding and Activation 
Glucocorticoids are steroid hormones that bind the glucocorticoid receptor 
(GR) and they are synthesized and released by the adrenal cortex in a circadian 
manner in response to various stimuli. This process is controlled by the 
hypothalamic-pituitary-adrenal (HPA) axis. The actions of glucocorticoids are 
mediated by glucocorticoid receptor (GR) binding, which is estimated to target 
10-20% of the human genome. In the absence of hormone, GR remains in the 
cytoplasm as a complex with chaperone proteins, such as hsp90, hsp70, and 
p23 [145]. These chaperone proteins help maintain a receptor conformation that 
is transcriptionally silent, but still favors ligand binding. Glucocorticoid binding 
induces a conformation change with results in the dissociation of chaperone 
proteins and exposure of its nuclear localization signal, resulting in nuclear 
translocation [146] and binding to its cognate response elements 
(GGAACAnnnTGTTCT) [147] to regulate target gene expression. The GR exerts 
its function via a glucocorticoid response element that consists of two 6-base 
pair half-sites. GR binds to its response element as a homodimer with a three 
nucleotide space [147]. Recently, a negative GR response element that is 
different from the classic GR response element has been identified (CTCC(n)0-
2GGAGA) and binding to this element mediates glucocorticoid-dependent 
repression of specific genes [146, 147]; this finding is relatively new and more 
studies are needed to elucidate the details of this mechanism.  
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The location of GR response elements and negative response elements 
have been observed to be at a considerable distance from the transcription start 
site [148], suggesting a potential for the response elements to form loops that 
facilitate interactions with the promoter area of target genes. Once bound to 
DNA, GR undergoes further conformational changes that allow for recruitment of 
nuclear cofactors and chromatin remodeling complexes. These coregulators 
include histone acetyltransferases and steroid receptor coactivators, which aid 
transcriptional activation, while NCoR and SMRT [149] are recruited for 
transcriptional repression. 
GR activation is dependent on ligand availability and chromatin 
accessibility. Some GR response elements are occupied at low concentrations 
of glucocorticoids, while others require high doses for GR binding and 
transactivation [150]. GR activation can occur via binding of endogenous steroid 
hormones such as cortisol or by synthetic ligands, including glucocorticoid 
drugs, such as dexamethasone (Figure 5) [150] and GR antagonists include 
mifepristone (RU-486) and ketoconazole. Both mifepristone and ketoconazole 
compete with GR agonists for receptor binding and result in repression of GR-
mediated gene expression [151].  In addition, selective GR modulators (SGRM), 
function in a similar matter to SERMs. SGRMs preserve the anti-inflammaotry 
and immunosuppressive (agonist) functions of glucocorticoids but do not exhibit 
the adverse effects, such as osteoporosis, diabetes, susceptibility to infection, 
and muscle atrophy [152]. 
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Figure 5. Structure of GR ligands. Cortisol is an endogenous ligand for GR while dexamethasone and 
RU-486 are synthetic ligands for GR. Reprinted with permission: Weikum E Glucocorticoid receptor control 
of transcription: precision and plasticity via allostery Nature Reviews Molecular Cell Biology 18; 2017 
 
 
 
GR Physiological and Pathophysiological Functions 
Glucocorticoids regulate various physiological functions and homeostatic 
balances, including metabolism, immune function, skeletal growth, reproduction, 
cognition, and carcinogenesis [153]. In addition to direct interactions with DNA, 
GR also interact with other transcription factors to induce physiological changes. 
Cooperative binding with members of the STAT family enhances target gene 
transcription [154]; the GR also directly interacts with proinflammatory 
transcription factors such as NFkB to suppress target gene transcription, and 
this is a mechanism for GR-mediated anti-inflammatory activity [155]. 
Glucocorticoids regulate various immune cells, such as dendritic cells, T-cells, 
and macrophages and alter or depress the immune response [155]. GR also 
acts in a sex-specific way, since glucocorticoids induce a stronger 
antiinflammatory response in male compared to female rats [156]. Additionally, 
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GR signaling enhances neutrophil phagocytosis and inhibits neutrophil infiltration 
of inflammatory sites, both of which also result in a depressed immune response 
[155, 157]. GR signaling also plays a role in inflammatory respiratory conditions 
such as asthma. These respiratory conditions are commonly aggravated by 
proinflammatory transcription factors, such as NFkB, which can be inhibited by 
glucocorticoid binding, resulting in decreased production of cytokines, 
chemokines, and cell adhesion molecules of the respiratory tract [158]. Due to 
their role in anti-inflammatory and immunosuppressive functions, glucocorticoids 
are among the most widely used drugs in the world for disease such as 
inflammatory bowel disease, asthma, and rheumatoid arthritis [152]. Despite 
their many applications, some major adverse effects of these drugs include 
osteoporosis, diabetes, obesity, glaucoma, hypertension, and growth retardation 
in children [147].  
In addition to these physiological effects, GR signaling also exerts anti-
proliferative and anti-apoptotic activity via its ligand-binding interactions. Studies 
have found that GR is expressed at high levels early during breast cancer 
development with expression levels decreasing during progression [159]. 
Furthermore, GR expression is associated with a favorable outcome [159]. In 
addition to breast cancer, glucocorticoids have also been used to treat lymphoid 
malignancies, such as acute lymphoblastic leukemia, chronic lymphocytic 
leukemia, and Hodgkin’s lymphoma [160]. The synthetic glucocorticoid drug 
dexamethasone is widely used and induces apoptosis in hematopoietic 
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malignancies. GR-mediated apoptosis occurs through various mechanisms, 
including activation of pro-apoptotic genes such as Bim and via NF-kB mediated 
downregulation of survival cytokines [161]. Recent studies have also identified a 
new role for GR signaling in mitosis since GR signaling is necessary for mitotic 
progression and knockdown of GR results in increased genetic aberrations and 
increased time to complete mitosis [162]. Furthermore, GR haploinsufficient 
mice have increased tumor formation [162]. These results indicate a role of GR 
and GR dependent signaling in tumorigenesis as well as in tumor formation.  
Retinoid X Receptors (RXR) 
RXR Structure and DNA-binding 
RXR belongs in the adopted orphan nuclear receptor subclass and 
includes three members, RXRa, RXRb, and RXRg, all of which have structural 
similarities. RXR exerts its function by heterodimerization with several other 
nuclear receptors including Constitutive androstane receptor (CAR), peroxisome 
proliferator-activated receptor (PPAR), and retinoic acid receptor (RAR) and 
functions as ligand activated transcription factors. Furthermore, RXR binds to 
specific hormone response elements (‘5-AGGTCA-3’) to regulate target gene 
transcription. This receptor primarily functions as a heterodimeric partner for 
other nuclear receptors that regulate retinoid and other signaling pathways [163]. 
Mutations to the amino acid sequence, such as tyrosine 402 in the helical 
structure of RXR, results in diminished capacity for form heterodimers, in which 
case homodimer formation is enhanced [164]. RXR interactions with other 
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nuclear receptors are linked to its potential to induce pleiotropic effect on various 
physiological pathways.  
RXR Ligand Binding and Dimerization 
Ligands for RXR have been identified and include 9-cis retinoic acid (RA) 
synthetic ligands called rexinoids that are RXR selective, phytanic acid, and 
decosahexaenoic acid [165, 166]. While 9-trans and -cis RA can bind all RXR 
isoforms, 9-cis RA has the highest affinity for RXRa [167]. Despite identification 
of these ligands, none have proven to be endogenous ligands for RXR. RXR is 
subject to ligand induced conformational change [168] which allows for homo or 
heterodimer formation. The conformational changes induced by ligand binding 
also repositions the protein into an active conformation that facilitates coactivator 
binding [169]. RXR signaling by rexinoid binding has been shown to increase 
oxidation and uptake of saturated fatty acids in diabetic skeletal muscle cells, 
which is important since insulin resistance is associated with intramuscular 
saturated fatty acid accumulation [170]. 
Some RXR target genes, such as fatty acid transporter (FAT/CD36) are 
upregulated in response to RXR ligand binding and increased FAT/CD36 
expression has been associated with increased uptake of saturated fatty acids 
into skeletal muscle cells [171]. In addition to FAT/CD36 upregulation, binding of 
other synthetic ligands to RXR resulted in induced expression of UCP3 
(Uncoupling protein 3) and PDK4 (pyruvate dehydrogenase lipoamide kinase 
isoenzyme 4) in skeletal muscle cells of mice and both of these genes lead to 
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increased uptake of saturated fatty acids [172, 173]. This demonstrates a 
mechanism by which RXR ligands can increase fatty acid uptake and oxidation 
and insulin sensitization.  
RXR Physiological and Pathophysiological Function 
RXRa is expressed in liver, kidney, spleen, and placenta tissues while 
RXRb is widely expressed and found in almost all tissues throughout the body 
[167]. In contrast, RXRg localization is limited to the muscle and brain [167]. 
While all three members of the RXR subfamily have similar structural 
homologies, their expression patterns can vary, and this may have implications 
for their respective functions. This diverse expression patterns observed for RXR 
is demonstrated by its varied role in pathophysiological and metabolic functions.  
Other nuclear receptors that regulate gene expression in cardiac 
metabolism, namely PPARa and LXR, require RXR as a heterodimeric partner 
[174], One example of this interaction is the role of PPAR, LXR, and RXR in 
atherosclerosis and cholesterol metabolism. Common lipid components of 
atherosclerotic plaques, such as 9- and 13-hydroxyoctadecadienoic acid, serve 
to activate PPAR, which leads to the transcriptional activation of LXR [175, 176] 
and thereby induction of key lipid transporters, ABCA1 (Cholesterol efflux 
regulatory protein) and ABCG1 (ATP binding cassette subfamily G member 1) 
[176]. This is indicative of a coordinated role of both LXR and PPAR in lipid 
signaling. RXR can play a role in this process via heterodimeric binding to LXR, 
resulting in formation of a complex that can be activated by oxysterol ligand 
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binding to LXR or rexinoid binding to RXR [177]. This suggests that rexinoids 
have the ability to regulate lipid homeostasis implicated in cardiovascular 
disease.  
In addition to their role in cardiovascular disease and metabolic 
processes, RXR signaling is also important in cancer. For example, RXR can 
cooperate with RAR to induce differentiation and apoptosis, which have direct 
protective effects on cancer development and growth. RXR activation induces 
apoptosis in immature acute promyelocytic leukemia cells while RXR 
antagonism inhibits this process [178]. Apoptosis of immature hematopoietic 
cells is regulated by RXR while apoptosis of mature hematopoietic cells is 
triggered by RAR agonists via induction of TRAIL (TNF-related apoptosis 
inducing ligand) [178], indicating distinctive roles of RXR and RAR signaling in 
triggering apoptosis. In addition to leukemia, RXR signaling also induces 
apoptosis in the retinoic acid resistant breast cancer cell line MDA-MB-231 via 
RXR/Nur77 heterodimers [179] and an unknown downstream mechanism. In 
addition to leukemia and breast cancer, RXRa knockout in an F9 murine 
embryonal carcinoma cell line resulted in impaired apoptosis and decreased 
proliferation as evidenced by chromatin condensation along the nuclear 
membrane, apoptotic bodies and endocytosis by nearby cells [180].  
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Peroxisome Proliferator-activated Receptors 
(PPAR) PPAR Structure and DNA-binding 
 Peroxisome proliferator-activated receptors (PPAR) also have diverse 
roles and regulate multiple biological pathways, including cellular differentiation, 
diabetes, atherosclerosis and cancer.  Studies on this receptor have shown that 
PPAR exerts its function through heterodimer formation with one of the retinoid 
X receptors (RXR) [181]. There are several PPAR isoforms, including PPARb/d 
PPARa, and PPARg (Figure 6), all of which bind to a PPAR response element 
(‘5-AGGTCANAGGTCA-3’) and have a structure similar to other NRs [181].  
Figure 6. Structural homology of PPAR isoforms. The N-terminal A/B domain contains ligand-
independent transcriptional activation (TA). The C domain is the DNA binding domain (DBD). The D domain 
includes the hinge (H) region. The E/F domain consists of the LBD, including the ligand-dependent 
activation function, and RXR interaction. Percentages are in reference to PPARd isoform structure. 
Reprinted with permission: Ehrenborg E Regulation of Skeletal Muscle Physiology and Metabolism by 
Peroxisome Proliferator-Activated Receptor δ Pharmacological Reviews 61;3 2009 
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PPARs interact with various coactivators and corepressors that interface the 
PPAR-RXR heterodimer with chromatin and transcriptional machinery, allowing 
for repression or activation of target genes [181]. Common coactivators 
observed for this interaction include members of the CBP/p300 and DRIP/TRAP 
families, which regulates chromatin acetylation, and transcriptional activity [182].  
Role of PPARs in Physiology and Disease  
PPARs regulate multiple genes/pathways, including adipogenesis, 
metabolism, and cardiomyocyte development. Ectopic expression of PPARg 
promotes adipogenesis in nonadipoegenic fibroblast cells, furthermore, when 
combined with a PPARg agonist and the pro-adipogenic protein C/EBPa 
myoblasts can be transdifferentiated into adipocytes; this points to a major role 
of PPARg in the generation of adipose tissue. Mouse studies have also 
demonstrated this effect in PPARg -/- mice which fail to develop brown adipose 
stores [182]. In vitro studies demonstrate that this receptor is integral for 
differentiation of ES cells into adipose cells [183]. In addition to its role in fat 
storage, PPARg is also crucial for placental and heart development. Previous 
studies have found PPARg to be essential as early as embryonic day 10 and 
plays a major role in establishment of trophoblast lineage cells [182]. 
Additionally, PPARg KO mouse placentas have major structural differences 
when compared to normal placental tissue, and loss of PPARg has a deleterious 
effect on the placental vasculature as well as maternal-fetal nutrient exchange 
[182]. Additionally, histological examination of PPARg null embryos revealed 
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degeneration of myocardial cell structures and ventricular defects when 
compared to normal mouse embryos. Furthermore, the PPARg null phenotype 
also includes premature cardiomyocyte differentiation, leading to developmental 
defects [182].  
 In addition to PPARg, PPARa and PPARb/d are also required for lipid 
homeostasis and to breakdown fatty acid for energy production, primarily during 
starvation [184]. This observation pointed to endogenous fatty acids as 
activators of PPARa. PPARa also improves insulin resistance in high fat diet 
rodent models of diabetes by altering gene expression of LPL and leptin, 
resulting in weight gain prevention [185]. Like the other PPAR isoforms, 
PPARb/d also regulates lipid and glucose homeostasis, with expression highest 
in the intestine, colon, and skin with some studies indicating its colocalization 
with RXR [169]. Ligand activation of PPARb/d decreases serum triglycerides, 
inhibits high-fat diet-induced obesity, and increase insulin sensitivity, primarily 
through regulation of genes that encode fatty-acid metabolizing enzymes and 
lipogenic proteins in the liver [186]. Furthermore, PPARb/d inhibits liver 
inflammation as a result of genetic, dietary, or chemical stimuli, and there is 
some evidence showing that this represses NFkB signaling and decreases 
inflammatory cytokine expression [185]. These results demonstrate a variety of 
potential PPAR targets that can be exploited in development of pan-PPAR and 
specific PPAR isoform specific ligands.  Endogenous ligands for PPAR include 
free fatty acids, eicosanoids, and arachidonic acid metabolites [186].  These 
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endogenous ligands act as PPAR agonists that activate genes involved in lipid 
and glucose homeostasis and this includes liver fatty acid binding protein, long 
chain fatty acyl-CoA synthetase, and peroxisomal acyl-CoA oxidase [187]. 
Additionally, various high affinity synthetic ligands have also been identified as 
PPAR ligands, which include thiazolidinedione drugs and aryl tyrosine 
derivatives, both of which have metabolic targets and have applicability to 
diabetes treatments [188]. Recent studies have found PPARa-active drugs to 
treat hypolipidemia, including benzafibrate, clofibrate, and fenofibrate [186].  
PPAR and Cancer 
 In addition to these biological functions, a number of studies have shed 
light on the role of all three PPARs in the development of cancer. Several 
studies have implicated PPARa in liver cancer development in humans, since 
long term administration of PPARa agonists induces liver cancer in rodents, a 
mechanism which is PPARa dependent, since PPARa null mice do not develop 
hepatocarcinoma when administered PPARa agonists [189]. Other studies have 
also found PPARb/d expression is higher in ovarian, endometrial, and breast 
tumors compared to non-transformed tissue [184]. Unlike PPARa, the evidence 
for the role of PPARb/d in cancer development has been controversial. There is 
a lack of consensus on its role in cancer due to contradictory studies in the 
literature. Two hypotheses have emerged from the published reports; (1) 
PPARb/d is overexpressed in tumors and can promote anti-apoptotic activity and 
increased cell proliferation and (2) PPARb/d can promote terminal differentiation 
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and inhibit pro-inflammatory signaling, which has antitumorgenic implications 
[184].  
In contrast, there are also data that supports the anti-tumorgenic effects 
of PPARb/d. There have been reports of higher PPARb/d expression in normal 
colonic epithelium in both human and mouse tissues [184], directly conflicting 
with other studies [184, 190-193]. There is some evidence that the differential 
expression can be attributed to APC/b-catenin mediated transcription [184]. Key 
concerns regarding these conflicting results is the lack of positive and negative 
controls to compare expression and the low number of samples examined was 
relatively low. In addition, there is evidence showing that PPARb/d promotes 
terminal differentiation in multiple cell types, including keratinocytes, intestinal 
epithelium, osteoblasts, and oligodendrocytes [184]. This mechanism is thought 
to occur via upregulation of genes required for terminal differentiation, an 
observation that is not seen in cells lacking PPARb/d expression [184]. 
Additionally, PPARb/d also inhibits expression of various proinflammatory 
signaling molecules, including NFkB, TNF, IL-6, and IL-1b [194]. This 
observation could have clinical impact on the role of PPARb/d in tumor 
development, and the application of PPARb/d ligands since inflammation is a 
key component of tumor development.  
PPARg is also implicated in carcinogenesis and several studies have 
demonstrated a role for PPARg as an inhibitor of colon, breast, prostate, and 
lung cancer via various mechanisms, including terminal differentiation, inhibition 
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of tumor promotion and cell growth, and induction of apoptosis. Tumor 
expression profiles indicate positive outcomes in colon cancer patients 
expressing high levels of PPARg [195]. Additionally, PPARg agonists have 
demonstrated modest efficacy in clinical trials as a chemoprevention agent in 
colon cancer [195, 196]. Furthermore, ligand activation of PPARg in cancer cell 
lines is associated with cell cycle arrest and induction of genes/proteins required 
for terminal differentiation, including E-cadherin, keratins, carcinoembryonic 
antigen [184]. PPARg also acts in concert with co-activators, such as HIC5 
(TGFB1I1), to cooperatively increase expression of proteins known to induce 
terminal differentiation, such as kruppel-like factor 4 and keratin 20 [188].  
In addition to its role in induction of differentiation, PPARg agonists can 
also modulate the expression of cell cycle and apoptosis regulators. Such 
actions include decreased expression of cyclin D1 and increased expression of 
cyclin-dependent kinase inhibitors p21 and p27 [196]. PPARg also plays a role in 
increased apoptotic signaling and PPARg agonists modulate the expression of 
apoptosis regulating genes, including increasing expression of pro-apoptotic 
BAX and BAD and decreased expression of anti-apoptotic proteins BCL-XL and 
Bcl-2 [188]. Ligand-bound PPARg also inhibits PI3K activity, AKT 
phosphorylation, and activation of JUN N-terminal protein kinase [184] and these 
activities are also linked to induction of apoptosis. Studies on all three PPARs 
demonstrate their diverse functions in disease processes, including insulin 
resistance, diabetes, obesity, chronic inflammation, and cancer risk. Therefore, 
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all forms of this nuclear receptor represent promising targets for receptor agonist 
or antagonists in treating a variety of diseases.  
ORPHAN NUCLEAR RECEPTORS 
Introduction 
Endogenous ligands have been identified for several members of the 
nuclear receptor superfamily, however, ligands have not yet been identified for 
those NRs designates or orphan NRs. While their structures and functions are 
similar to that of other nuclear receptors, there is evidence that some orphan 
nuclear receptors have target regions outside of the conserved ligand binding 
pocket that facilitate receptor-cofactor interactions and receptor functions. One 
such example is nuclear receptor 4A2 (NR4A2, Nurr1) and its agonist, 6-
mercaptopurine (6-MP) that activates NR4A2 through its AF1 domain [197]. 
Identification of ligands for orphan receptors can be achieved by various 
methods and the most frequently used approach is a cell-based assay in which 
cultured cells are transfected with an NR4A-responsive promoter construct 
linked to a reporter gene, such as luciferase or green fluorescent protein [198]. 
These transfected cells are then treated with ligands and activity (decreased or 
increased) of the reporter gene is assessed. This screening assay has resulted 
in identification of ligands for various receptors, including RAR, RXR, PXR, and 
PPAR, among others [198]. Another screening method uses an immobilized 
target protein on a solid support and mixtures containing possible ligands are 
passed over the immobilized target protein, washed, and the putative ligand is 
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eluted and analyzed by methods such as mass spectrometry [198]. Additionally, 
crystal structures of ligand binding domains have been important for identifiying 
ligands for orphan receptors. These crystal structure provide a detailed picture of 
the ligand binding domain, which facilitates the design of pharmacologically 
active ligands for these receptors. For example, analysis of the crystal structure 
for RAR related orphan receptor a (RORa) identified cholesterol as a potential 
ligand [199]. While crystal structure analysis can be beneficial, the emergence of 
virtual screening of molecular compound libraries to identify ligands has 
emerged as a powerful tool in this field. This process utilizes high-throughput 
molecular docking and allows for the filtering of a larger number of proteins, 
based on the crystal structure of the target protein, to screen a large number of 
proteins [200]. This technique has identified antagonists for RAR as well as 
selective estrogen receptor modulators (SERMs) [200]. As more ligands are 
identified, the field of orphan receptor drug discovery will progress and this is 
important since orphan receptors also play a major role in disease and are 
potential drug targets.  
NR0B Subfamily 
Members of the NR0B [201] subfamily include DAX1 (NR0B1) and SHP 
(NR0B2), which contain a classical LBD but not a DBD, and therefore their 
functions are dictated by receptor-protein interactions and not receptor-DNA 
interactions . The adamantly-derived retinoid CD437 and its derivatives bind 
SHP resulting in retinoid induced nuclear translocation of SHP that is 
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characteristic of retinoid binding [202, 203]. While ligands have been identified 
for SHP, identification of ligands for DAX1 has not yet been successful. Indeed, 
mithramycin was identified as a DAX1 ligand in a screening assay, however, the 
mithramycin-induced effects could very well be due to other functions of this 
drug, including its ability to inhibit transactivation from GC-rich promoter regions 
[204, 205]. The crystal structure analysis of DAX1 shows that the ligand binding 
pocket is filled with amino acid side chains [206], suggesting that identification of 
a classical nuclear receptor-ligand is unlikely.  
DAX1 is primarily expressed in the hypothalamic-pituitary-adrenal axis 
and mutations result in adrenal hypoplasia, hormone deficiencies, and gonadal 
dysfunction [201]. Conversely, SHP is highly expressed in the liver and small 
intestine, where it plays a role in cholesterol regulation and bile acid and glucose 
metabolism [118]. While both members have tissue specific expression, both 
SHP and DAX1 have been characterized as transcriptional repressors [206]. 
SHP has been identified as a corepressor of NF-kB during inflammatory 
signaling and as a repressor of OCT4, indicating its role in inflammatory 
signaling and embryonic stem cell pluriopotency [118]. 
In addition to these established physiological roles, both members of this 
subfamily are prognostic factors for cancer or overexpressed in some tumors. 
While DAX1 expression is limited in normal tissues, it is highly expressed in 
mammary, endometrial, ovarian, pituitary, lung, prostate, and Ewing’s sarcoma 
[201]. Several studies have correlated the expression level of DAX1 with cancer 
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prognostic factors. Higher levels of DAX1 expression were observed in 
endometrial tumors compared to normal tissues and this pattern was also 
observed in prostate tumors. In node-negative breast cancer cases, low DAX1 
expression is associated with poor survival while high DAX1 expression was 
associated with greater survival [207]. High DAX1 expression in lung cancer 
tumors is associated with lymph node metastasis and decreased disease-free 
survival [208]. Mechanistic studies on DAX1 have demonstrated that silencing in 
lung cancer decreases growth, survival, and invasion, pointing to its pro-
oncogenic role [201]. Furthermore, DAX1 cooperates with NR4A1 to mediate 
OCT4 activation, which is a stem cell marker and indicates a role for DAX1 in 
stem cells and cancer stem cell function [209]. 
Limited reports on SHP indicate high expression in hepatocellular 
carcinomas compared to normal liver and higher expression in intestinal 
precancerous lesions when compared with normal gastric mucosa [210]. 
Evidence of a role for SHP in hepatocellular carcinoma comes from observations 
that SHP null mice develop heptacellular tumors at one year of age [211], 
suggesting an inhibitory role for SHP in liver tumorigenesis. In contrast, SHP 
plays a tumor-promoting role in intestinal metaplasia by regulating expression of 
caudal-related homeobox gene (CDX1), which has a known pro-oncogenic role 
in intestinal precancerous lesions [210]. While there is limited data for the use of 
SHP as a cancer prognostic, one study found high SHP expression correlated 
with greater disease-free survival in breast cancer patients [212]. In addition, 
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high SHP expression is correlated with greater survival of hepatocellular 
carcinoma patients [211]. In addition, SHP is known to interact with various 
transcription factors, nuclear receptors, cofactors, and oncogenes [213]. SHP 
overexpression has been shown to enhance the ubiquitin ligase activity of 
Mouse double minute 2 homolog (MDM2), which induces p53 instability [214]. 
Taken together, these results demonstrate a role for NR0B orphan receptors in 
tumorigenesis and tumor development.  
RAR-related Orphan Receptor (ROR) Subfamily 
 The ROR subfamily of orphan receptors includes three isoforms, RORa 
(NR1F1), RORb (NR1F2), and RORg (NR1F3) that bind to their respective 
response elements as monomers to specific ROR response elements (ROREs) 
consisting of the consensus core motif AGGTCA preceded by a 5-bp A/T-rich 
sequence [215]. RORa is expressed in specific areas of the brain, including the 
cerebellum and SCN of the hypothalamus and also in the spleen and thymus 
[201]. Mutations of the RORa gene in mice result in an ataxia-like phenotype 
which is thought to be due to neurodegeneration in the cerebellum, resulting in 
major developmental defects [216]. RORb is expressed in areas of the CNS 
involved in sensory information processing and components of the mammalian 
circadian system, such as the suprachiasmatic nuclei and the retina. Suggesting 
a role for RORb in regulation of circadian rhythm and sensory information 
processing. RORb knockout mice display an altered gait, abnormal circadian 
behavior, as well as retinal degeneration [217]. RORg expression is 
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concentrated in skeletal muscle and thymocytes and RORg knockout mice have 
dysregulated thymocyte development and altered lymphoid organogenesis 
[218]. 
 While ligands for RORg have not been described, they have been 
identified for RORa and RORb. It has been reported that RORb transactivation 
is inhibited by all-trans retinoic acid, suggesting a role for retinoids in RORb-
related CNS diseases. Also, melatonin and cholesterol have been reported as 
potential endogenous ligands for RORa [216]. Studies supporting this 
conclusion found a reduction in RORa activity after depletion of cellular 
cholesterol, whereas high levels of cholesterol reactivated RORa [216]. This 
points to a role for RORa in cholesterol homeostasis and as a potential drug 
target for cholesterol-related diseases.  
In addition to these physiological roles, ROR also play a role in cancer. 
RORa expression is high in breast cancer tumors and is associated with higher 
relapse rates and metastasis [219]. RORa is also highly expressed in colorectal 
cancer and is associated with lymph node metastasis and decreased survival 
rates [220]. RORa mediates inhibition of Wnt signaling and Wnt target genes in 
colon cancer [221] and this is due to displacement of coactivators that bind to b-
catenin [221] by RORa, resulting in decreased expression of Wnt target genes 
such as cyclin D1 and c-myc. This provides evidence for a mechanism 
associated with RORa-induced tumor suppressive activity. Recent studies show 
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that activation of RORa by a synthetic agonist resulted in stabilization of p53 
protein expression via Mouse double minute 2 homolog (MDM2) repression 
[222], which has obvious implications for increased apoptosis in cancer. RORg is 
highly expressed in castration-resistant prostate cancer and metastatic prostate 
cancer [223]. Conversely, RORg expression is associated with increased 
disease-free survival of breast cancer patients [224], indicating its tumor type 
specific role. 
NR1D Subfamily 
 The NR1D subfamily include NR1D1 (Rev-erba) and NR1D2 (Rev-erbb) 
and have a protein structure similar to other NRs and exhibits high sequence 
homology (Figure 7).  
 
 
Figure 7. Structure homology of Rev-Erb subfamily. (A) The general organizational structure of 
members of the nuclear receptor superfamily compared to the (B) Rev-Erb family. Numbers above each 
receptor represent the amino acid position. Percentages indicate amino acid identity within a particular 
domain relative to REV-ERBα. A/B, C, D, E and F refer to classically defined regions in the nuclear receptor 
domain structure as previously described. DNA-binding domain (DBD); ligand-binding domain (LBD). 
Reprinted with permission: Kojetin D REV-ERB and ROR nuclear receptors as drug targets Nature Reviews 
Drug Discovery 13; 2014 
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This receptor subfamily is unique because they lack an alpha helix located in the 
AF-2 domain that plays a role in receptor-coactivator interactions, which results 
in a protein conformation that favors corepressor recruitment [225]. Members of 
this subfamily primarily exhibit transcriptional repressor activity and bind to 
response elements identical to that of ROR (NR1F) orphan receptors [226]. In 
the search for NR1D ligands, studies have identified heme as a ligand for both 
Rev-erba and Rev-erbb and heme-binding enhances cofactor recruitment as 
well as repression of circadian genes, such as BMAL1 and CLOCK [227, 228]. 
Furthermore, synthetic ligands for both Rev-erba and Rev-erbb have been 
developed [229], several with promising agonist or antagonist activity. The 
NR1D subfamily has also been implicated in various physiological processes, 
including cerebellar development, osteoarthritis, adipogenesis, and circadian 
rhythms. Mice lacking Rev-erb have decreased development and increased 
apoptosis in the cerebellum, and [230] Rev-erb has been shown to play an 
integral role in adipocyte differentiation [231]. While the localized expression of 
the NR1D members, if any, has not been determined yet, these receptors play a 
role in gene regulation, including that of Nmyc and deleted in breast cancer 1 
(DBC1) via promoter binding or protein-protein interactions [232-234]. 
Additionally, Rev-erba has been implicated as a negative prognostic factor in 
breast cancer, and its expression is correlated with poor clinical outcomes and 
was a significant predictor of breast tumor recurrence within 5 years in patients 
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with ER positive and negative tumors [235]. These results contrasted to a later 
study that found lower expression of Rev-erba in ER positive and negative 
breast tumors when compared to normal breast tissue [236]; this contradiction 
could be due to the variation in the number of patient samples taken in both 
studies, since the latter study was significantly more robust.  
NR2F Subfamily 
The NR2F subfamily includes NR2F1 (COUP-TFI), NR2F2 (COUP-TFII), 
and NR2F6 (EAR2) and are widely expressed in several tissue and tumor types. 
While the structure of these receptors is similar, COUP-TF1 and COUP-TFII 
exhibit the highest sequence homology (Figure 8). 
 
 
 
Figure 8. Structure of COUP-TFI and COUP-TFII. Sequence homology between COUP-TFI and COUP-
TFII. The DBD and LBD have the highest level of homology between them and significant homology in their 
AF1 domains. Reprinted with permission: Boudot A Involvement of COUP-TFs in Cancer Progression 
Cancers 3;1 2011 
 
 
 These orphan receptors have the highest affinity for the direct repeat sequence 
GGTCA motif with a 2-bp spacing and recognize direct and inverted half site 
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response elements of other NRs, including RAR, RXR, and vitamin D receptor 
(VDR) [237, 238], which gives them promiscuity and the ability to antagonize the 
action of other nuclear receptors. This subfamily generally exhibits 
transcriptional repressor activity which is mediated by heterodimerization with 
other transcription factors or with RXR [239]. While ligands have not been 
identified for all members of this family, 9-cis and all-trans retinoic acid bind 
COUP-TFII [201]. EAR2 also exhibits repressor activity and the ability to not only 
heterodimerize with other nuclear receptors, but also its other subfamily 
member, COUP-TF [240]. Most of the physiological roles of the NR2F subfamily 
have been elucidated via loss of function models. Both COUP-TFI and COUP-
TFII have essential functions in neural and retinal development, and in many 
cases, their functions overlap [239, 241] 
COUP-TFII expression is higher in prostate tumor samples compared to 
nontumor tissue and also predicted earlier recurrence of the disease [242]. In 
addition to prostate cancer, COUP-TFII expression was a negative prognostic 
factor for patient survival and was also associated with ERa expression [243], 
which points to the pro-oncogenic function of COUP-TFII. In addition to COUP-
TFII, EAR2 is also expressed in various tumor types. This receptor is highly 
expressed in both ER positive and ER negative breast tumors when compared 
to normal breast tissue [244] and lower levels of EAR2 conferred enhanced 
sensitivity to anticancer drugs [244]. Furthermore, EAR2 plays a role in 
development of lymphoma and colorectal tumors.  
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NR2E Subfamily 
 The NR2E subfamily includes TLX also known as NR2E1, as well as 
NR2E3, or PNR. TLX can act as a monomer that binds to 5′-AAGTCA-3′ half-
sites in the promoter regions of target genes, such as the retinal development 
gene Pax2 [245, 246] while PNR binds as a homodimer to direct repeats of 5′-
ANGTCA-3′ sites separated by 1 bp [247]. Recent studies show that PNR forms 
homodimers and heterodimers with PPARg and not other members of the PPAR 
subfamily [248]. Ligands for PNR have been identified using transactivation 
assays [249] but direct binding studies are necessary to confirm these 
interactions. PNR and PPARg are coexpressed in human retinal tissue while 
alterations in the PNR LBD result in human retinopathies and disruption of PNR/ 
PPARg complex formation [248], which is congruent with the localization of PNR 
in the retina and in retinal cells [250]. These observations suggest a role for 
PNR/ PPARg interactions in retinal development and disease. Additionally, PNR 
correlated with ERa expression in breast tumor and breast cancer cell lines 
[251] and expression in breast tumors has been associated with recurrence-free 
survivals of breast cancer patients [251]. Furthermore, PNR knockdown resulted 
in decreased estrogen induced cell proliferation and expression of estrogen 
responsive genes [201].  
TLX is an orphan receptor that is mainly expressed in the brain and plays 
an important role in neural development. It is also required for the formation of 
cortical layers in the embryonic brain and for timing of neurogenesis during 
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development [117]. TLX knockout mice also show an altered phenotype in 
embryonic stages as well as in adulthood, and mature mice have reduced 
cerebral hemispheres as well as severe retinopathy [252]. Additionally, TLX 
mutants also exhibit deficits in their limbic system, resulting in increased 
aggressiveness and violent behavior, reduced learning abilities, and decreased 
copulation [253]. TLX also plays a major role in retinal development and is 
critical in controlling the generation of retinal cells. TLX knockout mice have 
neural retinas that are significantly thinner than normal counterparts [254]. 
Furthermore, TLX plays an important role in neural stem cell maintenance and 
self-renewal capabilities since it keeps adult neural stem cells in a self-
renewable and undifferentiated state [117]. TLX-expressing cells from TLX-
heterozygote brains are able to proliferate, self-renew, and differentiate into all 
neuronal cell types in vitro, while TLX-null cells lack the ability to proliferate and 
reintroduction of TLX to TLX-null cells rescues this characteristic [252]. 
Furthermore, in vivo, neural stem cells of TLX mutant mice loose their ability to 
proliferate and show reduced neural precursors in adult brains [117], which 
again points to the role of TLX in regulating neuronal stem cell population 
characteristics.  
 Both TLX and PNR play a role in cancer development, and TLX 
overexpression results in increased cell proliferation, tumorigenesis 
enhancement, and glioma formation [252]. The mechanisms responsible for this 
activity are thought to be associated with TLX regulation of vascular endothelial 
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growth factor (VEGF) and activation of cyclin D1 [255]. Mechanistic studies on 
PNR have demonstrated that PNR works cooperatively with signal transducer 
and activator of transcription 3 (STAT3) to bind the ERa promoter and regulate 
changes in ERa gene expression [251]. Furthermore, genetic screening has 
showed that PNR interacts with p53 and the cofactor p300, further indicating its 
role in cancer signaling [256]. 
NR4A SUBFAMILY OF ORPHAN NUCLEAR RECEPTORS 
NR4A Structure and DNA-Binding 
 The NR4A subfamily of nuclear receptors is made up of three members, 
Nur77 (NR4A1), Nurr1 (NR4A2) and Nor1 (NR4A3) all of which have a similar 
structure to NRs (Figure 9). 
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Figure 9. Structure and domains of NR4A subfamily members. Sequence homology is shown above 
each receptor relative to NR4A1. Members of this family are highly conserved in the DBD (C domain; 
~90%) and LBD (E domain ~60%), but divergent in the N-terminal A/B region (~20%).  
 
 
They were initially identified as immediate-early genes induced by nerve growth  
factors in PC12 cells [257], their expression and activation is cell-type specific 
and they respond to a variety of signals, including mitogenic, growth factors, 
cytokines, hormone, neurotransmitters, and apoptotic signals [216]. Members of 
this subfamily bind to specific Nur-responsive elements (NuRE) as homo or 
heterodimers and to NGFI-B response element (NBREs), as monomers; NR4A1 
also forms a heterodimer with RXR (Figure 10) [216].  
 
 
A/B C D E F
ZnZn
Nur77
(NR4A1)
27% 92% 67%
Nurr1
21% 91% 64%
Nor1
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Figure 10. NR4A response elements. NR4A1 family members can bind as monomers to the NBRE (A), 
homodimers and NR4A heterodimers to the NuRE (B), or form RXR heterodimers (C). Reprinted with 
permission. (Maxwell M The NR4A subgroup: immediate early response genes with pleiotropic 
physiological roles Nuclear Receptor Signaling 4;2 2006) 
 
 
While NR4A1 and NR4A2 bind as heterodimers with RXR to mediate retinoid 
signaling, NR4A3 is unable to do this [216]. The classical understanding of 
nuclear receptor signaling includes a hydrophobic surface in the LBD, which acts 
to recruit cofactors for transcription. In contrast, NR4A subfamily receptors have 
a hydrophilic surface in the LBD, rather than the classical hydrophobic cleft, 
which mediates coactivator recruitment [258]. Crystallography studies show that 
the LBD of NR4A2 can adopt a folding pattern that resembles an agonist 
activated LBD [259], which can result in ligand-independent recruitment of 
cofactors and transcriptional activation.  
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The NR4A subfamily can be induced by various physiological signals, 
including growth factors, calcium, inflammatory cytokines, neurotransmitters, 
and fatty acids [216], indicating its ability to sense and respond to changes in the 
cellular environment. Recent studies have identified cytosporone B (CsnB) as a 
ligand for NR4A1 and 6-mercaptopurine, substituted benzimidazole, and 
pyridinone derivatives as Nurr1 ligands [197, 260-262]. While the activity of most 
of these ligands involves nuclear localization of the receptor, CsnB induces both 
nuclear retention and export and this directly affects the function of NR4A1 
[260]. CsnB can induce proapoptotic activity by inducing nuclear export of 
NR4A1 to the mitochondria [260] and can also decrease expression of 
antiapoptotic genes, such as brain and reproductive organ expressed (BRE) via 
nuclear NR4A1 dependent repression [263]. 
Physiological Role of NR4A 
The NR4A subfamily members are expressed throughout the body and 
play a tissue/organ-specific role in homeostasis and disease. NR4A2 is 
expressed in nervous tissue, and is a drug target for nervous system disorders, 
such as Parkinson’s Disease (PD) [264]. Studies have shown that Nurr1 
knockout mice have impaired dopaminergic function and increase apoptosis of 
dopaminergic neurons, which are cells that are lost as PD progresses [265]. 
Furthermore, NR4A2 activates tyrosine hydroxylase, an enzyme involved in 
dopamine synthesis, and it is essential for dopaminergic neuron development in 
the midbrain [266]. Furthermore, PD midbrains have decreased expression of 
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NR4A2, especially in cell types that are associated with neuronal degeneration 
in PD [266]. Nurr1 mutations have also been associated with the development of 
PD [264].  
NR4A receptors regulate genes in the hypothalamus-pituitary-adrenal 
axis, that are associated with steroidogenesis, inflammation, stress response, 
and energy storage, among others. Studies focused on steroidogenesis show 
that NR4A1 regulates steroid 17-hydroxylase and the 20α-hydroxysteroid 
dehydrogenase promoters and enhances gene expression of 
adrenocorticotropic hormone precursors, indicating its role in adrenal 
steroidogenesis [216]. Recent studies show that NR4A1 is elevated in 
macrophages after lipopolysaccharide or cytokine stimulation [216]. Specifically, 
NR4A1 is induced in response to inflammatory cytokines in rheumatoid arthritis 
[216]. In addition, NR4A1 also plays a role in atherosclerosis, and is expressed 
in human atherosclerotic lesions in various stages of atherosclerosis 
development and also in smooth muscle cells [216].  
NR4A3 is also expressed in vascular smooth muscle cells and Nor1 
inhibition decreases LDL-induced mitogenic proliferation of these cells [267]. In 
addition, mitogenic stimulation with PDGF results in induction of NR4A3 
expression in smooth muscle cells of atherosclerotic lesions, indicating its role in 
smooth muscle cell proliferation and atherosclerosis [268]. In addition, NR4A3 
expression in adipocytes has been linked to insulin signaling by stimulating 
insulin-dependent glucose update and is induced by insulin and 
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thiazolidinedione drugs used to treated type 2 diabetes [269]. NR4A3 
inactivation by lentiviral short hairpin RNA resulted in attenuated ability of insulin 
to stimulate glucose transport [269]. 
NR4A Expression and Prognostic Significance in Cancer 
NR4A receptors are expressed in many tumors and cancer cell lines, 
however, there is limited data on direct comparisons of all 3 receptors and their 
expression and prognostic significance in the same tumor type. NR4A1 is highly 
expressed in cancer cell lines and high expression groups have been observed 
in tumors from ER-positive and ER-negative breast cancer, colon, lung, and 
pancreatic cancer patients [236, 270-272]. Moreover, NR4A1 is a negative 
prognostic factor for lung and breast cancer patients [236, 270, 273]. High 
NR4A1 expression in colorectal cancer cells is also predictive of the resistance 
of cells to various chemotherapeutic agents [274], overall contributing to a 
negative prognosis. 
NR4A2 overexpression has been observed in tumors from bladder, 
prostate, and ER positive breast cancer patients [275-277]. NR4A2 expression 
in tumors is a negative prognostic factor for bladder, prostate, colon, and gastric 
cancer patients [274-276, 278] and potentially a positive prognostic factor for 
relapse free survival of breast cancer [277]. High levels of NR4A2 in the 
cytoplasm is also indicative of high tumor grade, decreased survival, and 
increased metastasis in bladder cancer patients [275]. 
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The studies on NR4A3 expression in cancer cells and tumors are limited, 
however, NR4A3 is overexpressed in ER positive and negative breast cancer 
compared to normal breast tissue [236]. In addition, NR4A1 and NR4A3 double 
knockout mice rapidly develop acute myeloid-type leukemia (AML) [279] and 
levels of NR4A1 and NR4A3 are low in AML [280] while low NR4A1 expression 
is associated with decreased survival [281] and NR4A3 expression is positively 
correlated with therapy success in AML patients [282]. 
Novel Role of NR4A1 in Solid Tumors 
The role of NR4A members can be tissue and disease specific, and this is 
evidenced by NR4A1 expression which is decreased in acute myeloid leukemia 
patients [283], and this is in contrast to the high expression and pro-oncogenic 
role of NR4A1 in solid tumors [201]. Knockdown of NR4A1 in acute myeloid 
leukemia cell lines resulted in increased growth and decreased apoptosis while 
this same treatment in pancreatic, colon, lung, melanoma, cervical, and ovarian 
cancer cell lines resulted in inhibition of cell growth, survival, migration, and 
invasion [270, 284-287]. Furthermore, many of these effects in solid tumors 
involve nuclear NR4A1 [201]. Retinoid induced proapoptotic responses that are 
NR4A1 mediated are blocked leptomycin B, a nuclear export inhibitor [288], 
indicating that NR4A1 mediated apoptosis induced by specific apoptosis-
inducing agents require nuclear export of the receptor. The mechanism behind 
this apoptotic pathway involves formation of a novel NR4A1/bcl-2 proapoptotic 
complex that results in cytochrome c release [288] and thereby activates the 
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intrinsic apoptosis pathways. Providing further evidence for this mechanism is 
the increased survival of liver cancer cells and platinum drug resistance as a 
result of CHD1L (chromodomain helicase/adenosine triphosphatase (ATPase) 
DNA-binding protein 1-like) expression which inhibits platinum drug-induced 
nuclear export of NR4A1 [203]. Taken together, these results demonstrate the 
diverse and tissue specific mechanisms behind the action of NR4A1 subfamily 
orphan receptors in normal and disease states.  
Development of NR4A1 Ligands 
Cruciferous Vegetables and Their Indole-Derived Anticancer Agents 
The effects of cruciferous vegetable consumption in mediating diseases, 
such as cancer, has been investigated showing that cruciferous vegetables are 
protective and therapeutic against cancer in human and in laboratory animal 
studies. The anticarcinogenic actions of cruciferous vegetables, such as brussel 
sprouts, cabbage, kale, and broccoli are due to breakdown products of sulfur 
containing compounds called glucosinolates, and more specifically 
glucobrassicin (3-indolylmethyl glucosinolate) [289] (Figure 11). When taken 
orally, the enzyme myrosinase is activated and catalyzes hydrolysis of 
glucobrassicin to give glucose and Indole-3-carbinol (I3C) [290] (Figure 11). In 
the acidic environment of the stomach, I3C forms several condensation 
products, one of which is 3,3’-diindolylmethane (DIM) [290] (Figure 11). While 
this hydrolysis predominates when cruciferous vegetables are consumed raw, 
cooking methods such as boiling, decreases myrosinase activity and 
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glucobrassicin hydrolysis is decreased. This does not entirely preclude 
hydrolysis of glucobrassicin, since there is myosinase activity in human intestinal 
bacteria. Cooking Brussel sprouts and broccoli for 9-5 minutes decreases 
glucobrassicin levels in the vegetables due to leaching into water [289]. 
 
 
 
Figure 11. Structure of DIM and its precursors. Glucobassicin is found in cruciferous vegetables and 
consumption results in myrosinase catalyzed hydrolysis into indole-3-carbinol and a condensation reaction 
results in DIM. Reprinted with permission: Fujioka, N Harnessing the Power of Cruciferous Vegetables: 
Developing a Biomarker for Brassica Vegetable Consumption Using Urinary 3,3′-Diindolylmethane Cancer 
Prevention Research 9;10 2016. 
 
 
DIM has been used to treat a variety of diseases but exhibits poor 
biodistribution and absorption in animal tissues [291]. The pharmacokinetics and 
bioavailability of several DIM formulations have been investigated and the 
highest bioavailability was achieved using liquid DIM in a solution of cod liver oil 
when compared to crystalline DIM formulations [291]. Previous studies have 
estimated DIM clearance in mice to be approximately 7 mL/h while blood 
concentrations peak from 45 to 60 minutes [291]. Physiologically based 
pharmacokinetic modelling (PBPK) has also been used to determine the 
pharmacokinetics of DIM. A phase I trial administered a range of doses of I3C 
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(200 and 400 mg/day) to women with cervical dysplasia and found that the that 
the time to max blood concentrations was 2 hours with max concentration levels 
near 15 ng/mL [292]. Doses in the same range have been used in studies to 
treat recurrent respiratory papillomatosis [293]. These clinical levels are 
significantly higher than dietary levels from cruciferous vegetable consumption 
which can range between 20 to 120 mg daily [292]. 
Diindolylmethane (DIM) 
DIM is a major metabolic product of glucobrassicin via indole-3-carbinol 
(I3C) and studies have demonstrated its role in cancer and autoimmune 
disorders. The mechanism behind the anticarcinogenic effects of DIM are due, in 
part to modulation of carcinogen metabolism into inactive and nontoxic 
metabolites. For example, DIM binds the aryl hydrocarbon receptor (AhR) which 
activates Ahr-dependent transcription of phase I and phase II enzymes, and the 
subsequent increased rates of toxicant and carcinogen elimination [294]. DIM 
induced hepatic levels of CYP1A2 upon initial exposure [294], and also induced 
CYP3A4 after chronic administration [295], demonstrating the role of DIM in 
induction of CYPs that enhance metabolism of carcinogens. Indeed, CYP3A4 is 
responsible for the metabolism of the majority of therapeutic drugs [296], and 
this may have implications for DIM induced adverse reactions or drug 
interactions. Additionally, DIM also regulates cell cycle progression, Akt/NFkB 
signaling, cyclin dependent kinase activity, caspase activation, estrogen receptor 
signaling, and estrogen metabolism, among others [297, 298]. Platelet derived 
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growth factor D overexpressing PC3 prostate cancer cells exhibit rapid growth 
and enhanced cell invasion that involves mammalian target of rapamycin 
(mTOR). In these cells, DIM inhibited mTOR and Akt, resulting in decreased cell 
invasion and proliferation [299]. In the same cell line, I3C induced G1 cell cycle 
arrest due to upregulation of p21 and p27 CDK inhibitor upregulation [300] While 
this treatment utilized I3C to demonstrate cell cycle arrest, this effect is likely to 
be mediated by DIM, since I3C is converted into DIM under cell culture 
conditions [289]. Additionally, in breast cancer cells, DIM treatment inhibited 
DNA synthesis and Bcl-2 expression and induced chromatin condensation as 
well as DNA fragmentation in both MCF-7 and MDA-MB-231 breast cancer cell 
lines [301]. Furthermore, DIM also inhibited cell adhesion and invasion via 
upregulation of the tumor suppressor PTEN and cell adhesion regulator E-
cadherin in breast cancer cells [302]. DIM induced ER calcium release in 
pancreatic cancer cells which was associated with increased expression of 
C/EBP homologous transcription factor (CHOP) [303]. This ER stress response 
was accompanied by apoptosis as evidenced by cleavage of caspase 8, 
caspase 3, Bid, and PARP [303]. These effects are comparable to those 
observed by treating these cells with known ER stress inducers, such as 
thapsigargin [92].  
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1,1-Bis (3’-indolyl)-1-(p-substitutedphenyl) methane (C-DIMs) as an NR4A1 
Ligand 
1,1-Bis (3’-indolyl)-1-(p-substitutedphenyl) methane (C-DIMs) are 
derivative of DIM that contain an aromatic ring and these compounds did not 
exhibit AhR activity but were potent anticancer agents [304]. Their role as 
receptor ligands was investigated using GAL4-receptor chimeras and a subset 
of these compounds containing p-trifluoromethyl, p-tbuty, and p-phenyl groups 
were identified as PPARd ligands. Their activity as PPARd ligands was 
investigated in several cancer cell lines and it was concluded that with the 
exception of colon cancer that PPARd was not a major factor in solid tumor-
derived cancer cell lines [304-312]. Several PPARd-inactive C-DIMs such as p-
methoxy- and p-hydroxyohenyl (DIM-C-pPhOH) analogs were also potent 
anticancer agents and a second round of GAL4-receptor screening assays 
identified NR4A1 as a target for C-DIMs [313]. 
Recently, our lab has synthesized and investigated a series of 1,1-bis(3-
indolyl)-1-(p-substituted phenyl)methane (C-DIM) analogs that bind NR4A1 and 
exhibit NR4A1 antagonist activity in cancer cells and inhibit cancer cell and 
tumor growth [271]. These are synthetic triaryl methane derivatives of DIM, 
which is a diaryl methane [271]. More recent studies have focused on two 
particular C-DIMs, namely C-DIM [1,1-bis(3-indolyl)-1-(p-
hydroxyphenyl)methane] (DIM-C-pPhOH) and [1,1-bis(3-indolyl)-1-(p- 
carboxymethylphenyl)methane]  (DIM-C-pPhCO2Me) which bind and inactivate 
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NR4A1 and acts as a NR4A1 antagonist [272, 303, 313]. C-DIMs have a 
substituted phenyl or another aromatic group and may also have ring indole 
substituents. They the ability to modulate nuclear NR4A1-dependent 
transactivation, similar to that reported for CsnB [260]. Previous studies have 
investigated binding and interactions of C-DIM analogs with the LBD of NR4A1 
using fluorescence assays. While binding was not observed for some of the 
analogs, KD values of compounds that bound NR4A1 ranged from 0.1 to 0.74 
µM [314]. These studies identified DIM-C-pPhOH as the most active ligand (KD= 
0.11 µM) that bound the LBD of NR4A1 [314]. Previous crystallography studies 
identified two separate binding sites on the surface of the NR4A1 LBD [315], 
which correspond to a LBD and a cofactor binding site. C-DIM analogs exhibit a 
low affinity for the cofactor binding site, suggesting that these analogs bind to 
the ligand binding site [314] and modeling studies found all C-DIM analogs are 
capable to interacting with the LBD of NR4A1. These interactions include 
hydrogen bond interactions with Glu445 and His516 and p interactions with 
Arg515, with a configuration similar to that of DIM-C-pPhOH [314]. Furthermore, 
mutation of His516 in the NR4A1 LBD resuled in the inability of DIM-C-pPhOH to 
bind the receptor [314], indicating the importance of this residue in NR4A1 ligand 
binding interactions. 
Functional results of C-DIM treatment has been established in several 
studies in cancer cell lines and in vivo [270, 272, 316, 317]. A subset of C-DIMs 
have also been shown to activate PPARg to induce growth inhibition and 
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transactivation in colon cancer cells [305]. Furthermore, the p-chlorophenyl C-
DIM analog (DIM-C-pPhCl) activates Nurr1 and also inhibited bladder cancer 
cell and tumor growth [316]. Specifically, the p-methoxyphenyl analog (DIM-C-
pPhOCH3) can also activate NR4A1 dependent transactivation and also 
inhibited cancer cell and tumor growth and induced apoptosis in lung and 
pancreatic cancer cells [270, 272]. In addition, another set of C-DIMs, DIM-C-
pPhOH and DIM-C-pPhCO2Me, inactivate NR4A1, resulting in cancer cell 
apoptosis and inhibition of cell and tumor growth [318].  
Subsequent studies using both NR4A1 silencing via siRNAs and DIM-C-
pPhOH have identified several NR4A1 dependent pathways that are also 
important chemotherapeutic targets. NR4A1 regulates expression of survivin 
and bcl-2 via interactions of NR4A1 and p300 with the DNA-bound transcription 
factor Sp1 bound to GC-rich promoter elements [272]; treatment of pancreatic 
cancer cells with DIM-C-pPhOH or transcfection with siRNAs targeted to NR4A1 
(siNR4A1) decreased survivin and bcl-2 expression in these cells [272]. A 
second NR4A1-regulated pathway that has been identified is p53-dependent 
and is only observed in p53 positive cancer cell lines. Mechanistic studies of this 
pathways found that NR4A1 binds and inactivates p53 and upon treatment with 
DIM-C-pPhOH or transfection with siNR4A1, these cells respond by activating 
p53, which induces sestrin2, and in turn activates phospho-cAMP activated 
protein kinasea (AMPKa), resulting in the inhibition of mTOR signaling [270]. 
Thus, NR4A1 regulates mTOR which plays an important role in cancer cell 
  86 
growth, proliferation, and protein synthesis and NR4A1 antagonists act as a 
novel class of mTOR inhibitors. A more recently identified pathways involves the 
regulation of oxidative stress by NR4A1. NR4A1 regulates expression of genes, 
such as isocitrate dehydrogenase 1 (IDH1) and thioredoxin domain-containing 
protein 5 (TXNDC5) and keeps their expression high, resulting in higher overall 
“reductant” levels and low oxidative stress levels in pancreatic cancer cells [303]. 
Treatment with DIM-C-pPhOH or transfection with siNR4A1 in pancreatic cancer 
cells decreased expression of these genes, resulting in induction of oxidative 
and endoplasmic reticulum stress and stress-induced apoptosis [303].  
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Figure 12. NR4A1-regulated pro-oncogenic pathways in cancer. NR4A1 regulates apoptotic, stress, 
and mTOR pathways in solid tumors. NR4A1 binds and inactivates p53, thereby inhibiting sestrin and 
AMPKa, allowing for mTOR signaling. NR4A1 activates transcription of the reductants TXNDC5 and IDH1 
that keep oxidative stress low. NR4A1 also forms a complex with Sp1 and p300 to transcriptionally activate 
pro-growth and pro-apoptotic genes such as surviving, bcl2, cyclin D1, and EGFR. Reprinted with 
permission: Safe S, The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic 
reticulum stress in pancreatic cancer cells Molecular Cancer Research 12(4); 527-38 2014 
 
 
 
 
Recently, these mechanisms have been identified in breast, colon, pancreatic, 
and kidney cancer cell lines [317]. The results of RNAi studies demonstrate that 
NR4A1 regulates multiple pro-oncogenic pathways (Figure 12) in solid tumors, 
and C-DIM/NR4A1 antagonists, such as DIM-C-pPhOH and DIM-C-pPhCO2Me 
are inhibitors of these pathways. Previous studies have shown NR4A1 is 
overexpressed in RMS, therefore I hypothesize that NR4A1 will contribute to the 
oncogenicity of RMS and serve as a driver of the more aggressive ARMS 
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subtype. In this thesis, I will investigate the function of NR4A1 in RMS (ARMS 
and ERMS), the anticancer activities of C-DIM/NR4A1 antagonists and the 
development of a new set of more potent “second generation” of C-DIM/NR4A1 
ligands for treatment of RMS.  
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CHAPTER II 
NUCLEAR RECEPTOR 4A1 (NR4A1) AS A DRUG TARGET FOR TREATING 
RHABDOMYOSARCOMA (RMS)* 
INTRODUCTION 
  Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma that 
is primarily observed in children and adolescents and accounts for 5% of all 
pediatric cancers and 50% of soft tissue sarcomas in children [319, 320].  
Embryonal RMS (ERMS) and alveolar RMS (ARMS) are the two major classes 
of RMS in children and adolescents and differ with respect to their histology, 
genetics, treatment, and prognosis [319-322].  ERMS accounts for over 60% of 
RMS patients and is associated with loss of heterozygosity at the 11p15 locus.  
ERMS patients have a favorable initial prognosis; however, the overall survival 
of patients with metastatic ERMS is only 40% [321].  ARMS occurs in a lower 
percentage of RMS patients and is associated with translocations resulting in 
formation of pro-oncogenic gene products resulting from the fusion of PAX3 or 
PAX7 with the Forkhead gene FOXO1A [323, 324].  ARMS patients have a poor 
diagnosis and patient survival is <10% for metastatic ARMS. 
  RMS patients are treated with radiotherapy, surgery, and chemotherapy  
using cytotoxic drugs and/or drug combinations, and successful treatment varies 
with tumor type (ARMS vs. ERMS) and extent of metastasis. 
*Reprinted with permission from “Nuclear Receptor 4A1 (NR4A1) as a Drug Target for 
Treating Rhabdomyosarcoma (RMS)” Lacey A, Hedrick E, Li X, Patel K, Doddapaneni 
R, Singh M, Safe S, 2016 Oncotarget, 7(21), 31257-69 Copyright [2016] Alexandra D 
Lacey 
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However, a recent study on adults treated for childhood cancers showed that 
over 90% of these individuals exhibited chronic adverse health conditions later in 
life [74], demonstrating that there is a critical need for development of new 
mechanism-based drugs for treatment of RMS. 
  The orphan nuclear receptor 4A1 (NR4A1, Nur77/TR3) does not have an 
endogenous ligand; however, this receptor plays a key role in cellular 
homeostasis and in several diseases including cancer [201, 325].  NR4A1 is 
overexpressed in lung, breast, pancreatic and colon cancer patients [201, 270, 
271, 326, 327], and functional studies show that NR4A1 is pro-oncogenic and 
plays a role in cancer cell proliferation, survival, migration and invasion 
[reviewed in 201].  Several structurally-diverse ligands that directly bind NR4A1 
have been characterized [260, 314, 315, 328] and studies in this laboratory have 
shown that among a series of 1,1-bis(3-indolyl)-1-(p-substituted 
phenyl)methanes (C-DIMs), several compounds including the p-hydroxy (DIM-C-
pPhOH) and p-carbomethoxy (DIM-C-pPhCO2Me) analogs directly bind NR4A1  
(Figure 13A).  Results of RNA interference (RNAi) studies show that NR4A1 
activates mTOR by binding and inactivating p53 [270], regulates genes such as 
isocitrate dehydrogenase 1 (IDH1) and thioredoxin domain-containing 5 
(TXNDC5) to decrease cellular stress [303], and regulates expression of growth 
promoting/survival genes such as survivin and epidermal growth factor receptor 
(EGFR) through NR4A1-Sp1 interactions with their proximal GC-rich promoter 
elements [272].  The pro-oncogenic NR4A1-regulated activities have previously 
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been characterized in colon, lung and pancreatic cancer cells [270, 272, 303, 
314], and the C-DIM/NR4A1 antagonists inhibited these pathways (Figure 13B) 
and gave results comparable to those observed for RNA interference (RNAi).  In 
preliminary data mining studies, we observed that NR4A1 was also 
overexpressed in RMS tumors compared to normal tissue and high levels were 
observed in prototypical ARMS (Rh30) and ERMS (RD) cell lines.  This study 
also demonstrates that NR4A1 regulates pro-oncogenic pathways (Figure 13B) 
in RMS cells and C-DIM/NR4A1 antagonists inhibit these responses, 
demonstrating that NR4A1 is a potential novel target for RMS chemotherapy. 
MATERIALS AND METHODS 
Cell Lines, Antibodies, Chemicals, and Other Materials   
 Rh30 and RD human RMS cancer cell lines were obtained from the 
American Type Culture Collection (Manassas, VA) and were maintained at 37°C 
in the presence of 5% CO2 in RPMI-1640 Medium or Dulbecco’s Modified 
Eagle’s Medium, respectively, both supplemented with 10% fetal bovine serum 
and 5% antibiotic.  Dulbecco’s Modified Eagle’s Medium, and RPMI-1640 were 
purchased from Sigma-Aldrich (St. Louis, MO), glutathione (GSH) reduced free 
acid were purchased from Millipore (Temecula, CA), and Lipofectamine 2000 
was purchased from Invitrogen (Grand Island, NY).  Apoptotic, Necrotic, and 
Healthy Cells Quantification Kit was purchased from Biotium (Hayward, CA).  
Cells were subsequently viewed using a filter set for FITC, rhodamine, and DAPI 
on an Advanced Microscopy EVOS fl, fluorescence microscope.  RGB-4103 
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GelRed nucleic acid stain was used in place of Ethedium Bromide from Phoenix 
Research Products (Candler, NC).  The C-DIM compounds were prepared as 
previously described [314] and a summary of the antibodies are provided in 
Supplemental Table B-1.  A summary of oligonucleotide for RNAi and real time 
PCR and ChIP primers are summarized in Supplemental Table B-2. 
Total RNA Expression Analysis   
 Patient sample data of total RNA was acquired from NCBI GEO dataset 
GSE28511 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28511) and 
was previously analyzed for quality control, quantile normalized.  In addition, 
multi-probe genes were averaged by the submitter.  Expression values were 
listed into non-tumor and RMS tumor groups in JMP® and a box plot was 
generated, from which a t-test was performed; significance was determined as a 
p-value less than 0.01, shown by an asterisk (Figure 13C).  
Cell Proliferation andTumor Growth Assay   
 Rh30 and RD cells were plated in 12-well plates at 1.0 x 105 and allowed 
to attached for 24 hr before treatment with DIM-C-pPhOH, DIM-C-pPhCO2Me, or 
transfected with siNR4A1, with DMSO (dimethyl sulfoxide) as empty vehicle or 
siCtl siRNA (with lipofectamine vehicle) as controls, respectively.  Cells were 
then trypsinized and counted at indicated times using a Coulter Z1 cell counter.  
Female athymic nude mice (6-8 weeks old) were obtained (Charles River 
Laboratory, Wilmington, MA) and maintained under specific pathogen-free 
conditions, and housed at Texas A&M University in accordance with the 
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standards of the Guide for the Care and Use of Laboratory Animals and the 
Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC).  The protocol of the animal study was approved by the Institutional 
Animal Care and Use Committee, Texas A&M University.  Rh30 cells (4x106 
cells) grown in RPMI media containing 10% FBS were detached, resuspended 
in 100 µl of phosphate-buffered saline with matrigel (BD Bioscience, Bedford, 
MA) (75:25), and implanted subcutaneously in the mice.  When tumors reached 
about 40-50 mm3 size, the animals were randomized into control and treatment 
groups (6 animals per group) and mice were treated with placebo or DIM-C-
pPhCO2Me (40 mg/kg/d) in corn oil by oral gavage every second day for 20 
days.  Tumor volumes and weights, and body weight were determined; the 
tumor size was measured using Vernier calipers, and the tumor volume was 
estimated by the formula: tumor volume (mm3) = (L x W2) x ½, where L is the 
length and W is the width of the tumor.   
Annexin V Staining   
 Rh30 and RD cells were seeded in 2-well Lab-Tek chambered B#1.0 
Borosilicate coverglass slides from Thermo Scientific and were allowed to attach 
for 24 hr before treatment with C-DIMs or DMSO for 48 hr and with siNR4A1 
(100 μM) or siCtl for 72 hr, and Annexin V staining was determined as described 
[314].   
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Immunofluorescence 
 Rh30 and RD cells were seeded at 1.0 x 105 in 2-well Lab-Tek 
chambered B#1.0 Borosilicate coverglass slides from Thermo Scientific and 
were allowed to attach for 24 hr in DMEM/Ham F-12 containing 5.0% charcoal-
stripped fetal bovine serum and treated with C-DIM compounds for 24 hr.  Cells 
were then treated with fluorescent NR4A1 antibody [Nurr77 (D63C5) XP®] and 
the manufacturer's protocol (Cell Signaling Technologies, Danvers, MA) was 
used to observe immunofluorescence.  Hoechst staining from the apoptotic and 
necrotic cells assay (Biotium, Hayward, CA) was used to visualize nuclear DAPI 
staining, while NR4A1 localization was determined by green fluorescence.  
Images were taken using an EVOS fluorescence microscopy from Advance 
Microscopy; NR4A1 and DAPI images were subsequently merged. 
Western Blot 
 Rh30 and RD cells were seeded in 6-well plates at 1.0 x 105 and allowed 
to attached for 24 hr before treatment with DIM-C-pPhOH, DIM-C-pPhCO2Me, or 
transfected with siNR4A1, with DMSO as empty vehicle or siCtl siRNA (with 
lipofectamine vehicle) as controls, respectively.  Cells were treated with C-DIMs 
or DMSO for 48 hr or transfected with siNR4A1 (100 μM) or siCtl for 72 hr, and 
Western blots of whole cell lysates were determined as described [314].     
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Transactivation, real-time PCR, and chromatin immunopricipitation (ChIP) 
assays 
 Real time PCR and ChIP assays using RMS cell lines transfected with 
oligonucleotides or treated with C-DIMs were carried out essentially as 
described [270, 272, 303, 314]. Transactivation studies were carried out in RD 
cells transfected with two NR4A1-responsive constructs, NuREx3-luc and 
NBRE3-luc, that bind NR4A1 as a homodimer or monomer, respectively, or 
transfected with a GAL4-NR4A1 (chimera) and a GAL4-responsive construct 
(UASx5-luc) essentially as described [329].  Real-time PCR and chromatin 
immunoprecipitation assays were carried out essentially as described [272]. 
Generation and Measurement of ROS 
 Cellular ROS levels were measured utilizing a cell permeable probe, CM-
H2DCFDA (5-(and-6)-chloromethyl-2'7'-dichlorodihydrofluorescein diacetate 
acetyl ester) from Invitrogen (Grand Island, NY).  CM-H2DCFDA diffuses into 
the cell, where its acetate groups are cleaved by intracellular esterases and 
upon oxidation, yields a fluorescent adduct that is measured by flow cytometry 
using Accuri’s C6 Flow Cytometer (Ann Arbor, MI).  Cells were plated in a 6-well 
culture plate and allowed to attach for 24 hr and treated for the indicated time 
with DIM-C-pPhOH, DIM-C-pPhCO2Me, or siNR4A1.  Subsequently, cells were 
trypsinized, neutralized, then loaded with 10 μM of probe for 20 min incubation, 
and were washed with serum free media for ROS quantification. 
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Statistics 
 Results for each treatment group were replicated (at least 3X) and 
expressed a means ± SE.  Statistical comparisons of the treated groups vs. a 
control for each treatment were determined using Student's t-test. 
RESULTS 
NR4A1 Expression and Transactivation 
 Examination of publically-available RMS array data show that NR4A1 
mRNA is more highly expressed in RMS tumors compared to non-tumor tissue 
(Figure 13C).  Previous studies show that the C-DIM compounds DIM-C-pPhOH 
and DIM-C-pPhCO2Me bind NR4A1 and act as NR4A1 antagonists for 
transactivation assays in colon cancer cells [314] and therefore these 
compounds were also used in this study on RMS cells.  RD cells were 
transfected with constructs containing the DNA binding domain of the yeast 
GAL4 protein fused to NR4A1 and the UASX5 luc construct containing 5 GAL4 
response elements, and treatment with DIM-C-pPhOH or DIM-C-pPhCO2Me 
decreased luciferase activity (Figure 13D).  DIM-C-pPhOH and DIM-C-
pPhCO2Me also decreased luciferase activity in RD cells transfected with 
NBRE3-luc and NuRE3-luc constructs containing 3 binding sites for NR4A1 
monomer and homodimer, respectively (Figure 13D). 
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Figure 13. NR4A1 expression and transactivation by C-DIMs. (A) Structure of C-DIMs and (B) NR4A1-
regulated pro-oncogenic pathways in cancer cells.  (C) Analysis of NR4A1 gene expression in patient-
derived mRNA acquired from the NCBI GEO dataset GSE2851.  (D) C-DIMs inhibit NR4A1-dependent 
transactivation.  RD cells were transfected with pGAL4-NR4A1/UASx5-luc, NBREx3-luc or NuREs3-luc, 
treated with DMSO or 15 µM DIM-C-pPhOH or DIM-C-pPhCO2Me, and luciferase activity was determined 
as outlined in the Materials and Methods.  Results are expressed as means +/- SE for at least 3 separate 
experiments and significantly (p < 0.05) decreased activity is indicated (*).  (E) Cellular localization of 
NR4A1.  Rh30 (A) and RD (B) cells were treated with DMSO or 20 µM DIM-C-pPhOH for 24 hr and cells 
were stained with DAPI and a fluorescent NR4A1 antibody.  The individual and merged staining was 
determined as outlined in the Materials and Methods. 
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Basal activity was low for both constructs but significantly enhanced by 
cotransfection with a FLAG-TR3 expression plasmid in RD cells.  These results 
were comparable to those previously observed in colon cancer cells [314] and 
demonstrate that the two C-DIM compounds exhibit antagonist activity for 
transactivation in RD cells.  Immunostaining of Rh30 and RD cells with DAPI 
and NR4A1 antibodies showed that NR4A1 was nuclear in these RMS cell lines 
(Figure 13E).  Moreover, after treatment with 20 µM DIM-C-pPhOH for 24 hr, we 
did not observe any nuclear export of NR4A1 which was comparable to 
observations in other cancer cell lines [270, 272, 303, 314].   
Role of NR4A1 in RMS Cell Growth and Survival  
 Transfection of Rh30 and RD cells with siNR4A1 significantly decreased 
proliferation of Rh30 and RD cells and comparable results were observed for 
two different siRNAs (Figure 14A).  Treatment of Rh30 cells with 7.5 to 22.5 µM 
DIM-C-pPhOH and 5 to 15 µM DIM-C-pPhCO2Me of the NR4A1 antagonists for 
24 hr also inhibited growth of RH30 (Figure 14B) and RD (Figure 14C) cells with 
IC50 values ranging from 6.6 to 29 µM.  Figure 14D also shows that although 
inhibition of RD cell growth after treatment with 15 µM DIM-C-pPhCO2Me was 
only 20-25%, after prolonged treatment (48 and 72 hr), more complete growth 
inhibition was observed.  In addition, we also observed that DIM-C-pPhOH (40 
mg/kg/d) inhibited tumor growth in athymic nude mice bearing Rh30 cells as 
xenografts (Figure 14E).   
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Figure 14. NR4A1 regulates growth of RMS cells which can be inhibited by C-DIM/NR4A1 
antagonists. (A) Rh30 and Rd cells were transfected with two different oligonucleotides targeted to NR4A1 
[siNR4A1(1) and siNR4A1(2)], and after 72 hr, the cells were counted and compared to the number of cells 
observed after transfection with a non-specific control (siCtl) oligonucleotide.  Rh30 and RD cells were 
treated with different concentrations of DIM-C-pPhOH (B) or DIM-C-pPhCO2Me (C) for 24 hr, and (D) RD 
cells were treated with 15 µM DIM-C-pPhCO2Me for 24, 48 or 72 hr.  Cells were counted and compared to 
the number observed after treatment with the solvent control (DMSO, set at 100%).  (E) In a preliminary in 
vivo study, we observed that after treatment of athymic nude mice with DIM-C-pPhOH (40 mg/kg/d for 28 
days), there was a small but significant inhibition of tumor growth and future studies will use a higher dose 
of this compound.  Results (A – E) are expressed as means ± SE for at least 3 separate treatments for 
each group and significant (p < 0.05) growth inhibition is indicated (*). 
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We also investigated the role of NR4A1 in mediating survival of Rh30 and RD 
cells, and Figure 15A shows that transfection of these cells with siNR4A1 
resulted in the induction of Annexin V staining.  Moreover, transfection of Rh30 
and RD cells with siNR4A1 also induced PARP cleavage, another marker of 
apoptosis in these cells (Figure 15B).  Treatment of Rh30 and RD cells with the 
NR4A1 antagonists DIM-C-pPhOH and DIM-C-pPhCO2Me also induced Annexin 
V staining (Figure 15C) and PARP cleavage (Figure 15D), thus confirming the 
pro-survival activity of NR4A1 in RMS cells and effects of C-DIM/NR4A1 
antagonists as inhibitors of cell growth and survival.   
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Figure 15. NR4A1 regulates RMS survival that can be inhibited by C-DIM/NR4A1 antagonists.  Rh30 
and RD cells were transfected with siNR4A1 or siNR4A2, and induction of Annexin V staining (A) or 
enhanced PARP cleavage (B) were determined as outlined in the Materials and Methods.  Rh30 and RD 
cells were treated with DIM-C-pPhOH or DIM-C-pPhCO2Me and effects on Annexin V staining (C) or 
enhanced PARP cleavage were determined as outlined in the Materials and Methods.  Results (A and C) 
were expressed as means ± SE for at least 3 replicate determinations per treatment group and significant 
(p < 0.05) induction is indicated (*). 
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NR4A1 Antagonists Inhibit Growth/Survival Pathways and Gene Products in 
RMS Cells 
 Previous studies show that NR4A1 acts as a coactivator of genes with 
GC-rich promoters (Figure 13B, pathway 3) that play a role in cancer cell 
proliferation and survival, and these include survivin, bcl-2, cyclin D1, epidermal 
growth factor receptor (EGFR) and the oncogene cMyc [272, 314].  Knockdown 
of NR4A1 by RNA in Rh30 and RD cells decreased expression of several genes 
with GC-rich promoters including EGFR, bcl2, c-Myc and cyclin D1, and this was 
accompanied by minimal effects on expression of Sp1 (Figure 16A).  Treatment 
of Rh30 and RD cells with the NR4A1 antagonists DIM-C-pPhOH (Figure 16B) 
and DIM-C-pPhCO2Me (Figure 16C) also decreased expression of survivin, bcl-
2, cyclin D1, EGFR and cMyc, and these results paralleled those observed after 
knockdown of NR4A1 in these cells lines (Figure 16A).  DIM-C-pPhCO2Me was 
used to further investigate the mechanism of downregulation of Sp-regulated 
genes at the transcriptional level.  In a ChIP assay, DIM-C-pPhCO2Me 
decreased binding of NR4A1 and p300 (but not Sp1) at the GC-rich region of the 
survivin promoter and pol II binding was also decreased (Figure 16D).  These 
results are comparable to previous studies in pancreatic cancer cells showing 
that p300/NR4A1 coregulated survivin expression by interacting with DNA-
bound Sp1 (Figure 13B) [272].  In addition, DIM-C-pPhCO2Me also decreased 
expression of survivin, cyclin D1 and EGFR mRNA levels (Figure 16E).  Thus, 
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NR4A1 also coregulates expression of Sp-regulated pro-survival/growth 
promoting genes with GC-rich promoters in RMS cells.   
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Figure 16. NR4A1 regulation of pro-survival/growth promoting genes and their inhibition by C-
DIM/NR4A1 antagonists. (A) Rh30 and RD cells were transfected with siNR4A1 or siCtl, and whole cell 
lysates were analyzed by Western blots as outlined in the Materials and Methods.  Rh30 and RD cells were 
treated with DMSO (solvent control), DIM-C-pPhOH (B) or DIM-C-pPhCO2Me (C), and whole cell lysates 
were analyzed by Western blot as outlined in the Materials and Methods.  (D) Rh30 and RD cells were 
treated with DIM-C-pPhCO2Me, and binding of NR4A1, Sp1, p300 and pol II to the survivin promoter was 
determined in a ChiP assay.  (D) Cells were treated with DIM-C-pPhCO2Me, and survivin, cyclin D1 and 
EGFR mRNA levels were determined by real time PCR.  Results are expressed as means ± SE (3 
replicates) and significant (p < 0.05) changes in gene expression are indicated (*). 
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  NR4A1 also regulates expression of TXNDC5 and IDH1 to maintain low 
oxidative and endoplasmic reticulum (ER) stress [303, 314], and transfection of 
Rh30 and RD cells with siNR4A1 induced ROS as determined using the cell 
permeable fluorescent indicator CM-H2DCFDA (Figure 17A) and similar results 
were observed after treatment with the NR4A1 antagonists (Figure 17B).  
Knockdown of NR4A1 (Figure 17C) or treatment of Rh30 and RD cells with the 
NR4A1 antagonists (Figure 17D) decreased expression of TXNDC5 and IDH1 
and this was accompanied by induction of several markers of ER stress 
including phosphorylated PERK (pPerk), ATF4 and CHOP.  Both TXNDC5 and 
IDH1 have GC-rich promoter sequences at -22 and -112, respectively, in 
untreated cells, and a ChIP assay showed binding of NR4A1, Sp1 and p300 to 
the GC-rich regions of the promoter in Rh30 cells (Figure 17E).  Treatment of 
these cells with the NR4A1 antagonist DIM-C-pPhCO2Me resulted in decreased 
interactions of NR4A1, p300 and pol II with the GC-rich TXNDC5 and IDH1 
promoters and also some loss of Sp1 from the TXNDC5 promoter, suggesting 
that like survivin, expression of these genes also involves interaction of the 
p300/NR4A1 complex with Sp1 at GC-rich elements (Figure 13B).  In addition, 
DIM-C-pPhCO2Me also decreased expression of TXNDC5 and IDH1 mRNA 
levels (Figure 17F).  The induction of ROS by inactivation of NR4A1 also has 
functional significance since DIM-C-pPhOH-induced cleavage of PARP, 
caspases 3 and 7 (markers of apoptosis), and growth inhibition were significantly 
reversed after cotreatment with 5 mM glutathione (GSH) (Suppl. Figure A-1).  
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  NR4A1 binds and inactivates p53 (Figure 13B) and knockdown of NR4A1 
or treatment with NR4A1 antagonists results in p53-dependent induction of 
sestrin 2, an upstream regulator of AMPKa in lung and colon cancer cells [270, 
314].  Even though Rh30 and RD cells are p53-negative; knockdown of NR4A1 
in Rh30 cells or treatment with DIM-C-pPhOH induced sestrin 2 and increased 
phosphorylation of AMPKa and this resulted in decreased activation of mTOR-
dependent phosphorylation of both 4EBP1 and 6SRP which are kinases 
downstream from mTOR (Figure 18A). Similar results were observed in RD cells 
(Suppl. Figure A-2A) and after treatment with DIM-C-pPhCO2Me (Suppl. Figure 
A-2B).  Sestrin 2 is also induced in response to ROS [330] and since C-
DIM/NR4A1 antagonists induce ROS (Figure 17B), the effects of the antioxidant 
GSH as an inhibitor of sestrin 2 induction after NR4A1 inactivation was 
investigated. Sestrin 2 induction in RD and Rh30 cells treated with DIM-C-
pPhOH or DIM-C-pPhCO2Me was attenuated after cotreatment with GSH 
(Figure 18B) and similar results were observed after NR4A1 knockdown (Figure 
18C).  DIM-C-pPhCO2Me also induced sestrin 2 gene expression in Rh30 and 
RD cells (Figure 18D), and the induction response was attenuated in cells 
cotreated with the antioxidant GSH (Figure 18E).  
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Figure 17. Role of NR4A1 in regulating oxidative stress. Rh30 and RD cells were either transfected with 
siNR4A1(1)/siNR4A1(s) (A) or treated with DIM-C-pPhOH or DIM-C-pPhCO2Me (B), and ROS was 
determined using the cell permeable fluorescent probe CM-H2DCFDA as outlined in the Materials and 
Methods.  Rh30 and RD cells were either transfected with siNR4A1 (C) or treated with DIM-C-pPhOH or 
DIM-C-pPhCO2Me (D), and whole cell lysates were analyzed for TXNDC5, IDH1 and various ER stress 
genes by Western blot analysis as outlined in the Material and Methods. (E) Rh30 cells were treated with 
DMSO or 20 µM DIM-C-pPhCO2Me, and binding of NR4A1, p300, Sp1 and pol II to the GC-rich regions of 
the TXNDC5 and IDH1 gene promoters were determined in a ChIP assay as outlined in the 24 hr and (F) 
mRNA levels were determined by real time PCR.  Results are expressed as means ± SE (triplicate 
determinations) and significant (p < 0.05) changes in gene expression are indicated. 
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  Thus, the NR4A1 antagonists block at least three NR4A1-regulated pro-
oncogenic pathways (Figure 13B) in RMS cells indicating that NR4A1 is a 
potential new drug target for treatment of RMS. 
DISCUSSION 
  The NR4A orphan nuclear receptors are immediate early genes induced 
by multiple stressors and there is increasing evidence that these receptors play 
a critical role in maintaining cellular homeostasis in multiple tissues and organs 
[325].  There is evidence that NR4A1 is important in metabolism and metabolic 
disease, cardiovascular and neuronal function, and inflammation in multiple 
tissues [325].  The function and mechanism of action of NR4A1 in cancer cells is 
complex; transgenic mice in which both NR4A1 and NR4A3 (Nurr1) have been 
knocked out rapidly develop an acute myeloid leukemia (AML) type of leukemia 
and there is evidence that NR4A1 is a tumor suppressor for AML [283, 331].  In 
contrast, NR4A1 is overexpressed in most solid tumors and is a negative 
prognostic factor for lung, breast and colon cancer patients and knockdown 
studies show that NR4A1 plays a role in cancer cell proliferation, survival, 
migration and invasion [201, 285-287, 326, 332, 333]. 
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Figure 18. NR4A1 regulates sestrin 2 and mTOR in RMS cells. (A) Rh30 cells were either transfected 
with siNR4A1 or treated with DIM-C-pPhOH, and whole cell lysates were analyzed as outlined in the 
Materials and Methods.  Rh30 and RD cells were either treated with DIM-C-pPhOH or DIM-C-pPhCO2Me 
alone or in combination with GSH (B) or transfected with siCtl/siNR4A1 alone or in combination with GSH 
treatment (C).  Whole cell lysates were analyzed for sestrin 2 (SESN2) by Western blots as outlined in the 
Materials and Methods.  Rh30 and RD cells were treated with DMSO and DIM-C-pPhCO2Me alone (D) or in 
combination with GSH (E), and expression of sestrin 2 mRNA levels were determined by real time PCR as 
outlined in the Materials and Methods.  Results (D and E) are expressed as means ± SE (3 replicates) and 
significant (p < 0.05) induction (*) or inhibition of induction (**) are indicated. 
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  Early studies on drug-mediated effects of NR4A1 demonstrated that 
many apoptosis-inducing drugs that do not directly bind NR4A1 induce nuclear 
export of this receptor which subsequently binds to mitochondrial bcl-2 to form a 
pro-apoptotic complex that disrupts mitochondria in cancer cells, resulting in 
increased cell death (24, 25).  However, more recently cytosporone B and some 
structurally-related compounds have been identified as NR4A1 ligands [260, 
315, 328] and studies in this laboratory have also identified C-DIMs as NR4A1 
receptor ligands and these compounds act as NR4A1 antagonists that inhibit 
cancer cell growth and survival by directly targeting nuclear NR4A1 [260, 314, 
315, 328].   
  NR4A1 is a nuclear protein expressed in RD and Rh30 cells (Figure 13E), 
and there is evidence from publically available array data from RMS tumors that 
NR4A1 mRNA is overexpressed in tumor vs. non-tumor tissue (Figure 13C).  
The functional role of NR4A1 in RMS was investigated by RNAi showing that 
this receptor plays a role in RMS cell proliferation and survival (Figs. 14 and 15) 
and these results are comparable to those observed in many other solid tumors 
[reviewed in 201].  NR4A1 knockdown studies also demonstrated that NR4A1 
also plays a role in activating mTOR and maintaining low stress levels through 
its regulation of TXNDC5 and IDH1 (Figure 17).  Both IDH1 and TXNDC5 are 
regulated by NR4A1 in pancreatic and colon cancer cells, and knockdown of 
either NR4A1 or TXNDC5 in pancreatic cancer cells results in the induction of 
ROS [303].  The results illustrated in Figures 17A and 17B show that knockdown 
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of NR4A1 in RMS cells also results in downregulation of TXNDC5 (and IDH1) 
and induction of ROS and ER stress genes, confirming that NR4A1 regulation of 
TXNDC5 suppresses ER and oxidative stress.  NR4A1 also regulates IDH1 
expression which also generates cellular reductants and complements the 
function of TXNDC5 in terms of stress suppression [330, 334].  In contrast to 
glioma and other cancer cells which express IDH1 mutations [335] enhancing D-
2-hydroxyglutarate production, this mutation has not been detected in RMS 
[336].  NR4A1-dependent maintenance of low oxidative stress levels also 
contributes to mTOR signaling since knockdown of NR4A1 results in oxidative 
stress-dependent induction of sestrin 2 [337] which in turn activates AMPKa and 
inhibits mTOR.  Genomic analysis coupled with high throughput screening of 
primary RMS cultures identified ROS inducers as a therapeutically relevant 
approach for treating ERMS [87].  Results of our studies implicate NR4A1 
regulation of TXNDC5 and IDH1 for maintaining low oxidative stress in RD and 
Rh30 cells and suppression of these gene by the C-DIM/NR4A1 antagonists 
induces ROS which in turn induces ER stress and also sestrin 2-dependent 
inhibition of mTOR (Figs. 17 and 18).  Induction of this latter pathway may be an 
important contributor to the efficacy of C-DIM/NR4A1 antagonists and other 
ROS-inducing agents since mTOR inhibitors show promise as mechanism-
based drugs for RMS chemotherapy [112, 338, 339].  Moreover, Supplemental 
Figure A-1 also demonstrates that DIM-C-pPhOH-mediated induction of ROS 
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plays a major role in growth inhibition and induction of apoptosis and this is due 
to the high sensitivity of RMS cells to ROS-inducing compounds [87]. 
  Nuclear receptors not only activate gene expression through direct 
binding to their cognate response elements but also indirectly through 
interactions with DNA-bound transcription factors such as Sp1, and this has 
been observed for several other nuclear hormone and orphan receptors [340-
346].  Similar results have previously been reported for NR4A1 which 
coactivates expression of growth-promoting and pro-survival genes with GC-rich 
promoters through interactions of p300/NR4A1-Sp1 bound to GC cis-elements 
[272, 314].  Knockdown of NR4A1 decreases expression of several Sp1-
regulated genes (but not Sp1) including survivin, bcl-2, EGFR, cyclin D1 and c-
Myc in Rh30 and RD cells as observed in other cancer cell lines and in this 
study, ChIP assays indicated that not only survivin (Figure 16D) but also 
TXNDC5 and IDH1 are regulated by interactions of p300/NR4A1 with Sp1 bound 
to GC-rich promoters (Figure 13B).  A previous study reported that Sp1 is 
overexpressed in RMS tumors and cells and Sp-regulated genes such platelet-
derived growth factor receptor a, hepatocyte growth factor receptor, insulin-like 
growth factor receptor and CXCR4 are important for the oncogenic phenotype of 
RMS [90].  Current studies using RNA-seq combined with receptor knockdown 
are focused on the role of NR4A1 in regulating expression of these genes and 
other pro-oncogenic factors in RMS cells via pathway 3 (Figure 13B). 
  113 
  The important pro-oncogenic functions of NR4A1 in RMS cells indicate 
that antagonists of this receptor represent a potential novel clinical approach for 
treating RMS.  DIM-C-pPhOH was initially characterized as an inhibitor of 
NR4A1-dependent transactivation and recent structure-binding studies 
demonstrate that DIM-C-pPhOH, DIM-C-pPhCO2Me and other C-DIMs bind the 
ligand binding domain of NR4A1 and exhibit NR4A1 antagonist activity in colon 
cancer cells [314].  In RMS cells, we have also observed parallel effects of 
NR4A1 knockdown and treatment with DIM-C-pPhOH and DIM-C-pPhCO2Me, 
demonstrating that C-DIM/NR4A1 antagonists represent a new class of 
mechanism-based drugs for treating RMS.  This observation is particularly 
important for RMS patients since their current treatment regimens rely on 
cytotoxic drugs which lead to serious health problems later in life [74, 320]. 
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CHAPTER III 
PAX3-FOXO1A EXPRESSION IS REGULATED BY THE NUCLEAR 
RECEPTOR NR4A1 IN RHABDOMYOSARCOMA AND CAN BE TARGETED 
BY NR4A1 ANTAGONISTS* 
INTRODUCTION 
 The orphan nuclear receptors NR4A1 (Nur77, TR3), NR4A2 (Nurr1) and 
NR4A3 (Nor1) play important roles in maintaining cellular homeostasis by their 
involvement in inflammation, immune and neuronal functions, metabolism, and 
differentiation [258, 325].  These receptors are early immediate genes induced 
by multiple stimuli and there is increasing evidence that NR4A receptors are 
potential drug targets for many diseases including cancer [201, 258, 283, 325].  
Among the NR4A receptors, there has been extensive research on the 
expression and role of NR4A1 in cancer and one study found the loss of both 
NR4A1 and NR4A2 in mice results in hematological malignancies [347], 
suggesting tumor suppressor-like activity for NR4A1.  In contrast, NR4A1 
exhibits tumor promoter activity [201, 283] in solid tumors.  NR4A1 is also 
overexpressed in tumors from breast, lung, pancreatic, colon and ovarian cancer 
patients and is a negative prognostic factor for breast, lung and ovarian cancer 
patients [236, 270-272, 285, 326, 327]. Although endogenous ligands for NR4A1 
and other NR4A receptors have not been identified, structurally-diverse 
*Reprinted with permission from “PAX3-FOXO1A Expression is Regulated by the 
Nuclear Receptor NR4A1 in Rhabdomyosarcoma and Can be Targeted by NR4A1 
Antagonists” Lacey A, Rodrigues-Hoffman A, Safe S, 2016 Cancer Research, 77(3), 
732-741 Copyright [2016] American Association for Cancer Research 
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compounds directly or indirectly target this receptor.  Initial studies demonstrated 
that several apoptosis-inducing agents activated nuclear export of NR4A1 and 
formation of a pro-apoptotic complex with bcl-2 which subsequently disrupted 
mitochondria [288, 348, 349].  Wu and coworkers identified cytosporone B and 
structural analogs as NR4A1 ligands and these compounds exhibited structure-
dependent activation of nuclear NR4A1 and nuclear export [260, 263, 315, 328].  
In contrast, studies in this laboratory have demonstrated that among a series of 
1,1-bis(3'-indolyl)-1-(p-substituted phenyl)methanes (C-DIMs), several 
compounds, including the p-hydroxy (DIM-C-pPhOH) and p-carboxymethyl 
(DIM-C-pPhCO2Me) bound and activated nuclear NR4A1 and acted as NR4A1 
antagonists [314].   
 In a series of studies, it was demonstrated that knockdown of NR4A1 
(siRNA) by RNAi or treatment with C-DIM/NR4A1 ligands inhibits pancreatic, 
lung, kidney, colon, rhabdomyosarcoma (RMS), and breast cancer growth and 
induces apoptosis [270-272, 303, 314, 317, 350-352].  Moreover, in breast 
cancer cells, these same treatments inhibit migration through downregulation of 
b1-integrin, an NR4A1-regulated gene [351].  Pro-oncogenic NR4A1-regulated 
pathways/genes in RMS and other cancer cell lines are summarized in Figure 
19A.  NR4A1 activates TXNDC5 and IDH1 to decrease reactive oxygen species 
which facilitates activation of mTOR, and NR4A1 also regulates pro-survival and 
growth promoting genes through an NR4A1/Sp complex interacting with GC-rich 
gene promoters [270, 272, 303].  The NR4A1/Sp gene regulation pathway does 
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not require direct NR4A1 binding to promoter DNA and is commonly observed 
for several nuclear receptors including orphan receptors [353, 354].  Sp 
transcription factors (Sp1, Sp3 and Sp4) are highly overexpressed in RMS cells 
[90, 96, 352], and the anticancer agent tolfenamic acid decreased expression of 
Sp1, Sp3, Sp4 and pro-oncogenic Sp-regulated genes including PAX3-FOXO1A 
[90], a critical pro-oncogenic factor in alveolar RMS (ARMS), a deadly form of 
RMS.  In this study, we hypothesize and subsequently confirm that PAX3-
FOXO1A is an NR4A1/Sp-regulated gene and treatment with NR4A1 
antagonists decreases expression of PAX3-FOXO1A and downstream genes in 
ARMS cells.  Thus, NR4A1 antagonists represent a novel approach for treating 
ARMS patients that overexpress this receptor.  
MATERIALS AND METHODS 
Cell Lines, Antibodies, Chemicals, and Other Materials  
 RD and Rh30 cell lines were purchased from the American Type Culture 
Collection and were authenticated in 2014 (Promega Powerplex 18D) at the 
Duke University DNA Analysis Laboratory. Rh18 and Rh41 cells were received 
from Texas Tech University Health Sciences Center-Children’s Oncology Group 
in 2015.  All cell lines were maintained at 37°C in the presence of 5% CO2 with 
Rh30 maintained in RPMI-1640 Medium supplemented with 10% fetal bovine 
serum and 5% antibiotic.  Rh41 and Rh18 cells lines were maintained in Iscove’s 
Modified Dulbecco’s Medium (IMDM) supplemented with 20% fetal bovine 
serum, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid), 
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and 5% antibiotic.  RPMI-1640 was purchased from Sigma-Aldrich (St. Louis, 
MO).  IMDM was purchased from ThermoFisher Scientific (Waltham, MA) and 
ITS was purchased from Sigma Aldrich (St. Louis, MO).  Lipofectamine 2000 
was purchased from Invitrogen (Grand Island, NY).  The C-DIM compounds 
were prepared as previously described [314].  Summaries of the antibodies and 
oligonucleotides for RNAi, real time PCR and ChIP primers are summarized in 
Supplemental Table B-3. 
Total RNA Expression Analysis 
Sample data of total RNA was acquired from NCBI GEO dataset 
GSE2787 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2787).  In 
addition, transcription profiles of competitively hybridized microarray samples 
were quantified and lowess normalization for each spot was performed and 
subsequently converted in logarithmic scale, with submitted expression values 
corresponding to a log(2) ratio of normalized intensities.  Expression values 
were listed into PAX3-FOXO1A positive and PAX3-FOXO1A negative groups in 
JMP® and a box plot was generated, from which a t-test was performed; 
significance was determined as a p-value less than 0.01, shown by an asterisk.  
Boyden Chamber Assay  
RMS cells were seeded for 24 hr in a 24-well plate and subsequently 
allowed to attach for 24 hr transfection with IL-24 overexpression vector, 
siPAX3-FOXO1A (100 μM), or siIL-24 (100 μM) with a control of siCtl. The cells 
were trypsinized, counted, placed in 24-well 8.0-μm-pore ThinCerts from BD 
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Biosciences (Bedford, MA), allowed to migrate for 24 h, fixed with formaldehyde, 
and then stained with hematoxylin. Cells that migrated through the pores were 
then counted.  
Western Blot   
Rh30, Rh18, and Rh41 cells were seeded in 6-well plates at 1.0 x 105 and 
allowed to attach for 24 hr before treatment with DIM-C-pPhOH, DIM-C-
pPhCO2Me, or transfected with siNR4A1, siPAX3-FOXO1A, or siIL-24 with 
DMSO as empty vehicle or siCtl siRNA (with lipofectamine vehicle) as controls, 
respectively.  Cells were treated with C-DIMs or DMSO for 48 hr or transfected 
with siNR4A1, siPAX3-FOXO1A, or siIL-24 (all at 100 μM) or siCtl for 72 hr, and 
Western blots of whole cell lysates were determined as previously described 
[314].    
Real-time PCR, and Chromatin Immunoprecipitation (ChIP) Assays   
Real time PCR and ChIP assays using RMS cell lines transfected with 
oligonucleotides or treated with C-DIMs were carried out using the SYBR Green 
RT-PCR Kit (Bio-rad Laboratories, Hercules, CA) and the ChIP-IT Expression Kit 
(Carlsbad, CA) following the manufacturers protocol. Oligonucleotides and 
primers used are summarized in Supplemental Table S1.  
Cell Proliferation and Tumor Growth Assay  
Rh30, Rh18, and Rh41 cells were plated in 12-well plates at 1.0 x 105 and 
allowed to attach for 24 hr before treatment with DIM-C-pPhOH, DIM-C-
pPhCO2Me, or transfected with siNR4A1, siPAX3-FOXO1A, or siIL-24 with 
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DMSO (dimethyl sulfoxide) as empty vehicle or siCtl siRNA (with lipofectamine 
vehicle) as controls, respectively.  Cells were then trypsinized and counted at 24 
hours using a Coulter Z1 cell counter.   
Female athymic nude mice (6-8 weeks old) were obtained (Charles River 
Laboratory, Wilmington, MA) and maintained under specific pathogen-free 
conditions, housed in isolated vented cages, and allowed to acclimate for one 
week with standard chow diet.  The animals were housed at Texas A&M 
University in accordance with the standards of the Guide for the Care and Use of 
Laboratory Animals and the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC).  The protocol of the animal study was 
approved by the Institutional Animal Care and Use Committee (IACUC), Texas 
A&M University.  Rh30 cells (4x106 cells) grown in RPMI media containing 10% 
FBS were detached, resuspended in 100 µl of phosphate-buffered saline with 
matrigel (BD Bioscience, Bedford, MA) (75:25), and implanted subcutaneously in 
the mice.  When tumors reached about 40-50 mm3 size, the mice were 
randomized into control and treatment groups (6 animals per group) and treated 
with placebo or DIM-C-pPhCO2Me (40 mg/kg/d) in nano liquid carrier 
(administered in sodium carboxymethyl cellulose) by oral gavage every second 
day for 3 weeks.  Tumor volumes and weights, and body weight were 
determined; the tumor size was measured using Vernier calipers, and the tumor 
volume was estimated by the formula:  tumor volume (mm3) = (L x W2) x ½, 
where L is the length and W is the width of the tumor.  All animals in the 
120 
treatment group presented with an infiltrative, densely cellular neoplasm with 
similar histological features as observed in the control group.  Multifocal areas of 
necrosis were also observed within the neoplasm in this group (Suppl.  S3). 
RESULTS 
NR4A1 Regulates PAX3-FOXO1A Expression in ARMS Cells 
Previous analysis of publically available patient arrays shows that NR4A1 
is upregulated in tumors from RMS patients and analysis of ARMS tumors 
showed that NR4A1 levels were also higher in PAX3-FOXO1A-positive vs. 
PAX3-FOXO1-negative tumors (Figure 19B) [352, 355].  This analysis was 
limited by the few studies available; however, there was a trend between 
expression of NR4A1 and PAX3-FOXO1A.  Transfection of Rh30 cells with siCtl 
(non-specific oligonucleotide) and siNR4A1 resulted in decreased expression of 
NR4A1 and PAX3-FOXO1A proteins and in a separate experiment, siNR4A1 
also decreased PAX3-FOXO1A mRNA (Figure 19C).  Transfection of Rh30 cells 
with siPAX3-FOXO1A decreased expression of PAX3-FOXO1A but not NR4A1 
protein confirming that NR4A1 regulated expression of the fusion gene in this 
cell line.  We also carried out an identical set of experiments in Rh41 (Figure 
19D) and Rh18 (Figure 19E) ARMS cell lines and the results were similar to that 
observed in Rh30 cells (Figure 19C), confirming that NR4A1 regulates PAX3-
FOXO1A expression.   
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Figure 19. NR4A1 regulates PAX3-FOXO1A expression in ARMS. (A) Pro-oncogenic pathways 
regulated by NR4A1 in RMS and other cancer cell lines.  (B) Analysis of PAX3-FOXO1A gene expression 
in ARMS tumors expressing high and low levels of NR4A1 in patient-derived mRNA acquired from the 
NCBI GSE2851 dataset.  Effects of knockdown of NR4A1 by RNAi (siNR4A1) in Rh30 (C), Rh41 (D) and 
Rh18 (E) on PAX3-FOXO1A protein and RNA was determined by western blot analysis of whole cell 
lysates and real time PCR of RNA extracts, respectively, as outlined in the Materials and Methods.  Results 
were compared to cells transfected with a non-specific control oligonucleotide, and RNA results are means 
± SE for three replicated determinations and significant (p<0.05) decreases are indicated (*). 
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The highly pro-oncogenic activity of PAX3-FOXO1A is primarily due to 
regulation of downstream genes which include the oncogene NMyc, ras-
association domain family 4 (RASSF4), myogenic differentiation-1 (MYOD1), 
gremlin 1 (GREM1) and death-associated protein kinase-1 (DAPK1) [356-359].  
Knockdown of NR4A1 in Rh30 cells resulted in decreased expression of NMyc, 
Rassf4, MyoD1, Grem1 and DAPK1 and similar results were observed in cells 
transfected with siPAX3-FOXO1A (Figure 20A).  Moreover, comparable results 
were observed in Rh41 (Figure 20B) and Rh18 (Figure 20C) cells confirming 
that NR4A1 downregulation results in decreased expression not only of PAX3-
FOXO1A but also PAX3-FOXO1A-regulated genes in ARMS cells. 
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Figure 20. NR4A1 regulates expression of PAX3-FOXO1A-dependent genes.  Rh30 (A), Rh41 (B) and 
Rh18 (C) cells were transfected with siCtl, siNR4A1 or siPAX3-FOXOA1 and after 72 hr, whole cell lysates 
were analyzed by western blots.  Common lysates were used for western blots illustrated in Figures 19 and 
20. 
NR4A1 Antagonists Decrease Expression of PAX3-FOXO1A in ARMS Cells 
Previous studies show that DIM-C-pPhOH and DIM-C-pPhCO2Me bind 
the ligand binding domain of NR4A1 [314] and act as NR4A1 antagonists in 
pancreatic, colon, breast, kidney and RMS cells [270, 303, 314, 317, 350-352].  
Treatment of Rh30 cells with DIM-C-pPhOH and DIM-C-pPhCO2Me decreased 
expression of PAX3-FOXO1A protein and this was accompanied by 
downregulation of NMyc, Rassf4, MyoD1, Grem1 and DAPK1 proteins (Figure 
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21A).  Similar results were observed in Rh41 (Figure 21B) and Rh18 (Figure 
21C) cells, confirming that knockdown of NR4A1 by RNAi (Figs. 19 and 20) or 
inactivation of NR4A1 by treatment with NR4A1 antagonists resulted in the 
abrogation of the PAX3-FOXO1A signaling pathway in ARMS cells.  Using Rh30 
cells as a model, we also observed that DIM-C-pPhCO2Me decreased 
expression of PAX3-FOXO1A (Figure 21D) and NMyc, Grem1, DAPK1, MyoD1 
and Rassf4 (Figure 21E) mRNA levels in Rh30 cells.  This is consistent with the 
potential role of NR4A1 as a regulator of PAX3-FOXO1A gene expression and 
PAX3-FOXO1A-mediated regulation of the downstream genes.   
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Figure 21. NR4A1 antagonists downregulate PAX3-FOXO1A. Rh30 (A), Rh41 (B) and Rh18 (C) cells 
were treated with the NR4A1 antagonists DIM-C-pPhOH and DIM-C-pPhCO2Me for 24 hr and whole cell 
lysates were analyzed by western blots as outlined in the Materials and Methods.  Rh30 cells were treated 
with 10 or 15 µM DIM-C-pPhCO2Me for 24 hr and RNA extracts were examined by real time PCR for 
expression of PAX3-FOXO1A (D) and PAX3-FOXO1A-regulated genes (E).  Results (D and E) are 
expressed as means ± SE for 3 replicate determinations and significantly (p<0.05) decreased expression 
compared to DMSO (control) is indicated (*). 
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Mechanism of NR4A1 Regulation of PAX3-FOXO1A 
Previous studies show that NR4A1, in combination with p300, act as 
nuclear cofactors for expression of some Sp1-regulated genes including 
survivin, TXNDC5, IDH1, a5-integrin and b1-integrin [272, 351, 352].  The 
PAX3-FOXO1A promoter has several GC-rich binding sites (Figure 22A), and 
we therefore investigated the role of Sp1 in regulating expression of PAX3-
FOXO1A and downstream genes by RNAi.  Knockdown of Sp1 decreased Sp1 
and p300 proteins but did not affect expression of PAX3-FOXO1A or 
downstream genes in Rh30, Rh41 or Rh18 cells (Suppl. Figure A-3A), 
suggesting that in contrast to previous studies on NR4A1/Sp1-regulated genes 
[272, 351, 352], neither Sp1 nor p300 were required.  This was confirmed by 
knockdown of p300 in ARMS cells which did not affect expression of PAX3-
FOXO1A and downstream genes (Suppl. Figure A-3B).  Since Sp3 and Sp4 also 
bind GC-rich promoter sites and are overexpressed in RMS cells [90, 96], we 
investigated the effects of Sp3 and Sp4 knockdown and downregulation of 
Sp1/3/4 (combined) (Figs. 22B-22D, respectively).  Knockdown of Sp3 had 
minimal effects on expression of PAX3-FOXO1A and downstream genes; 
however, knockdown of either Sp4 or Sp1/3/4 resulted in decreased expression 
of PAX3-FOXO1A, NMyc, Rassf4, Grem1, MyoD1 and DAPK1.  Results of these 
RNAi experiments indicated that Sp4 interactions with NR4A1 regulated PAX3-
FOXO1A expression and therefore we carried out ChIP assays on the three 
different GC-rich regions of the PAX3-FOXO1A gene promoter (Figure 22A) to 
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determine NR4A1/Sp4 promoter interactions.  In untreated Rh30 cells, NR4A1, 
Sp4, p300 and pol II were associated with the promoter and treatment with 20 
µM DIM-C-pPhOH for 6 hr decreased interactions of pol II, NR4A1 and Sp4 with 
the two distal and proximal regions of the PAX3-FOXO1A gene promoter (Figure 
22E).  P300 and other Sp proteins also interacted with the PAX3-FOXO1A 
promoter (data not shown); however, these genes did not play a functional role 
in regulation of PAX3-FOXO1A.  We also showed by RNAi that CBP knockdown 
did not alter expression of PAX3-FOXO1A (Suppl. Figure A-3C) and current 
studies are investigating other cofactors which may coregulate NR4A1/Sp4-
dependent expression of PAX3-FOXO1A. 
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Figure 22. Role of p300/NR4A1/Sp in regulation of PAX3-FOXO1A in ARMS cells. (A) GC-rich Sp 
binding sites in the proximal and two distal regions of the PAX3-FOXO1A gene promoter. ARMS cells were 
transfected with siSp3 (B), siSp4 (C), and siSp1/3/4 (D). Whole cell lysates were analyzed by western blots 
as outlined in the Materials and Methods.  (E) Rh30 cells were treated with 20 µM DIM-C-pPhCO2Me for 6 
hr and association of various factors with the proximal and two distal regions of the PAX3-FOXO1A 
promoter were determined in a ChIP assay as outlined in the Materials and Methods. Sp1 and Sp3 also 
bound the PAX3-FOXO1A gene promoter (data not shown). 
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Functional and in Vivo Studies 
Previous studies showed that PAX3-FOXO1A plays an important role in 
ARMS cell migration/invasion [360, 361] and this is confirmed in Rh30 cells 
where transfection of siPAX3-FOXO1A decreased migration in a Boyden 
chamber assay (Figure 23A).  Moreover, transfection of Rh30 cells with 
siNR4A1 or treatment with the NR4A1 antagonist DIM-C-pPhCO2Me also 
inhibited Rh30 cell migration, confirming that either direct (siPAX3-FOXO1A) or 
indirect downregulation of the fusion gene by inactivation of NR4A1 decreased 
Rh30 cell migration.  We recently observed that knockdown of b1-integrin by 
siNR4A1 or treatment with DIM-C-pPhCO2Me decreased migration of breast 
cancer cells and this involved an NR4A1/Sp1 complex binding to GC-rich 
elements in the b1-integrin promoter [351].  DIM-C-pPhCO2Me also decreased 
expression of b1-integrin and phosphorylation of FAK (pFAK downstream from 
b1-integrin) in Rh30 cells and knockdown of NR4A1 by RNAi also gave similar 
results (Figure 23B).  Moreover, using lysates from the Sp knockdown studies 
(Figure 22 and Suppl. Figure A-3), we also observed that only siSp4 and 
siSp1/3/4 decreased b1-integrin and pFAK (Figure 23C), suggesting that 
NR4A1/Sp4 regulated both b1-integrin and PAX3-FOXO1A, and knockdown of 
b1-integrin also decreased Rh30 cell migration (Figure 23D).  We conclude that 
NR4A1-mediated migration of Rh30 cells is dependent on both PAX3-FOXO1A 
and b1-integrin (Figure 23E) which can be targeted simultaneously by C-
DIM/NR4A1 antagonists.   
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Figure 23. PAX3-FOXO1A and b1-integrin are regulated by NR4A1/Sp4 and are both pro-migration 
genes. (A) Knockdown of PAX3-FOXO1A (siPF) or NR4A1 by RNAi and treatment with DIM-C-pPhCO2Me 
decreased Rh30 migration in a Boyden chamber assay as outlined in the Materials and Methods.  (B) Rh30 
cells were treated with DIM-C-pPhCO2Me or transfected with siNR4A1, and whole cell lysates were 
analyzed for b1-integrin/FAK expression by western blots.  (C) Rh30 cells were transfected with 
oligonucleotides targeted to Sp1, Sp3, Sp4 and Sp1/3/4 (combined), and whole cell lysates were analyzed 
by western blots.  Lysates were obtained from studies outlined in Supplemental Figure B-3 and Figures 
20B-20D. (D) Rh30 cells were transfected with b1-integrin and cell migration was determined in a Boyden 
chamber assay. (E) Model for NR4A1/Sp4 regulation of PAX3-FOXO1A and b1-integrin. Results (A and D) 
are expressed as means ± SE for 3 replicate determinations and significant (p<0.05) decreases are 
indicated (*). 
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 Previous studies showed that the NR4A1 antagonist DIM-C-pPhCO2Me 
(40 mg/kg/day) inhibited tumor growth in athymic nude mice bearing Rh30 cells 
as xenografts [352].  We examined lysates from tumors treated with corn oil 
(control) or DIM-C-pPhCO2Me and the treatment significantly decreased 
expression of PAX3-FOXO1A mRNA and protein and downstream genes nMyc, 
Rassf4, MyoD1 and DAPK1 (Figs 24A and 24B). This is consistent with the 
results of in vitro studies (Figure 21).  Moreover, using human b2-microglobulin 
mRNA as a unique marker, we observed decreased expression in lungs of mice 
bearing Rh30 cells as xenografts; this was consistent with decreased lung 
metastasis (Figure 24C). Histological analysis of RMS xenografts of DIM-C-
pPhCO2Me-treated and control-treated mice showed minimal differences (Figure 
24D). 
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Figure 24.  In vivo studies.  Tumors from mice treated with corn oil or DIM-C-pPhCO2Me (40 mg/kg/d) 
(25) were extracted for protein (A) and mRNA (B) analysis by western blots and real-time PCR, 
respectively.  (C) Human b2-microglobulin mRNA expression in lungs from control and DIM-C-pPhCO2Me-
treated mice were determined by real time PCR.  (D) Representative images of rhabdomyosarcoma 
observed on control (a, b) and treatment groups (c, d).  In both groups, the neoplasm was characterized by 
a population of round and pleomorphic cells arranged in sheets, with moderate to abundant cytoplasm and 
round nuclei.  Scattered multinucleated neoplastic cells were observed.  The neoplasm had multifocal 
necrotic areas in both the control and treatment groups.  Hematoxylin and eosin; 100X (a, c), 400X (b, d). 
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demonstrated that 2;13 and 1;13 chromosomal translocations generating PAX3-
FOXO1A and PAX7-FOXO1A fusion genes, respectively, are highly prevalent 
(55% and 22%, respectively) in tumors from ARMS patients.  The PAX3-
FOXO1A fusion gene is the critical prognostic marker for ARMS patients with 
metastatic disease, with an estimated overall 4-year survival of 8% compared to 
75% survival rate of patients with PAX7-FOXO1A-expressing tumors [362-364].  
Unfortunately, RMS patients that survive current cytotoxic drug therapies have 
an increased risk for several diseases later in life [74], emphasizing the critical 
need for development of new mechanism-based therapies which have fewer 
long term adverse effects.  Results of PAX3-FOXO1A knockdown or 
overexpression studies in RMS and other cell lines demonstrate the functional 
importance of this fusion gene in maintaining the aggressive cancer cell 
phenotype and this is due, in part, to the pro-oncogenic PAX3-FOX01-regulated 
genes [362, 365].  Development of agents that target PAX3-FOXO1A is ongoing 
and includes thapsigargin, fenretinide, HDAC inhibitors, and polo-like kinase 
inhibitors; however, the efficacy of these compounds for clinical applications in 
ARMS chemotherapy is not known [87, 366-369].   
 There is evidence that ROS-inducing anticancer agents such as HDAC 
inhibitors are effective anticancer agents against RMS in both laboratory rodent 
and cell models and that ROS decreases expression of Sp1, Sp3, Sp4 and pro-
oncogenic Sp-regulated genes [87, 96, 366].  In addition, ROS-independent 
downregulation of Sp transcription factors in RMS cells treated with tolfenamic 
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acid demonstrates that several pro-oncogenic genes in RMS including c-Met, 
CXCR4, insulin-like growth factor receptor (IGFR), and platelet-derived growth 
factor receptor a (PDGFRa) are Sp-regulated.  Tolfenamic acid also decreases 
PAX3-FOXO1A in Rh30 cells [90].  Knockdown of Sp transcription factors or 
NR4A1 in RMS cells resulted in decreased cell proliferation, induction of 
apoptosis, and inhibition of cell migration [90, 96].  The comparable functions of 
Sp transcription factors and NR4A1 are due, in part, to coregulation of genes by 
NR4A1/Sp complexes that bind GC-rich gene promoters such as survivin, 
TXNDC5, IDH1 and b1-integrin [272, 351, 352].  Ongoing RNAseq and array 
studies also show that there is a considerable overlap between genes 
coregulated by NR4A1 and Sp transcription factors, and we hypothesized that 
PAX3-FOXO1A is also an NR4A1/Sp-regulated gene.   
 Knockdown of NR4A1 or treatment of Rh30, Rh41 and Rh18 ARMS cells 
with NR4A1 antagonists decreased expression of PAX3-FOX01A (protein and 
mRNA) and downstream genes (Figs. 19-21) and similar results were observed 
after PAX3-FOXO1A knockdown by RNAi.  In vivo studies also showed that 
DIM-C-pPhCO2Me decreased PAX3-FOXO1A and downstream genes in Rh30-
derived tumors (Figure 24A).  The role of Sp transcription factors in mediating 
this response was investigated by RNAi (Figure 22) and the results indicated 
that Sp4 and not Sp1 or Sp3 was involved in expression of PAX3-FOXO1A.  A 
recent study showed that Sp1, Sp3 and Sp4 regulate expression of several 
genes in common; however, all three transcription factors also regulate unique 
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sets of genes [97] and in ARMS cells PAX3-FOXO1A expression is dependent 
on NR4A1 and Sp4; this was confirmed in ChIP assays (Figure 22).  We did not 
observe that p300 (or CBP) was required for NR4A1/Sp4-mediated regulation of 
PAX3-FOXO1A.  This differed from NR4A1/Sp1-dependent genes, and current 
studies are investigating the identity of factors that may be involved. 
 In summary, this study shows that the critical pro-oncogenic PAX3-
FOXO1A fusion gene is regulated by NR4A1/Sp4 interactions with GC-rich gene 
promoter elements.  PAX3-FOXO1A gene expression can be inhibited by 
targeting either the receptor or Sp4 since knockdown of NR4A1 or Sp4 by RNAi 
blocks PAX3-FOXO1A gene expression.  This study shows for the first time that 
C-DIM/NR4A1 antagonists represent a new class of mechanism-based agents 
that target PAX3-FOXO1A and other pro-oncogenic genes/pathways (Figure 
19A).  These antagonists also simultaneously decrease expression of PAX3-
FOXO1A and b1-integrin genes (Figure 23E) which play a role in ARMS cell 
migration/invasion.  Current studies are focused on development of more 
efficacious C-DIM/NR4A1 antagonists for clinical applications in ARMS 
chemotherapy and for combination therapies that will reduce requirements for 
cytotoxic drugs and thereby decrease the incidence of health effects later in life 
[74].  
 
 
 
  136 
CHAPTER IV 
ANTICANCER AGENTS DOWNREGULATE PAX3-FOXO1A IN ALVEOLAR 
RHABDOMYOSARCOMA (ARMS) CELLS AND INDUCE INTERLEUKIN-24 
INTRODUCTION 
Rhabdomyosarcoma (RMS is primarily observed in children and 
adolescents and accounts for approximately 5% of all pediatric cancers with 
incidence rates of 4.5/106 [319, 320, 370] . Embryonal RMS (ERMS) and 
alveolar RMS (ARMS) are the two major classes of RMS in children and 
adolescents and differ with respect to their histology, genetics, treatment, and 
prognosis [322, 370]. ERMS accounts for over 60% of RMS patients and is 
associated with loss of heterozygosity at the 11p15 locus [322]. ERMS patients 
have a favorable initial prognosis; however, the overall survival of patients with 
metastatic ERMS is only 40% [371]. Cytogenetic analysis of tumor from ARMS 
patients have identified that 2;13 and 1;13 chromosomal translocations 
generating PAX3-FOXO1A and PAX7-FOXO1A fusion genes, respectively, are 
highly prevalent (55 and 22%, respectively) [99]. The PAX3-FOXO1A fusion 
gene is the critical prognostic marker for ARMS patients with metastatic disease, 
with an estimated overall 4 year survival of 8% compared to 75% survival rate of 
patients with PAX7-FOXO1A-expressing tumors [364, 372, 373].  
Results of PAX3-FOXO1A knockdown or overexpression studies in RMS and 
other cell lines demonstrate the functional importance of this fusion gene in 
maintaining the aggressive cancer cell phenotype and this is due, in part, to the 
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pro-oncogenic PAX3-FOXO1-regulated genes [98, 356, 374]. Treatment of RMS 
patients include radiotherapy, surgery, and chemotherapy with cytotoxic drugs 
and/or drug combinations of vincristine, dactinomycin, cyclophosphamide, 
irinotecan, fosfamide, etoposide, doxorubicin, and others. A serious problem 
also exists for RMS patients that survive current cytotoxic drug therapies, since 
these individuals as adults have an increased risk for several diseases [74]. 
 The orphan nuclear receptor NR4A1 is overexpressed in colon, 
pancreatic, breast (estrogen receptor positive and negative), and lung tumors; in 
breast, colon, and lung tumor patients, high expression of NR4A1 predicts 
decreased survival [236, 270-272, 285, 327]. The functional activity of NR4A1 in 
cancer has been extensively investigated in cancer cell lines by either 
knockdown or overexpression. NR4A1 regulates one or more of cancer 
proliferation, survival, cell cycle progression, migration, and invasion in lung, 
melanoma, lymphoma, pancreatic, colon, cervical, ovarian, and gastric cancer 
cell lines [271, 272, 284, 286, 287, 303, 327, 332, 333, 352, 356, 375]. 
 Studies in this laboratory have reported that NR4A1 is also 
overexpressed in RMS tumor compared to normal muscle tissue [352] and 
NR4A1 regulated many of the same genes/pathways observed in other solid 
tumors [270, 272, 303, 314, 317, 350, 352, 376, 377]. The NR4A1 ligand 1,1-
bis(3-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-pPhOH) which acts as a 
receptor antagonist to inhibit growth, survival, and migration of RMS cells and 
also inhibits RMS tumor growth in a xenograft mouse model [352]. These 
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NR4A1 antagonists are particularly effective against ARMS cells/tumors since 
they block expression of PAX3-FOXO1A, an NR4A1 regulated gene [377]. The 
present study was initiated after analysis of RNASeq data showed that after 
knockdown of NR4A1 or PAX3-FOXO1A or treatment with DIM-C-pPHOH, the 
most highly induced gene in common was the tumor suppressor-like factor 
interleukin-24 (IL-24). Thus, the oncogenic activity of PAX3-FOXO1A is due, in 
part to suppression of IL-24 while the anticancer activities observed after PAX3-
FOXO1A knockdown/suppression are due primarily to induction of IL-24. We 
also observed that IL-24 overexpression inhibited ARMS cell growth, survival, 
and migration, suggesting that the clinically approved IL-24 adenoviral 
expression vector potentially [378] represents a promising new approach for 
ARMS therapy.  
MATERIALS AND METHODS 
Cell Lines, Antibodies, Chemicals, and Other Materials   
Rh30 human RMS cancer cells were obtained from the American Type 
Culture Collection and authenticated in 2014 (Manassas, VA) and were 
maintained at 37°C in the presence of 5% CO2 in RPMI-1640 Medium and 
supplemented with 10% fetal bovine serum and 5% antibiotic.  Rh18 and Rh41 
cells were received from Texas Tech University Health Sciences Center-
Children’s Oncology Group in 2015. Rh41 and Rh18 cell lines were maintained 
in Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 20% fetal 
bovine serum, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous 
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acid), and 5% antibiotic. IMDM was purchased from ThermoFisher Scientific 
(Waltham, MA). RPMI-1640 was purchased from Sigma-Aldrich (St. Louis, MO), 
and Lipofectamine 2000 for siRNA transfection was purchased from Invitrogen 
(Grand Island, NY).  Apoptotic, Necrotic, and Healthy Cells Quantification Kit 
was purchased from Biotium (Hayward, CA).  Cells were subsequently viewed 
using a filter set for FITC, rhodamine, and DAPI on an Advanced Microscopy 
EVOS fl, fluorescence microscope.  RGB-4103 GelRed nucleic acid stain was 
used in place of Ethedium Bromide from Phenix Research Products (Candler, 
NC). SB203580 was purchased from Cell Signaling Technology (Danvers, MA). 
The human IL-24 cDNA clone in a pCMV-6 vector was purchased from origene 
(Rockville, MD). The C-DIM compounds were prepared as previously described 
[272] and a summary of the antibodies aare provided in Supplemental Table B-
4. A summary of oligonucleotide for RNAi and real time PCR and ChIP primers
are summarized in Supplemental Table B-4. 
Total RNA Expression Analysis, RNASeq Analysis, IL-24 Overexpression, 
and CRISPR/Cas9 
Patient sample data of total RNA was acquired from NCBI GEO dataset 
GSE28511 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28511) and 
was previously analyzed for quality control, quantile normalized.  In addition, 
multi-probe genes were averaged by the submitter.  Expression values were 
listed into non-tumor and RMS tumor groups in JMP® and a box plot was 
generated, from which a t-test was performed; significance was determined as a 
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p-value less than 0.01, shown by an asterisk (Figure 25B). RMS cells were 
treated with DIM-C-pPhOH for 48 hr or transfected with siPAX3-FOXO1A or 
siNR4A1 for 72 hr after which RNA was extracted and sent to the Texas A&M 
AgriLife Sequencing Core for preparation, sequencing, and analysis.  IL-24 
cDNA was transfected into RMS cells using lipofectamine 2000 delivery at a 
concentration of 50 μM before endpoint analysis using western blot, PCR, or 
Annexin V staining. IL24 CRISPR guide RNA 3 plasmid [pSp Cas9 BB-2A-GFP 
(PX458)] was purchased from GenScript (Piscataway, NJ). To create a stable 
IL-24 KO cell line, DH5α supercompetent  bacterial cells were transformed using 
IL24 guide RNA. This included a preincubation of bacteria with plasmid for 30 
mins on ice, followed by a 1min 30 sec heat shock, then cells were allowed to 
recuperate on ice with 200 μl SOC broth supplement. Cells were then plated on 
LB agar plates and allowed to grow for 18-24 hr.  Cells were screened for GFP 
under microscope and selected to be innocuated overnight (18 hr) in LB media. 
IL24 CRISPR guide plasmid was then isolated using a DNA miniprep from Zymo 
Research (Irvine, CA) using manufacturer’s protocol. RD and Rh30 
rhabdomyosarcoma cells were seeded (1.2 x 105 per well) in six well plates in 
Dulbecco’s modified Eagle’s medium/Ham’s F-12 medium supplemented with 
2.5% charcoal-stripped fetal bovine serum and left to attach for 24 hours. Cells 
were transfected with IL24 CRISPR guide RNA plasmid using LIpofectamine 
2000 reagent according to the manufactures protocol. Cells were then visualized 
under the microscope to detect GFP fluorescence after a period of 6-12 hr. After 
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72 hr cells were then used for cell proliferation, apoptotic, migration, and western 
blot analysis. 
Cell Proliferation Assay   
Rh30, Rh18, and Rh41 cells were plated in 12-well plates at 1.0 x 105 
and allowed to attach for 24 hr before treatment with DIM-C-pPhOH, DIM-C-
pPhCO2Me, or transfected with siNR4A1, siPAX3-FOXO1A, or siIL-24 with 
DMSO (dimethyl sulfoxide) as empty vehicle or siCtl siRNA (with lipofectamine 
vehicle) as controls, respectively.  Cells were then trypsinized and counted at 24 
hours using a Coulter Z1 cell counter  
Annexin V Staining   
RMS cells were seeded at 1.0 x 105 in 2-well Lab-Tek chambered B#1.0 
Borosilicate coverglass slides from Thermo Scientific and were allowed to attach 
for 24 hr transfection with IL-24 overexpression vector, siPAX3-FOXO1A (100 
μM), or siIL-24 (100 μM) with a control of siCtl (with lipofectamine vehicle) for 72 
hr, and Annexin V staining was determined as described [Diindolylmethane 
analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells]. Hoechst 
staining from the apoptotic and necrotic cells assay (Biotium, Hayward, CA) was 
used to visualize apoptotic cells. Images were taken using an EVOS 
fluorescence microscopy from Advance Microscopy.  
Boyden Chamber Assay  
RMS cells were seeded for 24 hr in a 24-well plate and subsequently 
transfected with attach for 24 hr transfection with IL-24 overexpression vector, 
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siPAX3-FOXO1A (100 μM), or siIL-24 (100 μM) with a control of siCtl. The cells 
were trypsinized, counted, placed in 24-well 8.0-μm-pore ThinCerts from BD 
Biosciences (Bedford, MA), allowed to migrate for 24 h, fixed with formaldehyde, 
and then stained with hematoxylin. Cells that migrated through the pores were 
then counted.  
Western Blot   
Rh30, Rh18, and Rh41 cells were seeded in 6-well plates at 1.0 x 105 and 
allowed to attached for 24 hr before treatment with DIM-C-pPhOH, DIM-C-
pPhCO2Me, or transfected with siNR4A1, siPAX3-FOXO1A, or siIL-24 with 
DMSO as empty vehicle or siCtl siRNA (with lipofectamine vehicle) as controls, 
respectively.  Cells were treated with C-DIMs or DMSO for 48 hr or transfected 
with siNR4A1, siPAX3-FOXO1A, or siIL-24 (all at 100 μM) or siCtl for 72 hr, and 
Western blots of whole cell lysates were determined as previously described 
[314].    
Real-time PCR, and Chromatin Immunoprecipitation (ChIP) Assays   
Real time PCR and ChIP assays using RMS cell lines transfected with 
oligonucleotides or treated with C-DIMs were carried out using the SYBR Green 
RT-PCR Kit (Bio-rad Laboratories, Hercules, CA) and the ChIP-IT Expression Kit 
(Carlsbad, CA) following the manufacturers protocol. Oligonucleotides and 
primers used are summarized in Supplemental Table B3. Transactivation 
studies were carried out in Rh30 cells transfected with two NR4A1-responsive 
constructs, NuREx3-luc and NBRE3-luc, that bind NR4A1 as a homodimer or 
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monomer, respectively, or transfected with a GAL4-NR4A1 (chimera) and a 
GAL4-responsive construct (UASx5-luc) essentially as described [329]. 
Statistics   
Results for each treatment group were replicated (at least 3X) and 
expressed a means +/-SE.  Statistical comparisons of the treated groups vs. a 
control for each treatment were determined using Student's t-test. 
RESULTS 
Changes in gene expression in Rh30 cells after knockdown of NR4A1 
and PAX3-FOXO1A or treatment with DIM-CpPhOH were determined by 
RNASeq and comparisons with controls. Figure 25A illustrates the changes in 
gene expression in the three treatment groups and the overlap of common 
genes that were induced (6) or repressed (7). Among the treatment related 
induced genes, IL-24 was induced by up to 27.9-fold. Therefore, we examined 
the relative expression of IL-24 in ARMS tumors vs normal muscle (Figure 25B) 
using publically available databases. IL-24 levels were significantly higher in 
normal muscle vs ARMS and also higher in PAX3-FOXO1A negative vs PAX3-
FOXO1A positive tumors (Figure 25B). Furthermore, the expression of IL-24 and 
NR4A1 are inversely related in ARMS and normal muscle tissue samples 
(Figure 25B).  
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Figure 25. PAX3-FOXO1A and NR4A1 regulate IL-24. (A) RNASeq analysis identified IL-24 as a 
commonly regulated gene of NR4A1 and PAX3-FOXO1A. (B) Analysis of IL-24 gene expression in ARMS 
tumors in patient-derived mRNA acquired from the NCBI GSE2851 dataset. 
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 RNASeq analysis shows that both NR4A1 and its ligand (DIM-C-pPhOH), 
which acts as an antagonist induce IL-24 in Rh30 cells and transfection of 
siNR4A1 or treatment with DIM-C-pPhOH induced IL-24 protein levels in this cell 
line (Figure 26A). Similar induction was observed after treatment with DIM-C-
pPhCO2Me, another NR4A1 ligand (Figure 26A). A similar approach was used 
for Rh18 (Figure 26B) and Rh41 (Figure 26C) and both siNR4A1 and NR4A1 
ligands induced IL-24 expression. PAX3-FOXO1A expression is also regulated 
by NR4A1 [377] and results in Figure 26D show that knockdown of PAX3-
FOXO1A (siPF) induces IL-24 expression. These results are consistent with the 
RNASeq data (Figure 25A), confirming that PAX3-FOXO1A suppressed IL-24 in 
ARMS cells.  
 
  146 
 
Figure 26. NR4A1 antagonism or inactivation upregulates IL-24. Rh30 (A), Rh41 (B) and Rh18 (C) cells 
were transfected with siRNA for NR4A1 and treated with the NR4A1 antagonists DIM-C-pPhOH and DIM-
C-pPhCO2Me for 24 hr and whole cell lysates were analyzed by western blots as outlined in the Materials 
and Methods. (D) ARMS cells were transfected with siRNA targeted for PAX3-FOXO1A. 
 
 
Figure 27A shows that NR4A1 knockdown or treatment with NR4A1 antagonists 
DIM-C-pPhOH and DIM-C-pPhCO2Me induce IL-24 gene expression in Rh30, 
Rh18, and Rh41 ARMS cells and similar results were observed after knockdown 
of PAX3-FOXO1A (Figure 27B).  
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We further examined PAX3-FOXO1A-IL24 interactions and observed that 
the IL-24 promoter contains proximal PAX3 binding sites at -472 and -95 (Figure 
27C). Primers targeted to the PAX3 sites were used in a ChIP assay and 
showed PAX3-FOXO1A (PAX3), CBP, and p300 binding and in cells transfected 
with siPAX3-FOXO1A (siPF), the PAX3-FOXO1A interaction decreased, while 
the CBP and p300 was unchanged and poll interactions were enhanced (Figure 
27D). Previous studies indicated that HDAC4 inhibited transcriptional activation 
of IL-24 [379] and results of a ChIP assay showed that HDAC4 was associated 
with the IL-24 promoter (Figure 27E) as previously described and after 
knockdown of PAX3-FOXO1A, HDAC4 promoter interactions were decreased. 
These results are consistent with the gene/protein expression studies showing 
that PAX3-FOXO1A represses IL-24 gene expression. 
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Figure 27. Role of PAX3-FOXO1A in regulation of IL-24 in ARMS cells. (A) Rh30 cells were treated with 
DIM-C-pPhCO2Me or DIM-C-pPhOH for 24 hr and (B) transfected with siPAX3-FOXO1A for 72 hr and RNA 
extracts were examined by real time PCR for expression of IL-24 and are expressed as means +/- SE for 3 
replicate determinations. (C) IL-24 promoter shows PAX3 binding sites and GC-rich sequences. (D & E) 
Rh30 cells were transfected with siPAX3-FOXO1A for 6 hr and association of various factors with the 
proximal and two distal regions of the IL-24 promoter were determined in a ChIP assay as outlined in the 
Materials and Methods. 
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 The anticarcinogenic effect of IL-24 in ARMS cells was investigated by 
overexpression studies and Figure 28A shows the overexpression of IL-24 
inhibited Rh30, Rh18, and Rh41 cell proliferation. IL-24 overexpression induced 
activation of caspase-3, caspase-9 and PARP cleavage in Rh30 (Figure 28B), 
Rh18 (Figure 28C), and Rh41 (Figure 28D) cells and also induced Annexin V 
staining in the 3 ARMS cell lines (Figure 28E). IL-24 also inhibited migration of 
ARMS cells (Figure 28F) and these results were similar to those previously 
observed in ARMS cells treated with C-DIM/NR4A1 antagonists or transfected 
with siNR4A1 or siPAX3-FOXO1A [352, 377].  
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Figure 28. Anticarcinogenic effect of IL-24 overexpression. (A) IL-24 overexpression decreases ARMS 
cell proliferation. IL-24 overexpression induced apoptosis markers in (B) Rh30, (C) Rh18, and (D) Rh41 
ARMS cells. (E) Observed Annexin V staining upon overexpression of IL-24 in ARMS cells. (F) IL-24 
overexpression decreases cell migration/invasion as determined by Boyden Chamber assay.  
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Previous studies have characterized several other IL-24 induced 
responses in diverse cancer cell lines, including increased phosphorylation of 
STAT1 and STAT3, activation or induction of stress/survival genes including, 
Bax, PERK, p38, GADD45, and GADD34 and downregulation of survival genes 
Bcl-2 and Bcl-XL [380-385]. These responses were investigated by 
overexpression of IL-24 in Rh30 (Figure 29A), Rh18 (Figure 29B), and Rh41 
(Figure 29C) cells and all of the IL-24 mediated effects previously reported in 
other cancer cell lines were also observed in ARMS cells. Previous studies also 
showed that IL-24 mediated downregulation of Bcl-2 and Bcl-XL, induction of 
Bax, GADD45, and GADD34 were p-38 dependent and Figure 5D shows that 
the p38 inhibitor SB203580 also inhibits the same IL-24 dependent responses in 
Rh30 cells. Results illustrated in Figures 28 and 29 demonstrate that IL-24 
exhibits multiple anticarcinogenic activities in RMS cells, which are suppressed 
by PAX3-FOXO1A. 
 Previous studies show that knockdown of PAX3-FOXO1A by RNAi or by 
NR4A1 antagonists inhibit ARMS cell growth, survival and migration [377] and 
the role of IL-24 in mediating these responses was investigated by transfecting 
cells with siPAX3-FOXO1A (which induces IL-24) and siIL-24. Results 
summarized in Figure 30A show that transfection of ARMS cells with siPAX3-
FOXO1A inhibits cell growth and migration, whereas in ARMS cells 
cotransfected with siPAX3-FOXO1A+siIL-24, these inhibitory responses are 
significantly attenuated. Figure 30B confirms this as siPAX3-FOX1A decreases  
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Figure 29. IL-24 dependent responses. Overexpression of IL-24 regulates expression of apoptosis, 
survival, and cellular stress genes in (A) Rh30, (B) Rh18, and (C) Rh41 ARMS cells. Inhibition of p38 by 
SB203580 attenuates IL-24 induced responses (D).   
 
 
expression of PAX3-FOXO1A and induces IL-24 expression while cotransfection 
with IL-24 decreases IL-24 but not PAX3-FOXO1A expression. Using the same 
treatment protocol, we observed that transfection of siPAX3-FOXO1A induced 
caspase-3, PARP cleavage (Figure 30C), and Annexin V staining (Figure 30D) 
and in cells cotreated with siPAX3-FOXO1A plus siIL-24 these same markers of 
apoptosis were significantly attenuated.  
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Figure 30. Role of IL-24 in mediating PAX3-FOXO1A activity. siPAX3-FOXO1A inhibits cell growth, 
migration (A), and apoptosis demonstrated by caspase-3 and PARP induction (C) and Annexin V staining 
(D), and cotransfection of siPAX3-FOXO1A+siIL-24 attenuates these responses in ARMS cells. (B) 
siPAX3-FOXO1A induces IL-24 expression and cotransfection with siIL-24 decreases IL-24 but not PAX3-
FOXO1A. 
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Figure 31. CRISPER/Cas9 KO of IL-24. Knockout of IL-24 by CRISPR/Cas9 attenuates C-DIM and 
siPAX3-FOXO1A-dependent (A) cell proliferation, apoptosis, and migration in Rh30 cells. (B) IL-24 
CRISPR/Cas9 KO cells do not exhibit C-DIM-induced IL-24 expression.  
 
 
 
We also generated Rh30-IL-24 KO cells by CRISPR/Cas9 and results in 
Figure 31A show that DIM-C-pPhOH and siPAX3-FOXO1A-dependent 
proliferation, Annexin V staining, and migration were observed in wild-type but 
were significantly attenuated in (Figure 31A) Rh30-IL-24 KO cells in which DIM-
C-pPhOH does not induce IL-24 (Figure 31B). These data suggest that ARMS 
cell growth inhibition, anti-migratory and apoptotic responses triggered by 
downregulation of PAX3-FOXO1A are primarily due to derepression of IL-24 and 
this correlates with the anticancer activities of IL-24 in ARMS cells (Figs 28 and 
29) and other cancer cell lines [385-388].  
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DISCUSSION 
 NR4A1 regulates PAX3-FOXO1A gene expression in ARMS cells and 
treatment with the NR4A1 antagonist DIM-C-pPhOH downregulated PAX3-
FOXO1A expression, resulting in inhibition of ARMS cell and tumor growth. 
RNASeq was used to investigate the common and divergent effects of NR4A1 
and PAX3-FOXO1A knockdown and DIM-C-pPhOH treatment on expression of 
gene in Rh30 cells and we observed induction of 6 and inhibition of 7 genes in 
common after all 3 treatments (Figure 25A). The most dramatic response was 
observed for IL-24, which is highly expressed in ARMS tumors that 
overexpression PAX3-FOXO1A (Figure 25B and 25C), but was induced 2.9 to 
27.9-fold in the different treatment groups. IL-24, which is also known as 
melanoma differentiation associated gene 7 is somewhat of a unique tumor 
suppressor cytokine that is a member of the IL-24 subfamily. IL-24 activates 
signaling through the type 1 and type 2 IL-24 receptors (IL-20R), which consists 
of the IL20RA:IL-20RB and IL-22RA1:IL20RB heterodimeric receptors, 
respectively [389]. The tumor suppressor-like activities of IL-24 include inhibition 
of cancer cell growth and migration, induction of apoptosis, and inhibition of drug 
resistance, and these activities are observed in several different cancer cell lines 
through activation/repression of multiple genes/pathways (rev. in [385-388]).  
 Results of knockdown (NR4A1 and PAX3-FOXO1A) or treatment with 
DIM-C-pPhOH resulted in increased expression of IL-24 mRNA and protein in 
Rh30, Rh18, and Rh41 ARMS cells and ChIP assays confirmed that this was 
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accompanied by increased polII associated with the IL-24 promoter (Figs 26 and 
27). This was also associated with the loss of PAX3-FOXO1A and HDAC4 from 
the promoter and the loss of HDAC4 is consistent with a previous report showing 
that HDAC4 suppressed IL-24 expression is melanoma cells [379]. Since PAX3-
FOXO1A can be targeted by NR4A1 antagonists, we therefore examined the 
effects of IL-24 overexpression in ARMS cells (Figure 28) and also determined 
the relative contributions of IL-24 to the tumor suppressor like activity observed 
after knockdown of PAX3-FOXO1A (Figure 30). Overexpression of IL-24 in 
ARMS cells inhibited cell growth and migration, activated caspase-dependent 
PARP cleavage and Annexin V staining, confirming that the anticarcinogenic 
activities of IL-24 observed in ARMS cells are similar to those reported in other 
solid tumors [385-388]. Overexpression of IL-24 activates or suppresses multiple 
genes and pathways in cancer cells that contribute to its tumor suppressor like 
activity. For example, IL-24 induces activation (phosphorylation) of p38 (MAPK) 
[383, 390], and induces the growth arrest and DNA damage (GADD)-inducible 
genes GADD45 and GADD34 [383], activates STAT1 and STAT3 [380, 385], 
increases the Bax/Bcl-2 ratio, and activates (phosphorylation) the stress gene 
protein kinas R-like endoplasmic reticulum kinas (PERK) [382]. We also 
observed these same IL-24 dependent responses in ARMS cells and their 
inhibition by SB203580 in Rh30 cells confirmed that p38 activation plays an 
important role in mediating the effects of IL-24 in ARMS cells (Figure 29). 
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 Thus, the direct effects of IL-24 in ARMS cells are similar to those 
observed in other cancer cell lines and the contributions of IL-24 to the tumor 
suppressor like activities observed after PAX3-FOXO1A downregulation were 
further investigated by RNAi (Figure 30). Knockdown of PAX3-FOXO1A by RNA 
inhibited growth, migration, and induced apoptosis in ARMS cells as previously 
reported; however, cotransfection with siIL-24 significantly attenuated the 
siPAX3-FOXO1A mediated anticarcinogenic activity. Moreover, we also 
generated IL-24 KO Rh30 cells by CRISPR/Cas9 and transfection of siPAX3-
FOXO1A had minimal effects on ARMS cell proliferation, survival, and migration 
(Figure 31), confirming that the tumor suppressor like activity resulting from 
PAX3-FOXO1A suppression is primarily due to induction of IL-24.  
 In summary, we show that PAX3-FOXO1A suppressed IL-24 gene 
expression in ARMS and that knockdown or drugs (NR4A1 antagonists) target 
PAX3-FOXO1A induced IL-24 expression. The results of both in vitro and in vivo 
studies demonstrate that IL-24 exhibits tumor suppressor like activity in ARMS 
cells and these observations are similar to results observed in other solid 
tumors. The safety of adenoviral-delivered IL-24 has been shown in a phase I 
trial in patients with advanced tumor and our results in ARMS cells suggests that 
IL-24 therapy may be warranted for clinical application in treating ARMS 
patients. This approach may be particularly efficacious in light of toxic-side 
effects associated with current therapies.  
 
  158 
CHAPTER V 
POTENT BIS-INDOLE-DERIVED NUCLEAR RECEPTOR 4A1 (NR4A1) 
ANTAGONISTS INHIBIT RHABDOMYOSARCOMA (RMS) TUMOR GROWTH 
INTRODUCTION 
 Rhabdomyosarcoma (RMS) is primarily observed in children and 
adolescents and this represents approximately 50% of all soft tissue sarcomas 
in children [319, 320, 391].  Embryonal RMS (ERMS) is the most common form 
of RMS observed in children and represents approximately 60% of all cases.  
Alveolar RMS (ARMS) is observed in approximately 20% of all RMS patients 
and is characterized by chromosomal translocations generating PAX3-FOXO1A 
and PAX7-FOXO1A fusions, and patients expressing the former more prevalent 
fusion gene have a poor prognosis [321, 370].  ERMS and ARMS tumors are 
distinguished histopathologically and both types of RMS are treated with 
combinations of surgery, radiotherapy and cytotoxic drugs [392, 393].  ERMS 
patients without metastasis respond well to the various therapies, whereas 
ARMS patients are less responsive and the overall 4-year survival rate of 
metastatic ARMS patients is <8%.  RMS patients and survivors of other 
childhood cancers suffer the consequences from their aggressive therapies 
since it was reported that 95.5% of these individuals at 45 suffer from some 
increased chronic health problem [74].   
 Studies in this laboratory have been focusing on development of ligands 
that target (and inhibit) the orphan nuclear receptor 4A1 (NR4A1, TR3, Nur77) 
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[270-272, 303, 314, 317, 350-352, 394].  NR4A1 is overexpressed in estrogen 
receptor positive and negative breast tumors, pancreatic, colon and lung tumors 
and overexpression in breast, colon and lung tumors is a negative prognostic 
factor for patient survival [236, 270, 272, 285, 326, 327, 394].  Recent studies 
also show that NR4A1 is overexpressed in RMS tumors and knockdown 
experiments in these solid tumors demonstrate that NR4A1 is pro-oncogenic 
and regulates genes/pathways associated with cancer cell proliferation, survival 
and migration/invasion [352, 394].   
 Studies in this laboratory have identified a series of 1,1-bis(3-indolyl)-1-
(substituted phenyl)methane (C-DIM) analogs containing para-substituents on 
the phenyl ring that act as NR4A1 antagonists and block the NR4A1-regulated 
pro-oncogenic pathways/genes in RMS and other solid tumors [270-272, 303, 
314, 317, 350-352, 394].  One of the most active compounds containing the p-
hydroxyphenyl moiety, 1,1-bis(3'-indolyl)-1-(p-hydroxyphenyl)methane (DIM-C-
pPhOH, CDIM8), also bound with high affinity to NR4A1 [314] but exhibited low 
serum levels in pharmacokinetic studies [395].  Therefore, in this study we 
generated a series of C-DIM analogs containing a p-hydroxyphenyl group but 
also buttressed by one or two additional substituents ortho to the p-hydroxyl 
group.  Our results show that some of these "second generation" substituted 
DIM-C-pPhOH analogs exhibited up to an order of magnitude higher potency 
than DIM-C-pPhOH and represent a class of second generation C-DIM/NR4A1 
antagonists that are promising new agents for treatment of rhabdomosarcoma. 
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MATERIALS AND METHODS 
Synthesis of Substituted DIM-C-pPhOH Analogs 
 Indole, 3,5-dimethoxy-, 3,5-dimethyl-, 3-methyl-, 3-methoxy-, 3-chloro-, 
3-bromo-, 3,5-dibromo- and 3-chloro-5-methoxybenzaldehyde were purchased 
from Sigma-Aldrich (St. Louis, MO) and 3-fluorobenzaldehyde was obtained 
from Alfa Aesar (Ward Hill, MA).  Condensation of 2 mole equivalent of indole 
with 1 mole equivalent of the benzaldehyde derivative was carried out in 50 ml 
water plus 0.6 ml acetic acid at 90° C for 24-48 hr; the solid material was filtered 
and recrystallized from benzene or benzene/petroleum spirit.  Compounds were 
³98% pure and overall yields for all the condensation reaction were 80-95%.  
The compounds synthesized include 1,1-bis(3'-indolyl)-1-(3,5-dibromo-4-
hydroxy-phenyl)methane (DIM-C-pPhOH-3,5-Br2), 1,1-bis(3'-indolyl)-1-(3,5-
dimethoxy-4-hydroxyphenyl)methane [DIM-C-pPhOH-3,5-(OCH3)2], 1,1-bis(3'-
indolyl)-1-(3,5-dimethyl-4-hydroxyphenyl)methane [DIM-C-pPhOH-3,5-(CH3)2], 
1,1-bis(3'-indolyl)-1-(4-hydroxy-3-methylphenyl)methane (DIM-C-pPhOH-3-CH3), 
1,1-bis(3'-indolyl)-1-(4-hydroxy-3-methoxyphenyl)methane (DIM-C-pPhOH-3-
OCH3), 1,1-bis(3'-indolyl)-1-(3-fluoro-4-hydroxyphenyl)methane (DIM-C-pPhOH-
3-F), 1,1-bis(3'-indolyl)-1-(3-bromo-4-hydroxyphenyl)methane (DIM-C-pPhOH-3-
Br), 1,1-bis(3'-indolyl)-1-(3-chloro-4-hydroxyphenyl)methane (DIM-C-pPhOH-3-
Cl), and 1,1-bis(3'-indolyl)-1-(3-chloro-4-hydroxy-5-methoxyphenyl)methane 
(DIM-C-pPhOH-3-Cl-5-OCH3).   
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Cell Lines, Antibodies, Chemicals, and Other Materials 
Rh30 human RMS cancer cells were obtained from the American Type 
Culture Collection (Manassas, VA) and authenticated in 2014, and were 
maintained at 37°C in the presence of 5% CO2 in RPMI-1640 Medium and 
supplemented with 10% fetal bovine serum and 5% antibiotic.  RPMI-1640 and 
b-actin antibody were purchased from Sigma-Aldrich (St. Louis, MO).  The C-
DIM compounds were prepared as previously described above.  FOXO1 
antibody was purchased from Cell Signaling Technologies (Danvers, MA); 
TXNDC5 antibody was purchased from GeneTex (Irvine, CA); IL-24, GDA, and 
DCDC2 antibodies were purchased from Abcam (Cambridge, MA).  
Tumor Growth Assay   
Female athymic nude mice (6-8 weeks old) were obtained (Charles River 
Laboratory, Wilmington, MA) and maintained under specific pathogen-free 
conditions, housed in isolated vented cages, and allowed to acclimate for one 
week with standard chow diet.  The animals were housed at Texas A&M 
University in accordance with the standards of the Guide for the Care and Use of 
Laboratory Animals and the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC).  The protocol of the animal study was 
approved by the Institutional Animal Care and Use Committee (IACUC), Texas 
A&M University.  Rh30 cell lines (4x106 cells) grown in RPMI media containing 
10% FBS were detached, resuspended in 100 µl of phosphate-buffered saline 
with matrigel (BD Bioscience, Bedford, MA) (75:25), and implanted 
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subcutaneously in the mice.  When tumors reached about 40-50 mm3 size, the 
mice were randomized into control and treatment groups (6 animals per group) 
and treated with placebo or DIM-C-pPh-4-OH-3,5-Br2 (2.5, 5, 7.5, or 10 mg/kg/d) 
in nano liquid carrier (administered in sodium carboxymethyl cellulose) by oral 
gavage every second day for 3 weeks.  Tumor volumes, weights, and body 
weights were determined; tumor size was measured using Vernier calipers, and 
the tumor volume was estimated by the formula (mm3) = (L x W2) x ½, where L 
is the length and W is the width of the tumor.  Tumors and lung tissue were 
homogenized for protein isolation for subsequent western blot and RT-PCR 
analysis.  
Western Blot   
Rh30 cells were seeded in 6-well plates at 1.0 x 105 and allowed to attach 
for 24 hr prior to treatment with C-DIMs, with DMSO as empty vehicle at 
indicated time points.  Western blots of whole cell lysates were determined as 
previously described [352, 394]. 
Real-time PCR and Transactivation Assay  
Real time PCR was carried out using Rh30 RMS cells and treated with 
indicated C-DIMs for 10 hr and RNA extraction was carried out using Quick-RNA 
MiniPrep Kit from Zymo Research (Irvine, CA) following the manufacturer's 
protocol.  RT-PCR was carried out using SYBR Green RT-PCR kit (Bio-Rad 
Laboratories, Hercules, CA) essentially as previously described [352, 394].  
Values for each gene were normalized to expression levels of TATA-binding 
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protein. The sequences of the primers used for reverse transcription-PCR were 
as follows; b2 microglobulin:  5'-GCA ATC ACC TGT GGA TGC TAA-3' (sense), 
5'-TAA ATG GTT GAG TTG GAC CCG-3' (antisense); IL-24:  5'-ATG AAT TTT 
CAA CAG AGA GGG CTG-3' (sense), 5'-GCA GAA ATT CTA CAA GCT CTG A-
3' (antisense); DCDC2:  5'-GAC CCT CAA AGA CCS CCA AG-3' (sense), 5'-
AAA TGT TCT AAG CCA CGG CA-3' (antisense); GDA:  5'-ATT AGC GTG GTT 
CTG CAT CTC-3' (sense), 5'-TTA TGA ACC CTC TCA ACC AGA G-3' 
(antisense).  Transactivation studies were carried out in Rh30 cells transfected 
with two NR4A1-responsive constructs, NuREx3-luc and NBRE3-luc, that bind 
NR4A1 as a homodimer or monomer, respectively, or transfected with a GAL4-
NR4A1 (chimera) and a GAL4-responsive construct (UASx5-luc) essentially as 
described [314].  
Statistics   
Results for each treatment group were replicated (at least 3X) and 
expressed a means ± SE.  Statistical comparisons of the treated groups vs a 
control for each treatment were determined using Student's t-test. 
RESULTS 
 The buttressed analogs of DIM-C-pPhOH were synthesized by coupling 
two mole equivalents of indole with the corresponding substituted p-
hydroxybenzaldehyde to give the condensation products in 80-90% yield 
(crystallized from benzene or benzene/petroleum sprit).  Figure 32A illustrates 
the structure of the buttressed DIM-C-pPhOH which were further screened in 
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Rh30 cells. Previous studies show that DIM-C-pPhOH decreased thioredoxin 
domain-containing 5 (TXDC5) and PAX3-FOXO1A fusion gene expression in 
Rh30 cells [352, 394], and these NR4A1-regulated genes play a key role in 
maintaining low oxidative stress and regulating multiple pro-oncogenic 
pathways, respectively. DIM-C-pPhOH (0 – 20 µM) significantly decreased 
expression of both gene products in Rh30 (Figure 32B).  The buttressed 
derivatives of DIM-C-pPhOH were treated with 5 µM concentrations and all of 
the compounds significantly decreased expression of TXNDC5 and PAX3-
FOXO1A and their potency (at 5 µM) was similar to that observed for 20 µM 
DIM-C-pPhOH (Figure 32C). 
 Quantitative structure activity relationships were investigated using 3 
genes identified in RNAseq analysis of differences in mRNA expression in Rh30 
cells treated with DIM-C-pPhOH or DMSO (control) for 6 hr.  Three NR4A1-
regulated genes induced by DIM-C-pPhOH were interleukin-24 (IL-24), guanine 
deaminase (GDA), and double cortin domain-containing 2 (DCDC2).  The 
concentration-dependent induction of all 3 genes in Rh30 cells is illustrated in 
Figure 33.  The fold induction responses were variable for these compounds and 
DIM-C-pPhOH-3,5-Br2 and DIM-C-pPhOH being the most and least, 
respectively, potent inducers of IL-24, GDA and DCDC2 in terms of fold-
induction response. 
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Figure 32. Structure-activity for C-DIMs. (A) Structure of structure of the buttressed DIM-C-pPhOH 
analogs. (B) Rh30 cells were treated with DIM-C-pPhOH (A) and related compounds (C) for 24 hr, and 
whole cell lysates were analyzed by western blots as outlined in the Materials and Methods. 
 
 
EC50 values for induction of IL-24, GDA and DCDC2 by DIM-C-pPhOH were 5.2, 
7.4 and 6.1 µM, respectively, whereas EC50 values for the second generation 
analogs ranged from 0.54-1.58, 0.36-1.2 and 0.55-1.79 µM, respectively, for 
induction of the 3 genes.  These results suggest that these buttressed 
derivatives of DIM-C-pPhOH were up to ten times more potent than the parent 
compound in terms of activation or de-repression of NR4A1-responsive genes. 
Previous studies showed that DIM-C-pPhOH and DIM-C-pPhCO2Me inhibit 
tumor growth in mouse xenograft models at doses of 20-40 mg/kg/d 
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Figure 33. C-DIM analogs: quantitative structure-activity relationships.  Rh30 cells were treated with 
different concentrations of DIM-C-pPhOH (0, 1, 2.5, 5, 10, 15 and µ20 M) and related analogs (0, 0.5, 1.25, 
2.5 and 5 µM) for 10 hr.  RNA was isolated and expression of IL-24 (A), GDA (B) and DCDC2 (C) were 
determined by real time PCR using TATA binding protein as an internal control.  EC50 values for induction 
used the maximal induction response for each compound as the 100% value and results were analyzed 
using Prism Software to determine EC50 induction values. 
 
 
 [317, 350-352, 394] and in an RMS mouse xenograft model, 40 mg/kg/d 
DIM-C-pPhCO2Me inhibited approximately 50-60% tumor volume compared to 
control animals [352, 394].  In this study, we used DIM-C-pPhOH-3,5-Br2 to test 
the effect of buttressing the p-hydroxyphenyl group on tumor growth inhibitory 
activity in athymic nude mice bearing Rh30 cells as xenografts.  The results 
(Figure 34) of initial studies demonstrated highly significant inhibition of tumor 
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growth at concentrations of 10, 7.5, 5.0 and 2.5 mg/kg/d and there was almost 
complete tumor growth inhibition at all of these doses.   
 
 
Figure 34. In vivo tumor growth inhibition by DIM-C-pPhOH analogs.  Athymic nude mice bearing 
Rh30 cells as xenografts were treated with 10, 7.5, 5.0 and 2.5 mg/kg/d DIM-C-pPhOH-3,5-Br2 in corn oil 
every second day, and tumor values were determined for the duration of the 3-week study as outlined in the 
Material and Methods.  Significant (p<0.05) differences between tumor volumes in the treated and control 
mice are indicated (*). 
 
 
In addition, tumor weights were also decreased at all dose levels (Figure 35A) 
and expression of human B2-microglobulin in the lung, a marker for lung 
metastasis of the human RMS cells, was also decreased (Figure 35B) compared 
to controls.  In addition, we also observed decreased expression of NR4A1-
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regulated PAX3-FOXO1A and TXNDC5 and increased expression of IL-24, 
DCDC2 and GDA genes in the treatment groups (Figure 35C).  These results 
demonstrate the increased anticancer potencies of buttressed analogs of DIM-
C-pPhOH compared to the parent compound and their enhanced potential for 
clinical applications in RMS chemotherapy. 
 
 
Figure 35. In vivo tumor growth inhibitory effects.  (A) Tumor weights.  Tumor weights from mice 
treated with DIM-C-pPhOH-3,5-Br2 (outlined in Figure 34) were determined and are presented as means 
+/- SE [significant (p<0.05) inhibition is indicated (*)].  (B) Lung metastasis.  Lungs from animals treated 
with DIM-C-pPhOH-3,5-Br2 were analyzed for expression of human b2-microglobulin to determine the 
relative levels of metastasis of Rh30-derived tumors that have metastasized to the lung.  (C) Changes in 
gene product levels.  Tumor lysates from mice (described in Figure 34) were analyzed by western blot 
analysis as outlined in the Materials and Methods. 
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Figure 36. NR4A1-regulated genes/pathways.  NR4A1 regulates cell growth, survival and 
migration/invasion and related genes and these are also inhibited by C-DIM/NR4A1 antagonists. 
 
 
DISCUSSION 
 RMS patients routinely receive cytotoxic drug therapies and most of those 
patients who survive into their 40s experience serious chronic health problems 
due to their prior cancer treatment [74].  Therefore, it is imperative that new 
treatment regimens using mechanism-based drugs be developed for treating 
RMS.  Studies in the laboratory have characterized some of the pro-oncogenic 
pathways/genes regulated by NR4A1 in RMS and other solid tumors (Figure 36) 
and these can be targeted by NR4A1 antagonists [270-272, 303, 314, 317, 350-
352, 394].  Many of the currently used mechanism-based anticancer agents 
target a single critical gene or pathway and this includes inhibition of epidermal 
growth factor with receptor tyrosine kinase inhibitors (e.g. lapatinib and erlotinib) 
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or antibodies such as Herceptin that bind and inactivate the oncogene HER2 
receptor.  In contrast, NR4A1 antagonists such as the C-DIMs inhibit NR4A1-
dependent growth, survival and migration/invasion and many genes such as 
survivin, bcl-2, EGFR and integrins that are themselves individual drug targets 
(Figure 36).  The effectiveness of this approach is related to the fact that NR4A1 
is a nuclear transcription factor regulating multiple genes/pathways, whereas 
many mechanism-based drugs target a single gene product. 
 Previous studies showed that DIM-C-pPhOH and DIM-C-pPhCOOMe 
were effective inhibitors of solid tumor-derived cancer cells and tumors and this 
included RMS [270-272, 303, 314, 317, 350-352, 394]; however, 
pharmacodynamic studies indicated that DIM-C-pPhOH exhibited a short serum 
half-life [395].  Therefore, we synthesized a series of DIM-C-pPhOH analogs 
containing one or two (3- or 3,5-) substituents ortho to the p-hydroxyl group and 
we hypothesized that the substituents would enhance the effectiveness of the 
"second generation" C-DIM analogs by a buttressing effect and inhibit 
metabolism.  The rapid metabolism of DIM-C-pPhOH and other phenolics are 
due, in part, to conjugation (e.g. glucuronidation) of the para-hydroxyl group.  
However, previous studies indicate that the glucoronidation rates of various 
substrates can be inhibited sterically (buttressing) by nearby substitutents [396] 
and therefore, we synthesized DIM-C-pPhOH analogs containing one or two 
adjacent substituents at the 3- or 3,5- positions on the phenyl ring (Figure 32).  
This study then focused on the enhanced anticancer activities of the C-
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DIM/NR4A1 antagonists using Rh30 ARMS cells as a model since previous 
studies showed that DIM-C-pPhOH induced similar responses in a panel of 
ARMS cells (Rh30, Rh18, Rh41) [394]. 
 The DIM-C-pPhOH analogs decreased expression of the NR4A1-
regulated gene products TXNDC5 and PAX3-FOXO1A (Figure 32).  The PAX3-
FOXO1A fusion gene is a negative prognostic factor for ARMS patient survival 
and functions in ARMS cells as an oncogenic transcription factor that regulates 
expression of multipole genes including the oncogene NMyc [100, 358, 397-
399].  Our results suggest that the new analogs of DIM-C-pPhOH are more 
potent than the parent compound and this was confirmed by determining EC50 
values for induction of 3 NR4A1-repressed genes in Rh30 cells, namely IL-24, 
GDA and DCDC2 (Figure 33).  The in vitro quantitative structure activity 
relationships were complemented by in vivo studies showing that in initial 
studies DIM-C-pPhOH-3,5-Br2 inhibited tumor volume and weight and 
modulated NR4A1-regulated genes at concentrations as low as 2.5 mg/kg/d 
(Figure 34).  Moreover, using human b2-microglobulin as a marker gene in the 
lung (Figure 35), we also observed significantly lower levels of this gene in mice 
treated with DIM-C-pPhOH-3,5-Br2 indicating that this drug also inhibited 
metastasis of Rh30 cells to the lung.  Thus, we have identified members of a 
second generation set of DIM-C-pPhOH-substituted analogs that are 10 times or 
more potent than the parent compound.  Based on results of future 
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pharmacokinetic, receptor binding and toxicity studies, we plan to develop one 
or more of these analogs for clinical applications in treating ARMS patients. 
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
 NR4A1 is overexpressed in several solid tumors, including RMS, and 
serves as a transcription factor that mediates the expression of several genes 
and pathways that are involved in cancer cell proliferation, apoptosis, invasion, 
migration, and ROS. We have investigated a series of structurally diverse C-
DIMs that have the ability to antagonize NR4A1 and decrease the pro-oncogenic 
activity of NR4A1. Two NR4A1 ligands used in this study, 1,1-bis (3’-indolyl)-1-
(p-hydroxyphenyl)methane (DIM-C-pPhOH) and a p-carbomethoxy derivate 
(DIM-C-pPhCO2Me) bind NR4A1 and do not induce nuclear export of NR4A1, 
which is comparable to results observed for these compounds in other cancer 
cell lines. The C-DIM/NR4A1 antagonists or knockdown (siRNA) decreased 
proliferation of Rh30 (ARMS) and RD (ERMS) cells, induced apoptosis, as 
evidenced by PARP cleavage and Annexin V staining, and decreased RMS 
xenograft tumor growth in athymic nude mice. Previous studies in this lab 
showed that NR4A1 acts as a coactivator of Sp-regulated genes with GC-rich 
promoters, such as bcl-2, cyclin D1, EGFR, and cMyc and knockdown or 
antagonism of NR4A1 decreased expression of these pro-growth/pro-survival 
genes. ChIP assays were used to investigate downregulation of NR4A1/Sp-
regulated genes in RMS cells treated with DIM and we observed decreased 
interactions of NR4A1 and p300 on the GC-rich survivin promoter. In addition, 
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DIM-C-pPhCO2Me also decreased mRNA levels of survivin, cyclin D1, and 
EGFR.  
We also investigated the regulation of TXNDC5 and IDH1 expression by 
NR4A1 since both were previously identified by RNASeq analysis after siRNA-
mediated knockdown of NR4A1 or treatment with NR4A1 antagonist. Both 
TXNDC5 and IDH1 maintain low oxidative and ER stress levels to enable cell 
proliferation and this is important for RMS cells which have high basal levels of 
ROS, making them sensitive to ROS-inducing agents. Knockdown or 
antagonism of NR4A1 in these cells induced ROS and decreased expression of 
both TXNDC5 and IDH1, and resulted in induction of cellular stress markers, 
PERK, ATF4, and CHOP. In addition, ChIP assay of the TXNDC5 and IDH1 
promoters exhibit decreased levels of NR4A1 and Sp1 loss after treatment with 
C-DIM, indicating that both genes are regulated by NR4A1/Sp1 as described for 
survivin. These results point to the critical role of ROS in mediating C-DIM-
induced effects in RMS cells. 
C-DIMs also inhibited RMS cell growth by upregulation of sestrin 2 
(SESN2), which activated AMPKa, resulting in downregulation of mechanistic 
target of rapamycin (mTOR) signaling and a similar result was observed upon 
NR4A1 inactivation by RNAi. This result was observed in p53 mutant cell lines 
and demonstrated that SESN2 can be induced in a p53-independent manner. 
SESN2 is also induced in response to ROS and C-DIM/NR4A1 antagonists 
induced ROS and SESN2 and these effects were attenuated upon cotreatment 
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with the antioxidant glutathione (GSH). This is a novel observation demonstrates 
a p53-independent mechanism by which mTOR signaling may be inhibited.  
PAX3-FOXO1A is a critical prooncogenic factor in the more aggressive 
and deadly ARMS subtype. Sp transcription factors (Sp1, Sp3, and Sp4) are 
overexpressed in RMS cell lines and previous studies in this lab have identified 
PAX3-FOXO1A as a Sp-regulated gene that can be inhibited by the ROS-
inducing agent tolefemic acid. Analysis of patient tumors shows that NR4A1 is 
upregulated in ARMS (PAX3-FOXO1A-positive) compared to ERMS (PAX3-
FOXO1A-negative) tumors and knockdown of NR4A1 decreases PAX3-
FOXO1A expression in several ARMS cell lines and has no effect on normal 
muscle cells, confirming NR4A1 regulates PAX3-FOXO1A expression. The 
prooncogenic activity of PAX3-FOXO1A is due to, in part, its regulation of 
several genes, including myogenic differentiation-1 (MYOD1), death-associated 
protein kinase-1 (DAPK1), ras-association domain family 4 (RASSF4), and the 
oncogene nMyc, all of which play a role in myogenic differentiation, cell growth, 
and apoptosis. Antagonism or knockdown of NR4A1 inhibited expression of 
PAX3-FOXO1A-regulated genes in several ARMS cell lines. Furthermore, DIM-
C-pPhCO2Me (40mg/kg/day) inhibited ARMS tumor growth in athymic nude 
mice and also downregulated expression of PAX3-FOXO1A and its downstream 
genes, which is consistent with in vitro studies. Our observations align with 
previous studies demonstrating the importance of PAX3-FOXO1A as a 
contributor to the ARMS subtype.  
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Previous studies have shown NR4A1 regulates several genes, including 
survivin, TXNDC5, IDH1, a5-integrin and b1-integrin mainly via binding to GC-
rich promoters. The PAX3-FOXO1A promoter has several GC-rich binding sites 
and using siRNA targeted to Sp1, Sp3, and Sp4, we found Sp4 knockdown 
decreased expression of PAX3-FOXO1A and downstream genes. These results 
indicate a role for Sp4 interactions with NR4A1 in regulation of PAX3-FOXO1A. 
This observation was confirmed using ChIP assays showing that NR4A1/C-DIM 
antagonists decreased interactions of NR4A1 and Sp4 with the PAX3-FOXO1A 
gene promoter. Previous studies have found PAX3-FOXO1 plays a vital role in 
ARMS migration and we confirmed this using Boyden chamber assays showing 
decreased ARMS cell migration upon PAX3-FOXO1A or NR4A1 knockdown and 
C-DIM treatment. Studies in this lab have shown that NR4A1 and Sp1 
cooperatively regulate b1-integrin expression and C-DIM treatment or 
knockdown of b1-integrin by siRNA decreased breast cancer cell migration. 
While the role of b1-integrin has not previously been established in RMS, its 
expression in breast cancer is associated with negative prognosis and 
metastasis. In ARMS cells, C-DIM treatment and NR4A1 antagonism also 
decreased b1-integrin expression and phosphorylation of FAK, which is 
downstream of b1-integrin. We also observed Sp4 knockdown decreased b1-
integrin. In addition, PAX3-FOXO1A knockdown had no effect on b1-integrin 
expression, which demonstrates that NR4A1 and Sp4 are novel regulators of 
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both b1-integrin and PAX3-FOXO1A and both genes can be targeted by C-
DIMs.  
 RNASeq studies using NR4A1 knockdown and antagonism and PAX3-
FOXO1A antagonism revealed several genes that are commonly regulated 
(activated or repressed) by PAX3-FOXO1A and NR4A1, including the tumor 
suppressor-like factor interleukin-24 (IL-24). IL-24 inhibits cancer cell growth and 
migration, and mediates induction of apoptosis in several cancer cell lines and 
tumors. Analysis of gene expression results from ARMS tumors showed that IL-
24 and PAX3-FOXO1A and IL-24 and NR4A1 were inversely expressed in these 
tumors.  C-DIM/NR4A1 antagonists or PAX3-FOXO1A knockdown induced IL-24 
and this was confirmed via ChIP assay showing increased pol II upon PAX3-
FOXO1A knockdown. Loss of HDAC4 was also observed upon PAX3-FOXO1A 
knockdown, which is consistent with a previous report showing HDAC4 
suppressed IL-24 expression in melanoma cells. Functional studies showed that 
IL-24 overexpression decreased ARMS cell proliferation and invasion induced 
Annexin V staining and caspase 3, and -9, and PARP cleavage, confirming the 
anti-oncogenic activities of IL-24 in RMS cells as previously observed in other 
cancers. In addition, IL-24 regulates several genes and pathways involved in 
cancer and we found IL-24 overexpression activated STAT1, STAT3, and p38 
(MAPK), while inducing the growth arrest and DNA damage (GADD)-inducible 
genes GADD45 and GADD34 and increasing the Bax/Bcl-2 ratio. In addition, 
previous studies have reported p38 as a mediator of IL-24 responses and this 
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was confirmed in Rh30 cells upon IL-24 overexpression and cotreatment with 
the p38 inhibitor SB203580.  
 We further investigated the role of IL-24 in mediating the decreased 
growth, migration, and induced apoptosis induction in ARMS cells after PAX3-
FOXO1A knockdown. In cells cotransfected with siPAX3-FOXO1A and siIL-24, 
effects of siPAX3-FOXO1A were significantly abrogated. In IL-24 KO Rh30 cells 
generated by CRISPR/Cas9 transfection with siPAX3-FOXO1A had no effect on 
ARMS cell survival, proliferation, and migration. These data show that the 
oncogenic activity of PAX3-FOXO1A was due to, in part, IL-24 repression and 
IL-24 induction contributes to the anti-carcinogenic actions observed upon 
PAX3-FOXO1A suppression. Our findings represent a novel role of IL-24 in 
RMS that can be targeted using C-DIM/NR4A1 antagonists. 
 While DIM-C-pPhOH and DIM-C-pPhCO2Me are efficacious in in vivo and 
in vitro studies, pharmacodynamic studies showed that DIM-C-pPhOH has a 
short serum half-life, which is a concern for potential chemotherapeutic 
applications. Therefore, a second generation of C-DIM compounds have been 
synthesized using one or two substituents ortho to the p-hydroxyl group on DIM-
C-pPhOH to buttress the p-hydroxyl group since this structural feature increase 
the half-life of the compound. These second-generation DIM-C-pPhOH analogs 
decreased expression of NR4A1-regulated genes, including TXNDC5 and 
PAX3-FOXO1A in RMS cells and EC50 values for the induction of NR4A1-
repressed genes (IL-24, GDA, and DCDC2) in Rh30 cells were up to 10-times 
  179 
lower than observed for DIM-C-pPhOH. In vivo studies using one of the analogs 
(DIM-C-pPh-4-OH-3,5-Br2) showed decreased tumor growth at the lowest dose 
of 2.5 mg/kg/day compared to high doses (20-40 mg/kg/day) required for first 
generation C-DIMs, confirming the increased potency of the new analogs. In 
addition, using b2-microglobulin as a marker for metastasis, we found decreased 
levels in the lungs of DIM-C-pPh-4-OH-3,5-Br2-treated mice, indicating 
decreased lung metastasis. Our results demonstrate the increased therapeutic 
efficacy of “second generation” C-DIMs, which will be further developed for 
clinical applications. To further establish these second-generation C-DIMs as 
therapeutic agents, further studies should be carried out. The in vivo 
pharmacokinetic and pharmacodynamics should be determined to demonstrate 
increased serum half-life and any effects on internal organs. Furthermore, 
screening assays should be performed to elucidate any off-target effects of the 
second-generation C-DIMs.  
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APPENDIX A  
Supplementary Figure A-1 
 
Supplementary Figure A-1. (A) Apoptosis.  Cells were treated with DIM-C-pPhOH, glutathione 
(GSH) alone and in combination for 24 hr, and whole cell lysates were analyzed by western 
blots.  (B) Growth Inhibition.  Cells were treated as described in (A) and cell growth was 
determined.  [Significant (p<0.05) inhibition (*) and reversal (**). 
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Supplementary Figure A-2 
 
Supplementary Figure A-2. RD cells were transfected with siCtl or siNR4A1 or treated with 
DIM-C-pPhOH (A) and both RMS cell lines were treated with DIM-C-pPhCO2Me (B) and whole 
cell lysates were analyzed by Western blots as outlined in the Materials and Methods. 
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Supplementary Figure A-3 
 
Supplemental Figure A-3. Role of Sp1, p300 and CBP in PAX3-FOX01A expression.  ARMS 
cells were transfected with siSp1 (A), sip300 (B) and siCBP (C) for 72 hours, and whole cell 
lysates were analyzed by western blots. 
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APPENDIX B 
Supplemental Table B-1 
 
 
 
 
 
 
 
 
 
Supplemental Table B-1. Antibodies 
 
Antibodies 
 
Phospho PERK 
 
Biolegend (San Diego, CA).   
Sp1 antibody  Millipore (Temecula, CA) 
SESN2 Santa Cruz (Santa Cruz, CA) 
Bcl-2  Santa Cruz (Santa Cruz, CA) 
CHOP  Santa Cruz (Santa Cruz, CA) 
ATF Santa Cruz (Santa Cruz, CA) 
IDH1 Santa Cruz (Santa Cruz, CA) 
P300 Santa Cruz (Santa Cruz, CA) 
EGFR Santa Cruz (Santa Cruz, CA) 
Normal IgG Santa Cruz (Santa Cruz, CA) 
Cyclin D1 Abcam (Cambridge, MA) 
TXNDC5  GeneTex (Irvine, CA) 
RNA Polymerase II GeneTex (Irvine, CA) 
TXNDC5 GeneTex (Irvine, CA) 
NR4A1 Cell Signaling Technologies (Danvers, MA) 
c-PARP Cell Signaling Technologies (Danvers, MA) 
Survivin Cell Signaling Technologies (Danvers, MA) 
cMyc Cell Signaling Technologies (Danvers, MA) 
p/AMPKa Cell Signaling Technologies (Danvers, MA) 
p/S6RP Cell Signaling Technologies (Danvers, MA) 
p/4EBP1 Cell Signaling Technologies (Danvers, MA) 
p/mTOR Cell Signaling Technologies (Danvers, MA) 
b-actin Sigma Aldrich (St. Louis, MO) 
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Supplemental Table B-2 
 
Supplemental Table B-2.  Primers and oligonucleotides. 
 
Primers 
 
Survivin promoter 5'-TCC AGG ACT CAA GTG ATG CTC-3' (sense) 
 5'-TCA AAT CTG GCG GTT AAT-3' (antisense) 
  
TXNDC5 promoter 5'-CTC GCT CCA GCC CTT CCC TG-3' (sense) 
 5'-AGC AGC AGC AGC AGC GCA GTC A-3' (antisense) 
  
IDH1 promoter 5'-TTA CAT GGT TGA TGC GGC TT-3' (sense) 
 5'-GCC TAA TCT CGG CCA AAA GA-3' (antisense) 
  
Sestrin 5'-GGC ACT TCC GCC ACT CA-3' (sense) 
 5'-TCA GGT CAT GTA GCG GGT G-3' (antisense) 
  
Cyclin D1 5'-ACA AAC AGA TCA TCC GCA AAC AC-3' (sense) 
 5'-TGT TGG GGC TCC TCA GGT TC-3' (antisense) 
  
Survivin 5'-GCC CAG TGT TTC TTC TGC TT-3' (sense) 
 5'-CCG GAC GAA TGC TTT TTA TG-3' (antisense) 
  
EGFR 5'-TGC GTC TCT TGC CGG AAT-3' (sense) 
 5'-GGC TCA CCC TCC AGA AGG TT-3' (antisense) 
  
TXNDC5 5'-GGG TCA AGA TCG CCG AAG TA-3' (sense) 
 5'-GCC TCC ACT GTG CTC ACT GA-3' (antisense) 
  
IDH1 5'-AAG GAT GCT GCA GAA GCT ATA A-3' (sense) 
 5'-CCA TAA GCA TGA CGA CCT ATG A-3' (antisense) 
 
 
 
Oligonucleotides 
 
siCtl CGU ACG CGG AAU ACU UCG A 
siNR4A1(1) SASI_Hs02_00333289 
siNR4A1(2) SASI_Hs01_00182072  
 
 
 
 	
  227 
Supplemental Table B-3 
 
Supplemental Table B-3.  Antibodies, oligonucleotides and primers. 
 
Antibodies  
 
b-actin 
 
Sigma Aldrich (St. Louis, MO) 
Sp1 Millipore (Temecula, CA) 
RASSF4 GeneTex (Irvine, CA) 
RNA Polymerase II GeneTex (Irvine, CA) 
FOXO1A Cell Signaling Technologies (Danvers, MA) 
Nmyc Cell Signaling Technologies (Danvers, MA) 
Survivin Cell Signaling Technologies (Danvers, MA) 
Cmyc Cell Signaling Technologies (Danvers, MA) 
FAK Cell Signaling Technologies (Danvers, MA) 
p-FAK Cell Signaling Technologies (Danvers, MA) 
NR4A1 Cell Signaling Technologies (Danvers, MA) 
CBP1 Cell Signaling Technologies (Danvers, MA) 
P300 Santa Cruz (Santa Cruz, CA) 
MyoD1 Santa Cruz (Santa Cruz, CA) 
Nmyc Santa Cruz (Santa Cruz, CA) 
IgG Santa Cruz (Santa Cruz, CA) 
EGFR Santa Cruz (Santa Cruz, CA) 
Bcl-2 Santa Cruz (Santa Cruz, CA) 
Sp3 Santa Cruz (Santa Cruz, CA) 
Sp4 Santa Cruz (Santa Cruz, CA) 
b1 Integrin Santa Cruz (Santa Cruz, CA) 
DAPK1 Santa Cruz (Santa Cruz, CA) 
Gremlin Santa Cruz (Santa Cruz, CA) 
 
 
Oligonucleotides  
 
siCtl: 
 
5'-CGUACGCGGAAUACUUCG A-3'  
siPAX3-FOXO1A 5'-CCUCUCACCUCAGAAUUCATT-3' (sense) 
 5'-UGAAUUCUGAGGUGAGAGGTT-3' (antisense) 
siNR4A1: SASI_Hs02_00333289 
siSp1 SASI_Hs02_003 
siSp3 SASI_Hs01_00211941 
siSp4 SASI_Hs01_00114420 
siP300 SASI_Hs01_00052818 
b1-Integrin SASI_Hs02_00333437 
 
Primers  
PAX3-FOXO1A 5'-AGACAGCTTTGTGCCTCCAT-3' (sense) 
 5'-CTCTTGCCTCCCTCTGGATT-3' (antisense) 
  
PAX3-FOXO1A Distal #1 ChIP  5'-TCCTAGCCCAAGACTTCGTTC-3' (sense) 
 5'-TCAGCGTTTGTTCTCAGGAA-3' (antisense) 
  
PAX3-FOXO1A Distal #2 ChIP  5'-ATTCCTGAGAACAAACGCTG-3' (sense) 
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 5'-ACATATAGATCCCCGATGCG-3' (antisense) 
  
PAX3-FOXO1A Proximal ChIP  5'-GAGGCCTAACCTCTTCAGTCTC-3' (sense) 
 5'-ACAGAGAATTCCGGATGTGTT-3' (antisense) 
  
b2-Microblobulin 5'-GCAATCACCTGTGGATGCTAA-3' (sense) 
 5'-TAAATGGTTGAGTTGGACCCG-3' (antisense) 
  
TATA Binding Protein 5'-GCCAGCTTCGGAGAGTTCTGGATT (sense) 
 5'-CGGGCACGAAGTGCAATGGTCTTTA (antisense) 
  
Nmyc 5'-GTATTAAAACGAACGGGGCG-3' (sense) 
 5'-AAGTCATCTTCGTCCGGGTA-3' (antisense) 
  
Gremlin 5'-ATTTAAACGGGAGACGGCG-3' (sense) 
 5'-GGCCTGCGCTTTCGAC-3' (antisense) 
  
DAPK1 5'-GACTCGGCAACTCGCAG-3' (sense) 
 5'-GTCGGAGGCCGACCATA-3' (antisense) 
  
MyoD1 5'-CTTTTGCTATCTACAGCCGGG-3' (sense) 
 5'-GTCGTCATAGGAGTCGTCCG-3' (antisense) 
  
RASSF4 5'-AGGATACGATATATGTAGTGGTTTTTGGATT-3' 
(sense) 
 5'-ATTATAACCCCTAAATTACTTAACAAAAATA-3' 
(antisense) 
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Supplemental Table B-4 
 
Supplemental Table B-4.  Antibodies, oligonucleotides and primers. 
 
Antibodies  
 
b-actin 
IL-24 
PAX3 
 
Sigma Aldrich (St. Louis, MO) 
Abcam (Cambridge, MA) 
Abcam (Cambridge, MA) 
Sp1 Millipore (Temecula, CA) 
RASSF4 GeneTex (Irvine, CA) 
RNA Polymerase II 
p/PERK 
GeneTex (Irvine, CA) 
Biolegend (San Diego, CA) 
FOXO1A Cell Signaling Technologies (Danvers, MA) 
CBP 
p/p38 
p/STAT1 
p/STAT3 
c-PARP 
c-caspase 3 
c-caspase 9 
HDAC4 
Cell Signaling Technologies (Danvers, MA) 
Cell Signaling Technologies (Danvers, MA) 
Cell Signaling Technologies (Danvers, MA) 
Cell Signaling Technologies (Danvers, MA) 
Cell Signaling Technologies (Danvers, MA) 
Cell Signaling Technologies (Danvers, MA) 
Cell Signaling Technologies (Danvers, MA) 
Cell Signaling Technologies (Danvers, MA) 
P300 Santa Cruz (Santa Cruz, CA) 
IgG Santa Cruz (Santa Cruz, CA) 
Bcl-2 Santa Cruz (Santa Cruz, CA) 
Bcl-XL 
BAX 
GADD45 
GADD34 
Santa Cruz (Santa Cruz, CA) 
Santa Cruz (Santa Cruz, CA) 
Santa Cruz (Santa Cruz, CA) 
Santa Cruz (Santa Cruz, CA) 
 
Oligonucleotides  
 
siCtl 
 
5'-CGUACGCGGAAUACUUCG A-3'  
siPAX3-FOXO1A 5'-CCUCUCACCUCAGAAUUCATT-3' (sense) 
 
IL-24 
5'-UGAAUUCUGAGGUGAGAGGTT-3' (antisense) 
5’-GACTTTAGCCAGCAGACCCTT-3’ (sense)  
5’-GGTTGCAGTTGTGACACGAT-3’ (antisense) 
siNR4A1 SASI_Hs02_00333289 
 
Primers  
 
PAX3 (-95) ChIP  
 
5'- CAGTCTTGACACATCACGCT-3’ (sense) 
 5'- ACAGTAGTCCACAGCGAAGA-3' (antisense) 
  
PAX3 (-472) ChIP  5'- GCATGTCAGGAAACACTCCT-3' (sense) 
 5'- TTGCCTAGTCACCCATCACT-3' (antisense) 
 
 
b2-Microblobulin 5'-GCAATCACCTGTGGATGCTAA-3' (sense) 
 5'-TAAATGGTTGAGTTGGACCCG-3' (antisense) 
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IL-24 5'-ATGAATTTTCAACAGAGAGGGCTG-3' (sense) 
5'-GCAGAAATTCTACAAGCTCTGA-3' (antisense) 
 
 
 
 
 	
